MULTIPLE SOURCES OF PAH EXPOSURE, DNA METHYLATION AND BREAST CANCER by White, Alexandra
  
 
i 
 
MULTIPLE SOURCES OF PAH EXPOSURE, DNA METHYLATION AND BREAST 
CANCER  
 
Alexandra J. White 
 
A dissertation submitted to the faculty at the University of North Carolina at Chapel Hill 
in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the 
Gillings School of Global Public Health (Epidemiology).  
 
Chapel Hill 
2015 
 
                                                                               Approved by: 
                                                                                    Marilie Gammon 
                                                                            Larry Engel 
  Kathleen Conway-Dorsey 
                                                                              Amy Herring  
                                                                                   Regina Santella
 
 
ii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 
© 2015
  Alexandra J. White                                                                                                           
ALL RIGHTS RESERVED 
 
iii 
 
 
ABSTRACT 
Alexandra J. White: Multiple Sources of PAH Exposure, DNA Methylation and Breast 
Cancer  
(Under the direction of Marilie D. Gammon) 
 
Purpose. Epidemiologic studies have consistently linked long-term exposure to single-source 
polycyclic aromatic hydrocarbons (PAHs) to increased breast cancer incidence. It is unclear 
whether single sources, specific groups, or all PAH sources should be targeted for breast 
cancer risk reduction. Aberrant methylation may be an early event in carcinogenesis, but 
whether PAHs influence the epigenome is unclear. Few studies have evaluated whether PAHs 
are associated with methylation, particularly in breast tumors where methylation changes are 
particularly relevant. Methods. In a population-based case-control study (N=1,508 cases/1,556 
controls), Bayesian hierarchical regression was used to estimate adjusted odds ratios (ORs and 
credible intervals (CrI) for PAH exposure sources, considered singly and as groups: active 
smoking; residential environmental tobacco smoke (ETS); indoor and outdoor air pollution; and 
grilled/smoked meat intake. Promoter methylation of 13 breast cancer-related genes in breast 
tumor tissue (n=765-851 cases) and global methylation in peripheral blood (1,055 cases/1,101 
controls) were measured. Logistic regression was used to estimate ORs and 95% confidence 
intervals (CIs) for the association between individual PAH sources and methylation levels. 
Results. Breast cancer incidence was positively associated with ETS from a spouse (OR=1.20, 
95%CrI=1.03, 1.40) and residential synthetic firelog burning (OR=1.29, 95%CrI=1.06, 1.57). 
Additionally, PAH exposure groups, including ingestion (OR=1.44, 95%CrI=1.16, 1.78) and total 
indoor sources (active smoking, ETS from spouse, grilled/smoked meat intake, stove/fireplace 
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use, OR=1.45, 95%CrI=1.02, 2.04), were associated with increased breast cancer incidence. 
When comparing methylated versus unmethylated genes in tumor tissue, synthetic log use, 
residential ETS, current smoking and vehicular traffic were associated with both increased and 
decreased odds of methylation at a number of breast cancer-related genes. In controls, 
synthetic log use was inversely associated with LINE-1 methylation (OR=0.59, 95%CI=0.41-
0.86). Conclusions. Groups of PAH sources, especially those for ingestion and indoor sources, 
were associated with a 30-50% increase in breast cancer incidence. PAH exposure is 
ubiquitous and a potentially modifiable breast cancer risk factor. PAH sources were associated 
with hypo- and hypermethylation at multiple promoter regions in breast tumors and LINE-1 
hypomethylation in blood of controls. Methylation may be a potential biologic mechanism for the 
associations between PAHs and breast cancer incidence. 
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CHAPTER I. BACKGROUND 
This dissertation aimed to examine the association between multiple sources of polycyclic 
aromatic hydrocarbon (PAH) exposure and breast cancer risk and to investigate the role of 
global and gene-specific DNA methylation. This dissertation investigated multiple PAH sources, 
and groups of sources, assessed throughout the life course (tobacco smoke, grilled/smoked 
meat intake, vehicular traffic emissions and indoor stove/fireplace use) and examined the 
association with breast cancer risk. Further goals of this research involved investigation of the 
role of global and gene-specific promoter DNA methylation in the PAH-breast cancer 
association.   
 Chapter one provides a detailed review of the relevant literature in order to inform the 
study rational and approach. This chapter will summarize the biology and epidemiology of 
breast cancer (1.1), the biology and epidemiology of PAH and associations with breast cancer 
(1.2) and provide a biological and epidemiological rational for considering DNA methylation 
(1.3), which may play a role in the association observed between PAH and breast cancer. 
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1.1 Biology and Epidemiology of Breast Cancer Incidence 
Although many risk factors for breast cancer have been identified, many, such as reproductive 
history and genetics are not easily modified to reduce cancer risk [1]. Other lifestyle factors, 
such as physical activity, postmenopausal obesity and weight gain, may also not be easily 
modified for all women [2]. Therefore, there is an interest in identifying other modifiable breast 
cancer risk factors that impact all women [1]. Environmental risk factors are widespread and 
thought to be potentially modifiable risk factors [3]. Polycyclic aromatic hydrocarbons (PAHs) 
are a potential environmental risk factor that may be important for breast cancer risk [4].  
Elucidating the association between PAHs and breast cancer and identifying potential 
epigenetic markers that influence how PAHs are associated with breast cancer risk could 
advance the knowledge of breast cancer etiology and provide rationale to reduce exposure to 
ambient PAH in the general population. The follow section outlines trends in breast cancer 
incidence, risk factors for the disease and potential mechanisms.  
1.1.1 Trends in Breast Cancer Incidence 
Breast cancer is the most common cancer among women in the United States (US), excluding 
non-melanoma skin cancer [5]. It is also the second-leading cancer-related cause of death 
among women in the US. It is estimated that in 2015, there will be 231,840 new cases of 
invasive breast cancer and 40,000 deaths related to breast cancer [6] . In addition, there was an 
estimated 64,640 new cases of in situ breast cancer in women in 2013 [5]. Breast cancer 
incidence rates among women have remained relatively stable in the U.S. from 2005-2009, 
whereas death rates have steadily declined since 1989 [5]. The lifetime risk of breast cancer for 
women was recently estimated to be about 12%, equal to approximately 1 in 8 women [7]. In 
contrast, male breast cancer is very rare, with an estimated 2,260 new cases to be diagnosed in 
2013 and likely differs in etiology from female breast cancer [5]. Therefore, this investigation will 
focus primarily on female breast cancer. 
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 Summary. Breast cancer is the most commonly diagnosed cancer in the United States. 
Despite efforts to reduce the incidence, breast cancer remains a large burden, with 1 in 8 
women projected to be diagnosed with breast cancer [5, 8]. Therefore, it is of interest to identify 
additional risk factors for breast cancer than can be intervened upon in order to lessen breast 
cancer incidence [1]. 
1.1.2 Breast Cancer Risk Factor Epidemiology 
Numerous breast cancer risk factors have been previously identified, including demographic [7], 
reproductive and nutritional factors [7] as well as medical conditions/clinical characteristics [7] 
and environmental exposures [9].     
Demographic factors. Age. Age, race and family history are all non-modifiable risk 
factors for breast cancer incidence. As with many cancers, the risk of breast cancer generally 
increases with increasing age. The incidence is highest among women 75-79 years of age, and 
a decrease is observed for women 80 years of age and older [7]. The median age of breast 
cancer diagnosis in 2004-2008 was 61 years [7]. As women age, they accumulate cellular and 
molecular changes that can result in deterioration of genome integrity [10]. This underscores the 
need to control for age as a confounder in epidemiologic analyses as well as to consider that 
exposures throughout the life course can influence the rate and type of molecular and cellular 
alterations and thus contribute to breast cancer risk [11].  
Race. Although breast cancer incidence is higher among non-Hispanic white women 
compared to African American women, African American women have a higher incidence of 
breast cancer before age 40, are more likely to die from breast cancer and to present with more 
aggressive breast cancer subtypes [7, 12]. Differential incidence of certain subtypes across 
racial and ethnic groups is likely multifactorial in nature, a response to both genetics and 
variable distributions of risk factor history due to cultural differences in lifestyle and diet [13]. 
Therefore, an association between a potential risk factor and breast cancer may vary by racial 
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and ethnic populations.  
Family history. Family history of breast cancer represents both shared genetics as well 
as lifestyle and environmental factors and is a confirmed risk factor for the disease [7]. This is 
especially true in the case of having a first-degree relative with a history of breast cancer, or 
when more than one relative has been diagnosed [7].  However, most women who are 
diagnosed with breast cancer do not have a family history of the disease (estimated prevalence 
of first-degree family history is approximately 12%) [7]. Thus, while genetics may play a role in 
breast cancer development, other exogenous factors such as lifestyle and environment also 
influence breast cancer risk and remain of strong interest. 
Reproductive factors. Early menarche, late menopause, late age at first birth, low 
parity or nulliparity, little or no lactation. Many established breast cancer risk factors are related 
to reproductive hormones, which may increase cell proliferation and thus, increasing the 
possibility of uncorrected DNA damage [7, 9]. Early menarche and later age at menopause 
increases the lifetime exposure to reproductive hormones in the body [14, 15]. Later age at first 
birth as well as nulliparity or having fewer births has also been associated with an increase risk 
in breast cancer [14]. Additionally, a late age at menarche and an early age at first birth reduces 
the time that the breast is developing and may be most susceptible to carcinogens [1]. These 
reproductive factors are associated with modest increases in breast risk, with odds ratios (ORs) 
in the magnitude of 1.3-2 [14]. Breastfeeding decreases the risk of breast cancer by reducing 
ovulatory frequency; a dose-response association is observed with a longer duration of 
breastfeeding conferring a larger decrease in risk [16]. Reproductive risk factors are all 
reflections of increased endogenous estrogen exposure and were among the first established 
risk factors [14] and gave support to the interest in associations with environmental chemicals 
that may either result in an increase endogenous estrogens or act as exogenous estrogens[3].   
Nutritional factors. Alcohol use [17], dietary intake [18], postmenopausal obesity [19] 
and physical activity [20] levels are all potentially modifiable breast cancer risk factors. 
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 Alcohol use. Alcohol intake may increase estrogen and androgen levels [21]; a meta-
analysis found an excess breast cancer risk  of 22% for alcohol drinking [17]. Along with 
increasing hormone levels, alcohol may also be directly carcinogenic to the breast or possibly it 
may increase the levels of insulin-like growth factor (IGF) in circulation, which may function to 
promote breast carcinogenesis [22]. In the LIBCSP, average lifetime alcohol intake was 
associated with breast cancer risk and no evidence was found for an increase in risk for specific 
time periods of exposure [23]. This result emphasizes the need to consider long-term exposures 
but is not consistent with the windows of susceptibility hypothesis.  
Dietary intake. Despite years of study, most dietary factors have not been linked to 
breast cancer risk including intake of fat, fruit and vegetables and anti-oxidants[18]. For 
example, a pooled analysis of cohort studies reported no significant inverse association 
between fruit or vegetable intake and breast cancer risk [24] although some studies have 
reported a decrease in breast cancer risk [25-27]. An association with breast cancer risk has 
been reported in some dietary factors, in particular soy intake in Asian populations [28] and 
flavonoid intake among western populations [29] being associated with breast cancer risk. 
Exposure misclassification of dietary intake, similar to that of environmental risk factors [30], is a 
significant concern and may in part explain the inconclusive nature of results [31].  
Postmenopausal obesity. Obesity increases the risk of breast cancer in postmenopausal 
women, but may be inversely associated with premenopausal breast cancer [7]. In 
postmenopausal women, estradiol, a metabolically active form of estrogen, is produced by the 
aromatization of androgens in adipose tissue, increasing the levels of circulating estrogen and 
thus, breast cancer risk [19]. This suggests that obesity is likely related to postmenopausal 
breast cancer through a hormone mechanism [19]. However, obesity may also be related to 
breast cancer risk through other mechanisms, including inflammation, oxidative stress, and 
deregulated metabolism/insulin resistance [32, 33]. Obesity is associated with an OR of 
approximately 1.3 for postmenopausal breast cancer according to a recent meta-analysis [34]. 
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The recent increases in obesity prevalence [35] may substantially influence breast cancer 
trends in coming years.  
Physical inactivity. Physical activity has a modest inverse association with breast cancer 
risk and is observed most consistently in women who are postmenopausal at diagnosis [20, 36, 
37]. In the LIBCSP, physical activity is more strongly associated with postmenopausal breast 
cancer [38]. Physical activity may impact breast cancer risk by influencing insulin uptake, 
decreasing inflammation and oxidative stress [39], as well as by directly impacting body size 
[40]. Epidemiologic studies on the associations of obesity and physical activity suggest that 
other pathways, besides hormonal mechanisms, may be important for breast cancer - which is 
relevant in this dissertation as PAHs are known to have oxidative and genotoxic mechanisms as 
well [41-43].   
Medical conditions/clinical characteristics. Hormone replacement therapy (HRT) use.  
HRT is often used to control symptoms of menopause [44]. A Cochrane review  of double-blind, 
randomized trials found an increased breast cancer risk for 5.6 years of combined continuous 
HRT use (absolute risk (AR) =23 per 1000 women, 95%CI 4-11); however, they did not find an 
association with breast cancer for estrogen-only therapy [45]. This result is consistent with a 
summary estimate reported by the U.S. Preventative Task Force for estrogen plus progestin use 
(hazard ratio (HR)=1.25, 95% confidence interval (CI): 1.07-1.46), which is equivalent to 
approximately 8 more cases per 10,000 woman-year [44]. Current or recent exposure to HRT 
was found to be most relevant; with increasing years since cessation of HRT use the hazard 
ratios for breast cancer risk becomes attenuated to the null [44].   
Oral contraceptive (OC) use. OC use has been associated with a slight increase in risk 
of breast cancer. A pooled analysis of over 100,000 women found a slight increase in risk for 
current users (relative risk (RR)=1.24; 95%CI: 1.15-1.33), this association decreased with 
increasing time since last use and became null after 10 years of stopping OC use [46].  This is 
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an important finding that supported the hypothesis that for some risk factors, relatively recent or 
current exposure levels, similar to HRT use, may be the most important for breast cancer risk.   
 Non-Steroid Inflammatory Drugs (NSAIDs). NSAID use has been found to reduce overall 
cancer risk, and in particular breast cancer [47]. A meta-analysis of 38 studies found that NSAID 
use was associated with reduced risk for breast cancer (RR=0.88 (0.84-0.93)) and results were 
similar across specific NSAIDs, aspirin and ibuprofen [47]. NSAIDs are thought to reduce breast 
cancer risk by inhibiting cyclooxygenase (COX) enzyme, which is the rate-limiting enzyme of 
prostaglandin synthesis [48]. Prostaglandins encourage proliferation of cells and breast cancer 
tissue has been demonstrated to have higher levels of prostaglandins [49]. 
Mammographically dense breasts. Most studies conducted have found that having 
dense breast tissue (defined as more than 60% of the breast tissue) is associated with a 4-6 
fold increase in risk of breast cancer compared to women with less dense breast tissue [7, 50]. 
Mammographic breast density is hypothesized to be a measure of the number of at-risk cells in 
the breast tissue [1]; the more dense tissue may represent more at-risk cells.   
Medical radiation. High-dose radiation therapy as treatment, specifically between the 
ages of 10 and 30 years, has been linked to secondary breast cancer among childhood cancer 
survivors [7, 51]. One study reported a standardized incidence ratio for breast cancer of 24.7 
(95%CI: 19.3-31.0) for childhood cancer survivors who were treated with chest radiation therapy 
[51]. Evidence of associations with medical radiation also strengthens the biologic plausibility for 
environmental ionizing radiation.  
Environmental Exposures. Environmental chemicals are often suggested, especially 
by the lay population [7, 52], as potential modifiable breast cancer risk factors.  A recent Institute 
of Medicine (IOM) report recommended more extensive investigation into life course exposure 
to environmental risk factors for breast cancer as these topics have been understudied [3]. 
There are many challenges for determining which environmental exposures influence breast 
cancer, including: (1) difficulty adequately assessing exposure; (2) modest hypothesized 
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associations; and, (3) the changing, complex mixtures of chemicals that individuals are 
ubiquitously exposed to over the life course, which makes it difficult to determine and contrast 
exposure levels [3].  
Radiation. Ionizing radiation is one of the few environmental risk factors to be 
consistently linked to breast cancer and this association has been demonstrated in studies of 
atomic bomb survivors [53, 54]. Radiation can directly result in DNA damage, inducing 
mutations that may be initiation events in carcinogenesis [1]. While associated with a notably 
strong increase in risk of breast cancer, the number of women who are exposure to high levels 
of ionizing radiation exposure through atomic bombs or intense radiation therapy for childhood 
cancers and other disorders is low [55]. Non-ionizing radiation, such as low frequency electric 
and magnetic fields, although hypothesized to contribute to breast cancer risk, have not been 
linked to the disease according to a recent meta-analysis of 15 case-control studies [56]. 
Light at night. Electric light at night, which disturbs circadian rhythm and melatonin 
production, has been associated with to breast cancer [57, 58]. A meta-analysis of 13 studies of 
‘shift work’ at night estimated a risk ratio (RR) with breast cancer of 1.48 (95%CI: 1.36-1.61) 
[58].  Lower levels of melatonin may be related to breast cancer by resulting in increased 
estrogen production and disruption of the estrogen receptor [59] as well as other potential 
immune and anti-oxidant pathways [60]. Exposure to light at night is another example of a 
breast cancer risk factor with mechanisms in addition to hormones that may contribute to the 
observed increased risk.  
 Organochlorines. Organochlorines have long been hypothesized to increase breast 
cancer risk because of experimental evidence that demonstrates organochlorines to be 
hormonally-active and genotoxic [61]. There has been insufficient evidence to determine any 
increase in breast cancer risk from exposure to organochlorines [62, 63] although studies have 
reported significant association when considering early age at exposure defined as prior to age 
14 years [64] and potential acute exposure from fogger trucks [65].  
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Polycyclic aromatic hydrocarbons (PAH).  PAHs are formed from incomplete combustion 
of organic materials [66, 67] and are established carcinogens on the lung [68] and can induce 
mammary tumors in animal models [69]. PAHs have demonstrated estrogenic, anti-estrogenic, 
oxidative and genotoxic capabilities that may be relevant to breast carcinogenesis [70, 71].  
Individuals in the general population are continuously exposed to ambient levels of PAHs from 
numerous sources [41].  Previous studies have demonstrated associations between single PAH 
exposure sources (including active smoking [72], environmental tobacco smoke [73-79], 
grilled/smoked meat intake [80-82] and vehicular traffic emissions [83-86]) with breast cancer 
risk. In addition, PAH biomarkers (i.e. PAH-DNA adducts), are one of the few environmental risk 
factors to be consistently linked to breast cancer [87-92]. However, previous studies have been 
limited by not considering the multiple PAH sources women are exposed to, which is necessary 
in order to better estimate the association between PAHs and breast cancer. Despite evidence 
from single PAH sources and with biomarkers of PAH exposure, the relationship of PAH on the 
human breast remains unclear and is the subject of this investigation. PAH exposure sources, 
previous epidemiologic studies investigating relationships with breast cancer risk, and 
hypothesized mechanisms, will be further explored in much greater detail later in this chapter 
(Section 1.2).  
Summary. These established risk factors for breast cancer, especially reproductive 
history, support the hypothesis that endogenous estrogen and other hormone exposures are 
important predictors of breast cancer risk [15]. Research on many breast cancer risk factors 
have demonstrated that capturing long-term exposure history is crucial, as observed with 
alcohol intake in this study population [23]. In contrast, OCs and HRT use have demonstrated 
that associations observed for exogenous estrogens may dissipate with years since cessation 
[44, 46]. However, as PAH exposure is ubiquitous [41], it is unlikely that women will experience 
a cessation of PAH exposure at any point in time. Therefore, long-term estimates are important 
to consider in order to best estimate the relationship between PAHs and breast cancer risk. 
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Known modifiable risk factors for breast cancer (including postmenopausal obesity, HRT use, 
little to no breastfeeding, alcohol consumption and lack of physical activity) account for only 
approximately 25%-50% of all breast cancer cases [93, 94].  Many other breast cancer risk 
factors are not modifiable, such as reproductive history and genetic [1]. There is more research 
needed to determine additional modifiable risk factors, such as environmental contaminants that 
may impact all women [3], and to better understand how these risk factors act on the human 
breast across the life course. PAHs are a potentially important environmental risk factor for 
breast cancer risk; while individual PAH sources have been associated with breast cancer, 
research that incorporates multiple PAH sources is needed.  
1.1.3 Variability by Breast Cancer Outcome: Menopausal Status and Tumor Subtype  
Risk factor profile variability by menopausal status at diagnosis. Breast cancer risk 
profiles, and tumor subtype distributions [12], differ by menopausal status at diagnosis [95-97].  
An exponential increase in rates of breast cancer is observed until menopause, which is often 
approximated by age 50 years, followed by a slower rate of increase[10]. This inflection point is 
referred to as Clemmesen’s Hook, suggesting two different rate curves for early and late onset 
tumors [10]. As discussed above, obesity is a risk factor for postmenopausal women but has 
been found to be inversely associated with premenopausal breast cancer risk [7].  
Variability by tumor subtype.  Hormone Receptor Subtype. Breast cancer risk factor 
patterns differ by estrogen and progesterone receptor (ER/PR) status of the tumor [98-101]. 
Breast cancer risk factor patterns may further differ with respect to tumor subtype defined by 
other markers such as human epidermal growth factor receptor 2 (HER2), cytokeratin 5/6  and 
epidermal growth factor receptor proteins [102-104]. Breast cancer tumor molecular subtypes 
are usually defined as (1) luminal A (ER+ or PR+, HER2-), (2) luminal B (ER+ or PR+, HER2+),  
(3) HER2 type (ER-, PR-, HER2+) and, (4) triple-negative (ER-, PR-, HER2-). Triple negative 
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breast cancer can also be further categorized into basal-like (ER-, PR-, HER2-, CK5/6+ or 
EGFR+) and unclassified (ER-, PR-, HER2-, CK5/6-, EGFR-) subtypes [102, 103]. 
 Although yet to be firmly established, research suggests that triple negative breast 
cancers may differ in etiology from hormone-receptor positive cancer  and that reproductive 
patterns are more strongly associated with the risk of hormone receptor-positive breast 
cancer compared to triple negative [100, 103]. Contrary to associations typically observed in 
breast cancer research, positive associations have been reported between parity and 
premenopausal body mass index with triple-negative breast cancer [102, 104]. Luminal A 
and luminal B tumors, or hormone receptor positive tumors, are the most common breast 
cancer subtype regardless of race [105]. The prevalence of hormone receptor-positive 
subtypes is particularly high among white, postmenopausal women in the U.S. [103, 106]. In 
contrast, triple negative breast cancer accounts for approximately 11% [105] of breast 
cancers and is most common among premenopausal and African American women [12, 
103, 105]. Triple negative breast cancers are usually aggressive and have a poorer 
prognosis compared to hormone receptor-positive subtypes [12, 103]. Divergent incidence 
trends for hormone receptor-positive vs. hormone receptor-negative tumors demonstrate 
that the incidence of these tumors are shifting over time in response to changing 
distributions of breast cancer risk factors and thus, supports the hypothesis of differential 
etiology by hormone receptor status [107].  
 Summary.  Breast cancer risk factor profiles may differ by hormone receptor status [99], 
defined by the estrogen and progesterone receptors as well as by menopausal status at 
diagnosis [95-97]. Considering these breast cancer outcome characteristics in order to refine 
the outcome definitions may help to adequately capture any potential association and to 
estimate the most precise effect measures for PAH exposure.  
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1.1.4 Breast Cancer Mechanisms 
While not completely understood, there are several hypothesized biologic mechanisms for 
breast cancer. Prolonged exposure to circulating estrogen and progestin has long been 
hypothesized to be the prominent mechanism in breast carcinogenesis after the importance of 
reproductive history and the resulting impact on endogenous estrogen levels was established 
[14]. Increased hormone levels result in increased cell proliferation- a process that occurs from 
initiation to tumor metastasis [9]. This increased proliferation results in more frequent events of 
spontaneous DNA replication errors and the resulting DNA damage would more likely go 
uncorrected by DNA repair mechanisms [9, 108].  Further, it is hypothesized that estrogens may 
promote the growth of existing small tumors or initiated cells [9, 108].  Many established breast 
cancer risk factors work through this hormone pathway [1].  Early age at menarche and late age 
at menopause both increase the number of ovulatory cycles, and thus endogenous estrogen 
levels[1]. Alcohol consumption also results in an increase in estrogen levels [21], consistent with 
the increase in breast cancer risk observed among regular drinkers [17]. Similarly, oral 
contraceptives have both estrogenic and progestin effects [46]. In contrast, breastfeeding and 
parity decrease the frequency of ovulation, reducing endogenous estrogen levels and thus 
reducing breast cancer risk [1]. Among postmenopausal women, adiposity and the use of HRT 
both result in increased hormone levels in the body [1]. Estrogen exposure may be more 
important early in life, as demonstrated by age at menarche, which is known to increase risk 
decades later [1]. In contrast, cessation of estrogen exposures later in life, as observed with 
postmenopausal hormone use and oral contraceptives can result in the risk being reduced 
relatively quickly [1].   
Another potential mechanism is increased breast cancer risk via polymorphisms in 
breast cancer susceptibility genes. Confirmed genetic susceptibility genes can be defined as 
being rare and high-penetrance mutations (BRCA1, BRCA2, TP53, CDH1, PTEN, and STK11), 
rare and moderate-penetrance genetic mutations (CHEK2, ATM, BRIP1, and PALB2) or low-
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penetrance and common single nucleotide polymorphisms (SNPs) [109]. Multiple low-
penetrance, common mutations may interact together and be important factor in hereditary 
breast cancer on a population-level [109]. Current research has focused on finding these 
common, low penetrance polymorphisms which may confer a slight increase in risk.  
With a similar mechanism proposed for estrogen, insulin and IGF have been 
hypothesized to impact breast cancer risk via increased cell proliferation and apoptosis [1]. 
Insulin is positively associated with breast cancer [110]; insulin levels in the body are influenced 
by physical activity and central adiposity [110, 111]. Insulin reduces the synthesis in the liver of 
sex-hormone-binding globulin (SHBG), which functions to bind and transport estradiol [112]. 
With less SHBG present, there is more bioavailable estradiol [112]. Increased levels of insulin 
also result in increased IGF-1 levels and decreased levels of insulin-like growth factor binding 
proteins (IGF-BPs), which together inhibit apoptosis and encourage the progression of 
neoplastic mammary cells [112]. Physical activity and lower body weight both result in increased 
insulin resistance [111] and physical activity may increase levels of IGF-BP, decreasing IGF-1 
levels and thus lowering the levels of endogenous estrogen [113]. Additionally, alcohol may also 
contribute to the production of insulin-like growth factors, consistent with its observed 
association with an increase in breast cancer risk [22]. 
Inflammation is another potential breast cancer pathway [114]. Chronic inflammation is 
associated with obesity, as well as metabolic syndrome, both of which are relevant to breast 
cancer [32]. Inflammation may result in changes in the cell microenvironment, increased 
proliferation and increased oxidative stress [114]. Oxidative damage from both inflammation and 
metabolism results in increased DNA damage [33].  As oxidative damage may be important, 
dietary antioxidants such as fruit and vegetables [115] may reduce risk [1]. Physical activity is 
also associated with decreased oxidative damage and inflammation [113].  
The immune system may also be relevant to breast cancer formation by recognizing 
abnormal cells, and removing them from the body or slowing their growth and development 
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[116].  Light at night and physical activity have both been hypothesized to impact breast cancer 
risk via immune response [40, 60, 113]. Other potential breast cancer mechanisms, including 
DNA damage and epigenetic alterations via DNA methylation, could be particularly relevant to 
the relationship between PAH exposure and breast cancer risk. These will be explored later in 
this chapter.  
Summary. There are multiple potential mechanisms linking established and suspected 
risk factors with breast cancer risk [1]. The most commonly studied and well-understood 
mechanism involves increases in endogenous estrogen exposure, which increases cell 
proliferation rates and increases the likelihood that an induced mutation will go uncorrected [9]. 
Other potential biological mechanisms that influence breast cancer risk include genetic 
determinants [109], metabolic dysregulation and insulin resistance [1], oxidative stress [33], 
inflammation [114] and immune response [116]. The fact that there are numerous mechanisms 
influencing breast cancer underscore the fact that breast cancer is a multifactorial disease and a 
single risk factor, such as PAHs, may act in multiple mechanistic processes in order to influence 
a woman’s risk of developing breast cancer.   
1.1.5 Summary and Conclusions 
Breast cancer is the most common cause of cancer among women in the U.S., except non-
melanoma skin cancers and is the second leading cause of cancer-related death in women [8]. 
Therefore, it is of high importance to determine potentially modifiable risk factors for breast 
cancer because of the high incidence and resulting mortality from breast cancer [1]. The risk 
factors for breast cancer are not completely understood, however many have been identified. 
Established risk factors include age [7], genetics (e.g., BRCA1 or BRCA2 mutations [7] and 
single nucleotide polymorphisms (SNPs)[109]),  a family history of breast cancer [7],  
reproductive history (early menarche, late age at first birth, nulliparity, late menopause, lack of 
breastfeeding [7, 14-16]),  energy balance (body mass index [19], physical activity [20, 36, 37]), 
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external hormone use (hormone replacement therapy use [44, 45], recent oral contraceptive use 
[46]), alcohol intake [17] and exposure to ionizing radiation [7, 99]. These risk factors are 
important to consider to best determine how to categorize PAH exposure for this dissertation as 
well as how to address different definitions of breast cancer as an outcome. Also, a better 
understanding of established breast cancer risk factors informs a directed acyclic graph of the 
relationship between PAH exposure and breast cancer risk as these may be confounders or 
intermediates of the association.  
While mechanisms of breast carcinogenesis are not completely elucidated, it is 
proposed that exogenous hormone exposure and genomic integrity may be relevant 
mechanisms [1]. Additional mechanisms, including insulin-resistance, inflammation, oxidative 
stress and immune response are less well understood but supported by associations between 
physical activity, obesity and alcohol among other risk factors [22, 40, 114]. These pathways are 
important for PAH exposure, as it may act upon multiple breast cancer mechanisms [70, 71, 
117, 118]. In the following section, I describe the many sources of PAH exposure that have 
been investigated with breast cancer risk. Finally, I review DNA methylation which may play an 
important role in the etiology of breast cancer and provide rationale for examining the 
relationship between PAHs and DNA methylation with breast cancer risk.  
1.2 Biology and Epidemiology of Polycyclic Aromatic Hydrocarbons (PAH) 
PAHs are a large class of organic compounds which are widespread environmental 
contaminants and are defined as having at least two bonded aromatic rings [41, 68]. PAHs are 
formed by the incomplete combustion of organic matter (such as fossil fuels or vegetation) [66, 
68, 119]. Ambient exposure sources include tobacco smoke, grilled or smoked foods, indoor 
and outdoor air pollution; each exposure has varying levels and combinations of specific PAHs 
[41, 68]. PAH carcinogenicity varies based on differences in chemical structure and resulting 
reactivity [41]. Due to the variety of exposure sources, humans can be exposed to PAH sources 
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via inhalation of ambient and indoor air, ingestion from food sources and dermal absorption [42, 
120]. 
  PAHs have been observed to cause tumors in animal models [41, 69]. Due to extensive 
research with PAHs and lung cancer, specific individual PAHs have been classified as 
confirmed, possible and probable carcinogens [41, 68]. However, the relationship between PAH 
and the human breast remains unclear [4]. Previous research has been hindered by the fact that 
PAH exposure often occurs in mixtures of PAH and non-PAH chemicals, with varying levels of 
mutagenicity [41, 120]. Individuals are exposed to a wide-range of PAH sources across the life 
course, the extent of which is difficult to capture. Finally, differing individual susceptibility factors 
may alter the PAH-breast cancer relationship and may be highly variable across study 
populations resulting in variable estimates of association [41].  
1.2.1 Occupational PAH Sources 
Occupational exposure to PAHs occurs in several industries, including aluminum, coke 
production, coal gasification, iron and steel foundry, firefighting and in professions highly 
exposed to vehicular exhaust (such as toll booth operators, professional drivers, road workers) 
among others [4, 41, 68, 120]. There is a wide range of exposure levels for occupational PAH 
exposure (ranging from 0.1 to 100,000 ng/m3) [68, 121].  
 There has not been extensive research on occupational PAH exposures and breast 
cancer, due to the wide variety of PAH-related occupational exposures as well as the often 
limited numbers of women included in occupational research [122-128]. Elevated risks of breast 
cancer have been reported for women working in motor vehicle repair shops [126, 128], rubber 
production[127] and metal working[128]. One occupational investigation among premenopausal 
women reported a relationship for PAH exposure and overall breast cancer risk (OR=1.82, 95% 
CI 1.02-3.16) and the authors found the association to be limited to ER+ breast cancer cases 
(OR=2.27, 95%CI 1.14, 4.54) [91]. However, there was high correlation between PAH and 
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benzene exposure and therefore these associations could not be directly attributable to PAH 
[91]. Another study found that occupational PAH exposure to petroleum after age 36 years 
conferred an increase in postmenopausal breast cancer (OR=2.38, 1.00, 5.67) and specifically 
among ER+PR+ tumors (OR=3.00, 1.10, 8.13)[124]. Four studies found little or no increased 
risk of breast cancer with occupational exposure to PAHs or PAH sources [122, 123, 129, 130].  
 Summary. Occupational exposure to PAHs occurs across many different professions [4, 
41, 68, 120]; however, there has been limited research on occupational exposure to PAHs and 
the association with breast cancer at least in part due to the sparse women included in 
occupational studies [122-128]. There has been some suggestive evidence that occupational 
exposures to PAHs is associated with breast cancer [124, 125], but results have been 
inconclusive  [122, 123, 129, 130]. The suggested possible association between occupational 
PAH exposure and breast cancer found in occupational settings where exposure level is much 
higher bolsters the need to better understand the association between PAH exposures and risk 
of breast cancer among women who are ubiquitously exposed, although at a lower exposure 
level, in the general population [131].  
1.2.2 Biomarker PAH-DNA Adducts  
A biomarker is an evaluation of an agent’s exposure that is obtained by measuring either the 
agent itself or it’s metabolites in human tissue, blood or urine [132]. PAH-DNA adducts, one of 
the biomarkers used to assess PAH exposure [132], have been measured in blood cells, human 
breast tumor tissue and in breast milk [41]. Other existing biomarkers often rely on blood-protein 
adducts or urinary PAH metabolites (specifically 1-hydroxypyrene (1-OHP))[41, 121]. 
PAH-DNA adducts are hypothesized to represent the biologically effective dose of PAH, 
or the carcinogenic dose that actually affects DNA in the relevant tissue [132, 133]. These 
biomarker measurements are influenced by individual-level factors and susceptibilities in 
addition to PAH exposure levels [134]. The DNA adducts measurement takes into account 
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individual differences absorption and distribution of PAHs; metabolism into DNA reactive forms, 
detoxification to reactive intermediates and repair of resulting DNA damage [132]. Due to cell 
turnover rates, PAH-DNA adducts measured in lymphocytes represent recent exposures 
occurring in the order of months [121, 135].  However, PAHs are lipophilic in nature and can 
thus accumulate in adipose tissue and therefore, PAH adducts may also be released from 
adipose tissue over time [90].  It is unclear if adducts represent long-term exposure as well. 
Laboratory methods that have been utilized to measure PAH-DNA adduct levels with 
breast cancer include 32P-postlabeling of modified nucleotides, immunohistochemistry and 
competitive enzyme-linked immunosorbent assay (ELISA) assay. 32P-postlabeling is not specific 
to PAH-DNA adducts and measures bulky aromatic ring hydrophobic DNA adducts [121]. 
ELISA, in contrast, uses targeted antibodies to specifically measure the PAH diol epoxide 
adducts that form at the N2 position of the guanine base [41, 89]. 
A pooled analysis found a significant correlation between monitored personal exposure 
to ambient benzo[a]pyrene (B[a]P) levels and blood PAH-DNA adduct levels [121]. This 
correlation was highest when using the ELISA assay, which is the method utilized in this 
investigation, compared to 32P-postlabeling [121]. Associations between other PAH sources, 
including smoking, occupational PAH and the recent intake of charbroiled foods, have also been 
associated with PAH-related DNA adducts [121, 133, 134, 136-143]. However, some studies 
have not found PAH-DNA adducts to be related to all PAH sources of interest [91, 134].  For 
example, in the Long Island study active current and past cigarette smoking exposure was 
associated with blood adduct formation, whereas intake of all types of grilled/barbecue 
(BBQ)/smoked foods in the recent decade was not [134]. PAH-DNA adducts also correlated 
with the vehicular traffic model estimates [133]. These differences may be attributable to the 
variability of exposure route and dose, the timing of the PAH exposure relative to the adduct 
measurement, differences in metabolism or DNA repair across populations or by the impact of 
other unmeasured PAH and non-PAH chemicals [41, 134, 143]. Individual adduct levels may 
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vary with the same exposure levels, indicating that adduct formation is influenced by individual 
susceptibility factors [89]. Therefore, this suggests that an individual’s ability to detoxify 
carcinogens, repair DNA damage and other lifestyle, environmental and dietary factors may 
contribute to the differential formation of adducts given similar levels of exposure [136].  
 LIBCSP has found associations with adduct levels and current and past smoking status 
and soil B[a]P levels [134]. In addition, among women with detectable adducts there was an 
association reported with outdoor air pollution [133]. Inconsistent or lack of associations were 
reported between PAH-DNA adducts and smoked and grilled foods, dietary B[a]P intake and a 
smoking variable that considered active and passive smoke exposure together [134].  
 Consistent associations between adduct levels and breast cancer has been observed in 
hospital-based and population-based studies [74, 87-91]. Two small hospital-based case-control 
studies reported higher DNA adduct level in breast cancer cases compared to women without 
tumors undergoing breast surgery [87, 91].  A similar result was reported by Rundle et al., 2000, 
another hospital-based study that found that women with breast cancer (n=100) were more 
likely to have elevated adduct levels in tumor tissue compared to normal tissue of women with 
benign breast disease (n=105) (OR=2.56; 95%CI 1.05-6.24)[90]. Although not significant, a 
higher level of adducts was also measured in non-tumor tissue of cases compared to controls 
[90]. A non-significant increase in risk between adducts and breast cancer (detectable vs. 
undetectable, OR=1.14, 95%CI 1.15 (0.67-1.93) was reported in an Italian nested-case control 
study of 292 cases and 292 controls when assessing bulky DNA adducts in peripheral 
leukocytes at enrollment [144]. This study had a smaller sample size than the LIBCSP and used 
a different detection method (32P-postlabeling), which is not specific for PAH-DNA adducts 
[144]. 
 The Long Island Breast Cancer Study Project (LIBCSP), a population-based case-
control study, found a modest association by pooled analysis (OR=1.41, 95% CI: 1.07, 1.86) for 
highest vs. lowest quantile as well as for detectable vs. nondetectable adduct levels (OR = 1.29, 
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95% CI: 1.05, 1.58) [92].  Using the ELISA method, adduct levels were measured in circulating 
mononuclear cells rather than in tumor tissue as in previous research, which could explain in 
part the attenuated results [145]. The larger sample size in the LIBCSP relative to the hospital-
based studies may have also improved the stability of the estimates [92].  The lack of a dose-
response relationship between PAH-DNA adduct levels with breast cancer risk could indicate a 
threshold effect or a non-linear relationship [92].   
 Summary. PAH-DNA adducts are a useful biomarker of PAH exposure and resulting 
DNA damage [132] and have been consistently associated with breast cancer risk in other study 
populations [74, 87-91] as well as in the LIBCSP [92]. PAH-DNA adducts are not consistently 
associated with PAH source exposures, and thus may vary by PAH source type, timing of 
exposure and by individual susceptibility factors [121, 133, 134, 136-143]. The biomarker likely 
reflects recent exposure [121, 135] and does not provide information about long-term 
exposures. Therefore using other measures of PAH exposure, including self-report over 
extended periods of time, may be more relevant to understand breast cancer risk.  
1.2.3 Ambient PAH Sources: Exposure in the General Population 
Exposure to PAH is ubiquitous and most people in the general population have measurable 
levels of PAH metabolites in urine, indicating recent exposure [68, 146].  In the general 
population, the major PAH exposure sources include indoor and outdoor air pollution from 
industrial emissions, traffic and heating [41, 68, 147], tobacco smoke [148] and grilled, smoked 
or broiled foods [119]. The general population can also be exposed to PAHs from house dust 
[149], food crops and soil that are contaminated with PAHs likely via deposition from the air [41, 
42, 68, 119], candles and incense burning[150], wood, leaf and garbage burning [41] and 
tattoos [151]. In contrast, it is estimated the exposure from natural sources such as forest fires 
or volcanoes is quite low [41]. Although PAHs have been measured in water supply, which as 
with leafy vegetables is likely from contamination, these levels tend to be low in part due to the 
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relative insolubility of PAHs and effective water treatment procedures [68]. It has been 
previously estimated that on average the total PAH exposure from all sources is approximately 
3 µg per day [121].  
Environmental ambient PAH is monitored relatively infrequently, unlike US 
Environmental Protection Agency (EPA) criteria pollutants [41]. Measurement of ambient PAHs 
requires collection on specialized filters, extraction using organic solvents and analysis with gas 
chromatography/mass spectrometry or high performance liquid chromatography [68, 121, 152-
154].  In order to measure specific PAH compounds, extensive separation schemes are 
required [68]. In epidemiologic studies, ambient PAHs have also been measured using personal 
monitors or biomarkers [68].  However, personal monitors are expensive and difficult to conduct 
on a large scale. Although biomarkers are also used to asses ambient PAH exposure, as 
previously discussed, the limitations of PAH-DNA adduct biomarkers are difficulty in 
interpretation due to variations in PAH exposure types, timing and dose over time relative to 
study assessment and variability based on individual-level susceptibility factors [134].  
Studies that do measure ambient PAHs usually are only equipped to measure and report 
on a relatively small number of specific PAHs, which could potentially exclude PAHs that may 
be most relevant [41, 68, 121]. There is also little consistency across reports with investigators 
measuring different specific PAHs, as PAH profiles vary based on the exposure source of 
interest [41, 68, 121].  Many researchers rely on B[a]P as a surrogate marker for all ambient 
PAH [41, 121].  However, this measurement does not fully account for the complex mixture of 
PAHs and thus likely results in some exposure misclassification [41, 121]. Despite this, B[a]P is 
common to all ambient PAH sources and is one of the PAHs with the most demonstrated 
carcinogenic activity [41, 121]. Similarly, the LIBCSP has reported that soil B[a]P levels are 
strongly correlated with other high molecular weight soil PAHs, which tend to be more 
carcinogenic than lower weight PAH molecules [41, 133]. The following sections will cover the 
common, ambient PAHs that women in the general population are exposed to on a daily basis: 
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indoor air pollution, vehicular traffic, tobacco smoke and grilled/smoked meat intake. Later in the 
chapter, I will discuss the relative contributions of the PAH sources as well as possible 
mechanisms to explain associations reported between PAHs and breast cancer. Associations 
between the PAH sources, indoor and outdoor air pollution, active smoking and environmental 
tobacco smoke and grilled/smoked meat intake in other study populations are included in Table 
1.1.  
Summary. Exposure to PAH is ubiquitous, including indoor and outdoor air pollution 
from industrial emissions, traffic and heating [41, 68, 147], tobacco smoke [148] and grilled, 
smoked or broiled foods [119]. Environmental ambient PAH is monitored relatively infrequently, 
unlike US EPA criteria pollutants [41]. PAHs can be measured using personal monitoring 
systems[68] or by the biomarker PAH-DNA adducts [134]. Studies can often only measure a few 
specific PAH compounds, usually B[a]P, but with little consistency across studies [41, 68, 121].  
However, these methods are not accounting for the fact that PAHs often occur as a complex 
mixture and thus, may result in misclassification [41, 121]. 
1.2.4 Indoor Air Pollution 
Indoor air pollution, or household air pollution, is a major PAH source and is of significant world-
wide public health concern [155].  As of 2010, less than 20% of the population in the Americas 
and Europe rely mainly on solid fuels, whereas use is highest in Africa and Southeast Asia, at 
approximately 60% [156]. Wood burning for fuel and domestic heating releases many known 
genotoxic PAHs [157]. Homes burning wood stoves for heating purposes have more high 
molecular-weight PAHs indoors than measured outside the home [158]. Additionally, other 
materials burned in homes, such as coal, gas and synthetic logs may result in exposure to 
specific PAHs with carcinogenic activity [41, 157, 159]. Outdoor air pollution, house 
characteristics and cigarette smoking are also contributors to indoor PAH levels [133, 160]. 
Indoor air is likely to be an important exposure route as US adults spend most of their time 
indoors [131].  
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PAH emissions from wood stoves are estimated to range from 1.7-12.6 µg/m3 [131]. 
There has been limited testing on the emission profiles of synthetic logs, consisting of wax and 
sawdust, compared to natural logs. A report by Gullet et al. [159] measured emission factors of 
various pollutants (including polychlorinated dibenzodioxins and dibenzofurans, polychlorinated 
biphenyls, hexacholorbenzene, particulate matter (PM) and PAHs) from fireplace and 
woodstove combustion emissions. Synthetic log burning produced elevated levels (mg/kg) of 
almost all measured PAHs compared to the combustion of wood, but not higher levels of the 
other pollutants measured [159]. Specific PAHs that were particularly high in concentration in 
the synthetic log emissions included chrysene/triphenylene, benzo(e)pyrene and retene [159]. 
Chrysene in particular is a documented tumorgenic PAH [41]. Another emission analysis also 
reported higher PAH levels and a wider range of specific PAH compounds present in synthetic 
log emissions compared to wood emissions [161]; similarly, another report found a specific 
brand of artificial logs to have higher PAH emission factors compared to cordwood [162]. These 
results suggest that PAHs may be one of the more relevant emission factors from synthetic log 
burning for breast cancer risk. However, other reports have found similar PAH levels across 
synthetic logs and natural wood logs or possibly lower PAH levels for synthetic logs [163, 164]. 
These inconsistencies could be due to differing synthetic log components or testing conditions, 
and thus variable emission characteristics [165].  
A Washington state department of health study estimated that 40% of people currently 
used some type of wood burning device (lower than the ~50% prevalence observed in LIBCSP, 
which was defined as ever use in a Long Island home) [166]. Among the Washington users of 
wood burning devices, approximately 50% used woodstoves, 50% used fireplaces and 17% 
used both devices [166].  Synthetic logs are manufactured to be used in open fireplaces, which 
tend to emit more PAHs than wood stoves per hour of operation [167]. In fact, an open fireplace 
burning natural wood can result in PAH concentrations comparable to those of ambient urban 
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air [168]. Open fireplace use has also been associated with increased DNA adduct levels in 
both mothers and their newborns [169]. 
Surrogate measures of PAH exposure from indoor air pollution are often measured in 
epidemiologic research using air samples, personal monitors or self-reported use of indoor 
stoves and fireplaces [68]. However, personal monitors and current air samples do not 
represent historical exposures needed for studies focused on cancer etiology and are logistically 
challenging for large-scale epidemiologic research.  Monitoring of specific PAHs is especially 
challenging and studies often rely on measuring a small, variable number of PAHs which may 
not include those that are biologically relevant [41, 68, 121]. This is further complicated as PAH 
profiles tend to differ by exposure source and temperature of combustion [41, 68, 121].  
Previous research on the health impacts of indoor air pollution has predominantly 
focused on outcomes of respiratory health effects or cancer outcomes in developing countries 
where exposure levels are high compared to the United States [170]. Indoor air pollution, from 
burning of wood or coal, has been associated with cancers of the lung according to an 
international pooled study [171], upper aero-digestive tract in India [172] and been observed to 
interact with human papillomavirus (HPV) in association with cervical cancer [173]  in South 
America  Although much of the research on indoor air pollution is occurring outside of the U.S., 
solid fuel remains the primary heating source for approximately 6.5 million U.S. citizens [174].  
Based on findings in the LIBCSP, a 45% increase in risk of breast cancer was observed 
for women who had ever burned synthetic logs in their homes (OR=1.45, 95%CI 1.17, 1.80), but 
no association was found for wood burning alone (OR=0.93, 95%CI 0.79, 1.08) [175]. The risk 
associated with synthetic log burning increased with 7 or more years of use and among p53-
mutation-negative tumors, but was not found to vary by menopausal status at diagnosis, 
gluthathionine-S-transferase (GST) polymorphisms, smoking history or tumor subtype defined 
by HR status [175]. A nonsignificant increase in breast cancer risk was associated with any 
stove/fireplace use for 21-30 years of exposure (OR=1.19, 95%CI 0.94, 1.47) [175].  
 25 
Summary.  Indoor air pollution, from the burning of wood, coal, gas and synthetic logs in 
the home, increases indoor PAH exposure levels and is a public health concern world-wide 
[155].  Indoor PAH exposure is often measured using air samples, personal monitors or self-
reported use of indoor stoves and fireplaces [68]. Previous research on indoor air pollution has 
been relatively limited; investigating respiratory health effects or cancer outcomes is mainly in 
developing countries where exposure levels are higher than in the U.S. [170]. Indoor 
stove/fireplace use, in particular burning of synthetic logs, but not wood, has been associated 
with breast cancer in this study population [175]. 
1.2.5 Outdoor Air Pollution and Traffic Emissions 
Vehicular traffic emissions are often considered to be the most predominant source of airborne 
PAH in urban and suburban areas [41, 176-178]. Outdoor air pollution infiltrates indoor spaces 
quite effectively [179], suggesting that outdoor air pollution is also a contributor to indoor PAHs 
[133, 160, 176]. Typical measured levels of total ambient PAHs range from 1 to 30 ng/m3  for 
total ambient PAHs, excluding naphthalene [68]. Vehicles emit a mixture of by-products such as 
carbon monoxide, nitrogen oxides, sulfur dioxide, PM, and volatile organic compounds [178, 
180]. Traffic emissions also include significant concentrations of the following PAHs: 
benzo[g,h,i]perylene, pyrene, fluoranthene, phenanthrene and other PAHs [41]. 
In general, there has been a decreasing trend in ambient PAH levels in the U.S. mainly 
due to the introduction of catalytic converters in gasoline vehicles [41]. However, increased 
vehicle use has tempered this decrease in emissions [181]. Although there is overall less PAH 
exposure from vehicular traffic in the U.S., vehicular traffic emissions remain high in other 
countries [182, 183]. Despite these decreases in emissions, women who live in high traffic 
density areas may still have high PAH exposure levels.  
Ambient PAH from vehicular traffic varies based on a number of factors. Seasonal 
variation is observed, with highest ambient levels of PAH in the winter [184, 185]. Driving 
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conditions, traffic patterns, fuel characteristics and vehicular properties all affect emissions [178, 
180]. For example, higher emissions are associated with both low and high speeds [186]. Traffic 
emissions are higher at intersections because of the acceleration and deceleration [133, 181] 
and are higher under cold-engine compared to warm-engine conditions [41, 133, 181-183]. 
Studies suggest that gasoline engines are the major source of heavy mass PAHs and that 
diesel engine PAH emissions are comprised of less carcinogenic lighter weight PAHs [41, 181]. 
Gasoline vehicular emissions are reduced by more than 10-fold in vehicles with catalytic 
converters [178]. 
Adequate measurement of ambient PAHs when investigating health outcomes is 
undoubtedly challenging, as ambient PAH is not monitored in a similar manner to US EPA 
criteria pollutants [41]. Some studies have used personal monitoring of PAH [187]. Other studies 
have used PM and some other traffic-related pollutants as surrogates of ambient PAH or traffic 
exposure [86]. To measure exposure to traffic specifically, previous studies have used 
measures such as distance to major roads or traffic density [85]. This crude measurement may 
not adequately capture exposure levels and doesn’t capture other PAH sources to which 
women are ambiently exposed.  
There have been a few studies investigating the association between vehicular traffic 
and breast cancer risk, with most reporting modest positive associations [83-86, 188-191]. 
Breast cancer risk has been correlated with US traffic density patterns in ecological analyses 
[189, 190]. Lewis-Michl and colleagues reported a non-significant positive association between 
high residential traffic in 5 km2  grids and breast cancer among participants in Nassau country 
on Long Island [84]. A hospital-based case-control study found associations between the 
pollutant nitrogen dioxide and postmenopausal breast cancer [83]; similarly, other non-PAH 
traffic emission compounds were linked to breast cancer risk in another study although the 
estimates were attenuated after adjustment [189].  A Danish cohort study found a non-
significant increase in breast cancer risk in association with crude traffic measures [188]. 
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In the LIBCSP, a modest increase in risk of breast cancer was associated with recent 
vehicular traffic exposure (OR=1.14; 95%CI 0.80-1.64) and results were stronger, but less 
precise for long-term PAH exposures [192]. A significant interaction was found between fruit and 
vegetable intake, with the association of vehicular traffic strongest among women with low 
levels of fruit and vegetable intake. This association was also most prominent among 
premenopausal women, women with ER-/PR- tumor subtype and in situ breast cancers [192].  
Summary. Vehicular traffic emissions are an important PAH source, particularly in urban 
areas [41, 176-178].  Vehicle emissions of PAHs depend on a variety of factors, including 
season, driving conditions, traffic patterns, fuel characteristics and vehicular properties [178, 
180]. To measure PAH exposure from vehicular traffic emissions, some studies have relied on 
personal monitoring of PAH [187], proxy measures of other traffic-related compounds [86] and 
crude measures such as distance to major roads or traffic density. Studies have consistently 
reported positive, modest association between vehicular traffic and breast cancer risk [83-86, 
188-190] and correlations between US traffic density patterns and breast cancer trends over 
time [189, 190]. Findings in the LIBCSP are consistent with previous studies, with an increase in 
breast cancer risk for higher PAH exposure measured using a sophisticated traffic model [133, 
192].  
1.2.6 Tobacco Smoke 
Tobacco smoke is a known and prevalent PAH source and contains several specific PAH 
compounds, including benzo[a]pyrene, naphthalene, pyrene and fluoranthene among others 
[193], which are potent mammary carcinogens in experimental research [69, 194].  Tobacco 
smoke also contains non-PAH carcinogenic chemicals such as aromatic amines and N-
nitrosamines [78].  Tobacco smoke exposure can be inhaled from both active and secondhand 
smoking, which is also referred to as environmental tobacco smoke. Environmental tobacco 
smoke (ETS) incorporates both the sidestream smoke from the burning of the tobacco as well 
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as the mainstream smoke that is exhaled from smokers [195]. Active smokers and those 
exposed to ETS have increased urinary levels of the PAH metabolite, 1-hydroxypyrene [68, 78]. 
Much of the existing laboratory evidence on the carcinogenicity of PAHs has relied on 
cigarette smoke.  Both active smoking and ETS induces DNA damage according to in vivo and 
in vitro studies [196]. Benzo[a]pyrene from cigarette smoke induces neoplastic transformation of 
human breast epithelial cells in vitro [197]. Specific PAHs, including those found in cigarette 
smoke [69], are highly carcinogenic to the mammary gland in laboratory animals [117, 194, 
198].  In addition to being carcinogenic, PAHs exhibit weak estrogenic activity [117] and interact 
with the estrogen receptor [199]. However, smoke exposure is also associated with 
antiestrogenic properties as found in both in vitro and in vivo experimental research [117, 199-
201]. It is been previously hypothesized that the antiestrogenic properties of smoking may 
hinder the detection of any association with breast cancer [72].  For example, active smokers 
have an earlier age at menopause, which is believed to result from toxic effects of smoke 
exposure on ovarian function [117, 200, 201]. Smoking has been associated with decreased 
overall exposure to estrogens from early initiation of menopause and altered hormone 
metabolism  [202].  However, a recent pooled analysis found moderately higher levels of 
hormones, including estrogen, in current, heavy smokers compared to never smokers [203]. 
Therefore, the association between estrogen levels and smoking is not yet well-established or 
understood [72].  
 It is known that metabolites and chemicals from cigarette smoke reach the breast, as 
both nicotine and cotinine have been detected in breast fluid [69].  Smoking has been 
associated with PAH-DNA adducts measured in breast tissue and blood [69, 87, 89, 91] and 
p53 mutation smoking signatures have been detected in breast tissue [204].  In support of this, 
cigarette smoking is an established risk factor for other cancers where the site does not come 
into direct contact with smoke, including cervical cancer [205].  
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Cigarette smoking history should be investigated if possible using information on timing, 
frequency, intensity, duration and time since quitting [78]. Because epidemiologic studies almost 
exclusively rely on self-report to assess an individual’s history of active cigarette smoking, the 
data is often subject to recall bias and social desirability bias [206].  However, there is evidence 
to suggest that self-reported smoking history is a valid measurement, with over 80% sensitivity 
and specificity according to a meta-analysis [207]. Self-reported smoking levels have been 
validated using the metabolite cotinine [108], which reflects recent smoking. However, cotinine 
measurements cannot provide evidence on intensity or long-term history of smoking [208].  
There has been extensive interest and reporting on the relationship between tobacco 
exposure and breast cancer. Early expert panel agency reviews of active smoking and breast 
cancer concluded there was a decreased risk associated with active smoking, followed by many 
expert panels concluding the results at each point in time were inconclusive [195]. However, 
recent expert panels, including those from the California EPA (2005) [209], the Canadian Panel 
(2009) [210], the International Agency for Research on Cancer (IARC) monograph (2012) [211] 
and the IOM report on breast cancer and the environment (2012) [3] concluded that there was a 
positive association between active smoking and breast cancer “consistent with causality” [210]. 
Some of the earlier studies on active smoking and breast cancer included women who were 
exposed to environmental tobacco smoke, potentially attenuating any association towards the 
null [212].  Newer studies have also included more detailed exposure assessment and better 
confounding control, which may have contributed to previous inconsistencies [195]. A recent 
meta-analysis of 15 prospective cohort studies published in 2013 reported a higher incidence of 
breast cancer among current (HR=1.12, 95%CI 1.08, 1.16) and former smokers (HR=1.09, 
95%CI 1.04, 1.15) [72]. There have been studies published since this meta-analysis, with all 
[213-217] but one [218], finding a positive association between active smoking and breast 
cancer risk. The one study that did not find a positive association included women with ETS 
exposure in their referent group, likely biasing the estimate towards the null [218].  
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Both the California and the Canadian Panel concluded that regular exposure to passive 
smoke is causally related to breast cancer among premenopausal women [210, 219].  However, 
many of these studies have relied on using ever/never definitions which has made it difficult to 
make strong conclusions on the subject [211]. Long-term residential ETS tends to have more 
consistent associations [73, 74, 77]. In addition, more consistently positive associations have 
been reported among susceptible subgroups, including women who smoked before first live 
birth, women with NAT2 slow acetylators and other genetic polymorphisms [76, 78].  A 2013 
meta-analysis did not conclude that there was an association between ever passive smoking 
and breast cancer; however, the analysis was unable to consider long-term exposure histories 
[220]. Studies published since this meta-analysis uniformly report an increase in breast cancer 
risk with environmental tobacco smoke exposure [213, 214, 216, 221, 222]. 
A 2004 meta-analysis did not find evidence of heterogeneity of the association between 
tobacco smoke and breast cancer by subtype [98]. However individual investigations have 
reported evidence of differential associations of smoking by tumor subtype, with recent studies 
reporting stronger associations among hormone receptor positive breast cancer [74, 101, 213, 
217, 221]. Although cigarette smoking has been associated with the presence of breast tumor 
p53 mutations [204, 223], this relationship was not replicated in the LIBCSP investigation, which 
had more power [224].  
In the LIBCSP, neither self-reported former or current smoking was substantially 
associated with breast cancer risk [74]. However, a positive association was found among 
women who lived in the same home with a smoking spouse for more than 27 years (OR=2.10; 
95%CI 1.47, 3.02) [74]. Among women with hormone receptor positive tumors only, the OR for 
combined active smoking and ETS was elevated (OR=1.42, 95%CI 1.00, 2.00) [74]. These 
results suggest that any detectable associations with ETS may be limited to specific subgroups 
of women.  
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Summary. Tobacco smoke is a known and prevalent PAH source which contains 
several specific PAH compounds as well as non-PAH carcinogens [193]. Tobacco smoke 
exposure can be inhaled from both active and environmental tobacco smoke. Epidemiologic 
studies most often use self-report history of cigarette smoking and environmental tobacco 
smoke [206], which is considered to be a valid measurement [207]. Recent studies have 
reported an increase in breast cancer risk for active smoking [72]. Additionally, studies 
investigating long-term residential exposure to environmental tobacco smoke or living with a 
smoking spouse have more consistently reported associations with breast cancer risk [73, 74, 
77, 225-228].The research on long-term environmental tobacco smoke is consistent with 
findings in the LIBCSP study population, which reported an increase in breast cancer for long-
term exposure to environmental tobacco smoke of a spouse [74].  
1.2.7 Grilled and Smoked Meat Intake 
 PAHs can form on or near the surface of foods that have been grilled, barbecued and smoked 
[229]. PAHs are produced as part of the smoke forming from the incomplete combustion of 
carbon and hydrogen in fat when it comes into contact with the flame during barbequing and 
grilling [230]. The smoke then rises and results in PAHs being deposited on the food. Smoke 
curing of meat also deposits PAHs on the meat [155]. Additionally, if meat is directly in contact 
with flame, PAHs can be formed directly on charred meat from pyrolysis of the fat [119, 231].  
The amount of PAH depends on the type of meat, the portion size, the cooking method, length 
of time cooked and the level of doneness [231]. Grilled, barbecued (BBQ) and smoked meats 
on average have the highest PAH levels of any food at approximately 10µg/kg of food [121, 
231]. Grilling and smoking meat result in similar levels of PAHs [232]. The daily dietary intake of 
total PAHs has been estimated to be approximately 2µg in the U.S. [233].  Cooked meat also 
contains heterocyclic amines, which are non-PAH carcinogens that may be relevant to breast 
cancer [234].  
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 Dietary intake in epidemiologic studies is largely collected using dietary questionnaires, 
in particular food frequency questionnaires (FFQ).  Questionnaires can be used to assess 
dietary PAH exposure with questions on intake of PAH-containing foods and cooking methods. 
From the responses to these questions and in conjunction with a database of measured PAH 
concentrations, a dietary PAH exposure index can be created [230, 231].  
 There are some important limitations to dietary questionnaires. Specifically, recall error 
may result in misclassification of the dietary exposure [31]. Although recall error is often 
assumed to be non-differential in a cohort study [31], recall is often assumed to be biased in a 
case-control study. Regardless of the study design, if the dietary exposure variable is multi-
level, which is the usual approach in nutritional epidemiology, the resulting bias could be difficult 
to predict and may be towards or away from the null [230].  In addition, many dietary questions 
focus on eating habits of the previous year, whereas more long-term exposure may be the more 
relevant time period for breast cancer. Another important limitation is that many food frequency 
questionnaires do not assess meat cooking methods, and if they do, the assessment is not 
consistent across questionnaires [230, 235].  As the cooking method, in particular whether meat 
is grilled, smoked or barbecued, is indicative of the PAH content, this could result in instability of 
effect estimates for the association between meat intake and breast cancer risk.  
Despite extensive previous research, the association between well-done cooked meat 
intake and breast cancer risk has been somewhat inconsistent [80, 230, 236-239]. However, 
without taking into account cooking method it may be difficult to adequately capture any PAH-
related effect [230]. Those that did take into account whether meat was grilled, barbecued, 
smoked or charred report inconsistent associations with breast cancer [80-82, 235-238]. 
However, none of these studies took into account exposure across the life course, which may 
be crucial when considering cancer risk. More recent reports have found modest associations 
between grilled meat intake and breast cancer risk even with exposure assessed in the previous 
 33 
year [80-82]. In one study, the association observed with grilled meat and breast cancer risk 
was attenuated when other cooking methods were considered [81].  
 In the LIBCSP, lifetime intake of grilled and smoked foods was assessed using a 
structured questionnaire including four categories of grilled, barbecued or smoked meats over 
each decade of life since teenage years [230]. An association was reported between lifetime 
intake and postmenopausal breast cancer and was most pronounced in women with low intake 
of fruit and vegetables [230].  
Summary. Grilled, barbecued and smoked meats are a notable PAH source [230]. PAH 
content may vary by the type of meat, the portion size, the cooking method, length of time 
cooked and the level of doneness [231]. FFQs and other dietary questionnaires are used to 
assess grilled/smoked meat intake in epidemiological studies. Unfortunately, many 
questionnaires do not assess cooking method which is an important factor in PAH formation 
[230, 235]. The few studies that have taking into account whether meat was grilled, barbecued 
or charred have had inconsistent findings with breast cancer risk, although more recent studies 
have found modest associations [80-82, 235-238]. This study population took into account 
grilled/smoked meat across the life course, which is important for the etiology of breast cancer, 
and found an increase in breast cancer risk associated with lifetime intake [230].  
1.2.8 Relative Contributions of Ambient PAH Sources 
The relative contributions of different sources to total PAH exposure and internal PAH dose are 
still very uncertain and are likely population-specific [41].  These relative contributions likely vary 
widely by lifestyle (active smoking status, environmental tobacco smoke and diet choices) as 
well as geographic location (urban vs. rural). Domestic wood burning for heating is regarded as 
a prominent contributor to airborne PAH levels in the United States and Europe, particularly in 
rural areas [41]. Vehicle exhaust is also an important source especially in central parts of large 
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cities [41] and during periods of high traffic [150].  As well, studies suggest that outdoor 
pollutants may also dominate indoor PAHs [41].  
Smokers may have the highest PAH dose [131]. Studies have consistently demonstrated 
that PAH uptake from diet may be the largest source of PAH exposure, or dose, among non-
smokers, ranging from several nanograms to several micrograms per day [41, 68, 119, 240]. 
Grilled, smoked and barbecued foods are the largest source from the diet, but PAH exposure 
levels can be increased by PAH intake from contaminated food sources, such as fruit, 
vegetables, dairy products and seafood, as well as other foods that have been processed or 
preserved [68, 240].  PAH dose from inhalation of indoor and outdoor air pollution is estimated 
to be lower, only a fraction of the dose from diet (5-10%) [241]. For example, one investigation 
calculated that among male non-smokers, dietary contributions to PAH dose were 96.2%, 
whereas ambient sources were 1.6% relying on previously published concentrations of ambient 
PAH sources [68, 131]. Similarly, a study conducted in the U.S. using benzo[a]pyrene levels as 
a marker of PAH exposure levels, estimated that among nonsmokers who did not burn coal in 
their homes, 70% of PAH exposure occurred from the diet [119]. However, active smoking may 
double PAH dose, making active smoking the most predominant source [131].  
The impact of different exposure routes on the effective biological dose in humans is not 
very well established [41]. However, animal models suggest that carcinogenic potential varies 
by exposure route [240] and may be highest for inhalation [131, 242]. Thus, while total PAH 
exposure may be dominated by diet intake and exposure via inhalation may be a small 
proportion of the overall PAH dose in non-smokers, ambient air sources may be more 
biologically relevant. In support of this, environmental or airborne PAH sources tend to show 
stronger associations with PAH-DNA adducts compared to diet, smoking or occupational 
exposures and therefore may be more relevant to breast cancer risk [133, 143]. Therefore, it is 
important to still consider all PAH sources when evaluating relationships with breast cancer risk.  
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Summary. Relative contributions of PAH sources to total PAH dose is not well 
established and varies by geographic location and lifestyle [41]. Studies suggest that wood-
burning and vehicular traffic are the largest sources for airborne PAH [41]. Despite this, diet 
sources appear to be the largest PAH contributor among non-smokers [41]. Smokers may have 
double the PAH dose compared to non-smokers [131]. Additionally, while the importance of 
exposure routes on the carcinogenicity are also not well established [41], some animal studies 
suggest inhalation may be the most important route [131, 242]. So while diet may be the largest 
exposure source, dose via inhalation may be the most relevant to breast cancer risk. These 
variations across exposure type and route of exposure support the need to consider multiple 
PAH sources when evaluating the relationship between PAH and breast cancer risk.  
1.2.9  PAH and Breast Cancer Mechanisms  
As discussed previously, women are exposed to PAHs from numerous sources, including indoor 
and outdoor air pollution, active smoking and environmental tobacco smoke and intake of grilled 
and smoked foods [41]. Many of these PAH sources have been associated with breast cancer 
risk in epidemiologic studies [72, 74, 86, 230]. The evidence for the relationship between PAHs 
and breast cancer is also biologically plausible [4]; PAHs may act upon the carcinogenic 
process in numerous ways [70, 71, 117].  
PAHs can be rapidly absorbed into the human body after inhalation, ingestion or skin 
contact, and are soon released into the general circulation [68, 243-246]. Ambient PAHs, from 
indoor and outdoor air pollution and cigarette smoke, are absorbed through airway epithelium, 
whereas ingested PAHs, such as those from grilled and smoked foods or from deposition of 
ambient PAH, are absorbed by diffusion through the gastrointestinal tract epithelium[68]. 
Absorption timing is influenced, among other factors, by PAH size and number of aromatic 
rings, with the larger molecules been absorbed more slowly [68]. The impact of different 
exposure routes on effective biological PAH dose in humans is unclear [41], however, an in vitro 
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study in animal models suggested that carcinogenic potency varies by route of exposure and 
may be highest for inhalation [242].  
After being distributed to the circulation and other tissues, PAHs are metabolized 
through activation and detoxification pathways [4, 41, 121].  PAHs are distributed preferentially 
in fatty tissues[68], such as the breast[7]. PAHs are lipophilic and can accumulate in adipose 
tissue of the breast to be released over time and redistributed to breast epithelial cells[90]. 
Experimental studies suggest that PAHs can be metabolized by human mammary epithelial 
cells in vitro [41, 42, 78] as well as in the mammary gland in animal models.   
Phase I enzymes, predominately cytochrome p450 enzymes, break down PAHs to 
reactive metabolites which can then be detoxified by Phase II metabolic pathways (e.g., the 
GSTs) [4, 42, 68, 247, 248]. When exposure levels are high, or detoxification processes are not 
adequate, these reactive PAH metabolites produced from Phase I metabolism may 
subsequently bind to DNA to form bulky adducts [4].  If DNA repair processes are unable to 
rectify this DNA damage, it can ultimately lead to somatic mutations in breast cancer-related 
genes, an initiation step of carcinogenesis [41]. Metabolism of PAHs in relation to breast cancer 
risk is displayed in Figure 1.1.  
There are several mechanisms that could be relevant to the association between PAHs 
and breast cancer risk. There has been experimental evidence suggesting that PAHs are direct 
carcinogens in animal models as well as in humans [41]. PAHs have many properties that may 
be relevant to breast carcinogenesis, including the induction of DNA damage, both by formation 
of PAH-DNA adducts and via oxidative stress-related mechanisms [249]. Further, it has been 
hypothesized that PAHs may interact with DNA repair pathways and GST variants to influence 
breast cancer risk [4]. These pathways will be summarized and discussed below.  
 Several PAHs, including benzo[a]pyrene, can induce mammary tumors in laboratory 
rodents [68, 194]. The induction of mammary tumors has been consistently observed via many 
exposure routes; whether PAHs are administered orally [194], by absorption through skin 
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painting[198], by direct injection into the mammary gland [69] or intracolonic instillation[68]. One 
study did report a positive association between inhaled diesel exhaust (which includes PAH as 
well as other carcinogens) and mammary adenomas in rats [250]. 
Certain PAH compounds, tobacco smoke and specific PAH-related occupational 
exposures are classified as known human carcinogens by IARC [68, 251, 252]. Other PAHs 
(including chrysene, benz[a]anthracene, ideno[1,2.3-cd]pyrene, beno[b]fluoranthene) and PAH-
containing mixtures (such as diesel and gasoline engine exhaust) are classified as probable or 
possible human carcinogens [41, 68, 178]. These classifications are made with consideration of 
experimental, epidemiologic and mechanistic data. However, this research has often relied on 
associations with lung, bladder or skin cancers due to the limited nature of the research with 
breast cancer [68]. In addition, many of the mixtures that have been characterized as 
carcinogens also may contain other carcinogenic or mutagenic compounds [41].    
Individual PAHs differ in metabolic and carcinogenic properties, with more structurally 
complex PAHs tending to have a higher carcinogenic effect [41].  Several PAHs are known to 
be complete carcinogens, meaning that the compound can act as an initiator, promoter or 
progressor through a combination of genotoxic and estrogenic mechanisms [41-43]. The 
initiation stage of carcinogenesis involves mutations from carcinogens in tumor suppressor 
genes or proto-oncogenes [41]. Initiation is followed by the promotion phase, which is the 
proliferation of the initiated cells [41]. The final phase, progression, is an irreversible process by 
which a cell becomes increasingly genetically unstable and becomes capable of autonomous 
cell growth, which results in the cell being considered malignant [41].    
PAHs may exhibit estrogenic, anti-estrogenic [117], inflammatory [71, 118], pro-oxidant 
[70, 71] and genotoxic [70] properties that may be relevant to breast cancer mechanisms [4]. 
PAHs are similar to estrogens in structure, metabolism and transport [42]. As discussed in the 
previous section on breast cancer mechanisms (1.1.2), circulating estrogen levels are an 
important factor in breast carcinogenesis [9, 108]. Similar to estrogen, benzo[a]pyrene increases 
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proliferation of human mammary epithelial cells and human breast carcinoma cells in vitro [68, 
253]. Research has been relatively inconsistent on whether specific PAH compounds exhibit 
estrogenic or antiestrogenic activity [117]. Whereas some studies have observed evidence of 
predominately antiestrogenic activity by PAH compounds in breast cancer cell lines [201, 254], 
there has been more recent evidence of certain PAHs and their metabolites exhibiting estrogen-
like activity in both cell lines [255-257] as well as in animal models  [258, 259]. More research is 
needed to better understand the potential for estrogen-like activity of PAHs in humans and by 
the main PAH exposure sources. Table 1.2 includes a summary of the laboratory-based 
evidence of either estrogen or antiestrogen activity for relevant PAH compounds by exposure 
source.   
PAHs may also be acting through immunotoxic or inflammatory mechanisms [41, 68, 71, 
118, 251]. Although the evidence is sparse, epidemiologic and clinical evidence suggest that 
PAHs may impact immune function in humans [68]. In addition, PAHs may contribute to breast 
carcinogenesis through the induction of DNA damage [249].  For example, PAHs might induce 
mutations on the p53 gene, which are common and important event in breast 
carcinogenesis[260]. While there are many mechanisms proposed to explain PAH induction of 
carcinogenesis, the metabolic formation of diol epoxides is the most widely accepted [249]. 
However, each of these processes may damage DNA and thus, eventually result in mutations in 
tumor suppressor genes or proto-oncogenes to initiate carcinogenesis. These proposed 
mechanisms likely function together, through a combination of processes to induce DNA 
mutations and encourage proliferation of these damaged cells [68, 249]  
Interactions between PAHs with genes or environment and lifestyle factors may be 
relevant for their carcinogenic effect on the breast [41]. For example, PAHs may interact with 
genes that are relevant to their metabolism and deactivation, such as the GSTs [4, 261], or with 
those that are important for oxidative stress detoxification [4]. Additionally, and as is the focus of 
this dissertation, PAHs may be associated with, or interact with, DNA methylation which could 
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be relevant to breast carcinogenesis. This latter issue will be further discussed in Section 1.3.4., 
DNA Methylation and PAH.  
Summary. PAHs are rapidly absorbed into the human body after inhalation, ingestion or 
dermal absorption, and are soon released into the general circulation and consequently stored 
in fat tissue [68, 243-246]. PAHs are metabolized through activation and detoxification pathways 
[4, 41, 121]. Specific PAH compounds are hypothesized to be complete carcinogens, acting as 
an initiator, promoter and progressor through a combination of genotoxic and estrogenic 
mechanisms [41-43]. Further, PAHs exhibit anti-estrogenic [117], inflammatory [71, 118] and 
pro-oxidant [70, 71] characteristics that may contribute to breast carcinogenesis [4]. A prominent 
proposed PAH mechanism is the metabolic formation of diol epoxides [249]. Additional 
mechanisms are likely, including the hypothesis that PAH might induce mutations on the p53 
gene, an important event in breast carcinogenesis [260]. Genes, environment and lifestyle 
factors may also interact with PAH exposure to impact the carcinogenic effect on the breast 
[41]. Finally, PAHs may interact or impact epigenetics, in particular DNA methylation, to 
influence breast cancer risk [11]. 
1.2.10 Summary and Conclusions 
Women in the general population are ubiquitously exposed to PAHs, which are formed from the 
incomplete combustion of organic matter.  PAHs are known carcinogens to the lung [68], and 
possibly to the breast [69, 194].  PAHs have demonstrated estrogenic, anti-estrogenic, oxidative 
and genotoxic capabilities that may be relevant to breast carcinogenesis [70, 71]. PAH-DNA 
adducts, a biomarker for PAH exposure, are one of the few environmental exposures to be 
consistently linked with breast cancer risk. Few studies have reported associations with 
occupational sources of PAH exposure and breast cancer risk. However, women in the general 
population have many routes of exposure, with predominant PAH exposure sources being traffic 
emissions [41], tobacco smoke [148], indoor stoves [262], smoked and grilled foods and leafy 
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vegetables [67, 68, 240].  Despite studies demonstrating associations between single PAH 
exposure sources (including tobacco smoke [73-79], grilled/smoked meat intake [230], burning 
synthetic logs [175] and vehicular traffic emissions [83-86]) and breast cancer risk, the 
relationship between PAH and the human breast is not well understood. In particular, the Long 
Island Breast Cancer Study Project has previously reported 35-75% increases in breast cancer 
risk associated with PAH source exposures, environmental tobacco smoke [74] and lifetime 
intake of grilled/smoked red meat [230] and vehicular traffic [192] based on geographical 
modeling estimates [133, 181]. LIBCSP results are consistent with others, who have also 
reported increases in breast cancer risk for long term exposure to ETS [78, 79], intake of grilled 
meat [80-82], and outdoor air pollution [83-86]. While both short-term and long-term measures 
of PAH have been linked to breast cancer, no previous study has incorporated multiple PAH 
exposure sources and investigated profiles of PAH exposure to assess the association with 
breast cancer risk (Figure 1.2).  
1.3 Biology and Epidemiology of DNA Methylation  
DNA methylation is a modification of DNA that alters expression and has been found to be 
relevant to numerous diseases, including breast cancer [263, 264]. Here, I will give an overview 
of the biology of DNA methylation, predictors of methylation levels and the epidemiology of DNA 
methylation with health outcomes, focusing on cancer. This section will also cover laboratory 
methods used to measure both global and gene-specific DNA methylation, and focus more 
specifically on the biology and epidemiology of global and gene-specific DNA methylation and 
their relationship with breast cancer. Finally, I will end this section discussing the relationship to 
date with PAHs and DNA methylation. This section will inform why DNA methylation having a 
role in the PAH-breast cancer association is both biologically plausible and supported by 
previous epidemiologic evidence.  
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Overview of DNA Methylation Biology. Epigenetic modifications are heritable changes 
in DNA structure that do not involve sequence changes and result in some alteration of gene 
expression. Epigenetics include the processes of DNA methylation, modification of histone 
proteins and noncoding microRNAs [265]. DNA methylation, specifically, is the addition of a 
methyl group to cytosines within CpG dinucleotides (cytosine base preceding a guanine base), 
to form 5-methylcytosine (5meC), a reaction that is catalyzed by the enzyme DNA 
methyltransferase [266]. CpG islands (CGI), defined as clusters of CpG nucleotides, are located 
in approximately half of all human genes [266]. The DNA methyltransferase enzyme is largely 
dependent on the 1-carbon metabolism pathway, requiring folate, homocysteine and choline 
and other micronutrients from the diet [267]. Although 70% of CpG dinulceotides are methylated 
in the human genome, CpG islands tend to be unmethylated. Gene methylation can be 
measured on a ‘global level’, often relying on surrogate markers which characterize the amount 
of methylation in repetitive transposable elements. In addition, methylation can be measured for 
specific genes and at particular regions within a gene. It is unclear whether promoter 
methylation and genome-wide methylation are mechanistically linked or independent processes 
[268]. 
Two main waives of epigenome-wide reprogramming occur during the zygote stage and 
during primordial germ-cell formation [269]. During the preimplantation phase, the genome 
becomes demethylated, resulting in a zygote that can generate any cell type [269]. When 
implantation occurs, DNA methylation levels are restored by de novo methylation to facilitate 
cell lineage differentiation [270]. The second reprogramming event also occurs during 
embryogenesis, but only in the primordial germ cells in which DNA methylation patterns are 
erased at all single copy genes and some repetitive elements [271].  
 Determinants and Function of DNA Methylation Levels. While DNA methylation may 
be largely determined by genetics and early life or in utero exposures [272], methylation levels 
at certain genes does appear to be influenced at least in part by environmental and lifestyle 
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factors [273-277]. For example, twin studies show that discrepancies in global methylation 
increases as the twins age [276, 277]. As such, DNA methylation is of interest as a potential 
mechanism for associations between lifestyle and environmental factors and disease. There is 
also evidence suggesting that some gene methylation levels can be heritable and influenced by 
genetics, including the methyltransferase gene [274, 278]. While some research suggests that 
DNA methylation can directly affect gene function, it has also been hypothesized that DNA 
methylation may be a marker for another mechanistic process (such as epigenetic histone 
modification) that is resulting in the silencing of genes [266, 279]. Similarly, the purpose of DNA 
methylation may be to maintain ‘silencing’ of a gene that has already been induced by another 
biological process [266].  
DNA Methylation and Disease. Aberrant DNA methylation has been found to be 
associated with various human health outcomes, including cancer, cardiovascular disease and 
autoimmune diseases [263, 264]. DNA methylation is increasingly being recognized as an 
important factor for breast cancer detection, prognosis and treatment [280]. Many studies have 
suggested the potential of using methylation markers for the early detection of cancer [281] 
including breast cancer [282]. Methylation is hypothesized to influence carcinogenesis in 
multiple ways. In normal tissue, methylation is important for maintaining cell growth and 
differentiation [283]. Interruption of these processes can contribute to cancer [283]. DNA 
methylation may be an important factor in disease initiation and promotion by silencing specific 
genes important in DNA repair, cell cycle regulation, transcription and tumor suppression via 
hypermethylation (increased methylation) or activating genes via hypomethylation (decreased 
methylation) at CpG islands near promoter regions [266, 274, 283]. The implication of DNA 
methylation at regions that are not CpG-islands at promoter regions is less well understood 
[266].  DNA methylation can independently repress DNA transcription by preventing binding of 
DNA polymerases and transcription factors and can also interact with methyl binding domain 
proteins and other epigenetic mechanisms including histone marks [265, 284]. Along with gene-
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specific methylation, lower genome-wide methylation (i.e. global methylation) in regions that are 
typically methylated, such as repeated or transposable elements, can result in genomic 
instability and is hypothesized to impact normal growth and development in target tissues via 
altered gene transcription [265]. 
 Both gene-specific and global methylation are posited to be early, causative events in 
carcinogenesis, however, there is still some debate on the topic [274, 285, 286]. In support of 
this hypothesis, aberrant methylation has been detected in cancer precursor lesions as well as 
in non-tumor adjacent tissue [282, 287, 288].  Animal models with experimentally induced 
genome-wide hypomethylation resulting in tumor formation also suggest a causative role [289]. 
However, there are some studies showing cancers without global hypomethylation 
characteristics [285]. In addition, the progression of global hypomethylation and gene-specific 
hypermethylation with cancer stage may suggest that methylation is an event resulting from 
cancer formation [285].   
1.3.1 Measurement of DNA Methylation 
The methods used to measure DNA methylation vary widely across studies. Results of 
epidemiologic studies investigating risk factors associated with DNA methylation as well as 
studies investigating associations between methylation and breast cancer are often 
inconsistent, likely due to the challenges inherent in interpreting results from a range of assays 
and different DNA sources (i.e., tissue vs. blood samples) [281]. This section summarizes the 
methods used to assess global and gene-specific methylation.  
Measurement of Global Methylation. A variety of methods have been used to 
investigate genome-wide DNA methylation in population-based studies. This research has 
predominately relied on blood DNA [265]. Early methods included 5meC-specific antibodies 
[290], methyl-acceptance assays [291] and high-performance liquid chromatography [292]; 
however, these assays were limited in their inability to differentiate the location of the DNA 
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methylation. Most DNA methylation assays utilize bisulfite-converted DNA, which is the result of 
a process involving the incubation of DNA with sodium bisulfite to result in the conversion of 
unmethylated, but not methylated, cytosine bases to uracil [293]. This process has been 
deemed the “gold-standard” [294, 295]. Studies have also used real-time PCR [296], microarray 
methods [295] and assays utilizing restriction enzymes [293, 297]. The LUminometric 
Methylation Assay (LUMA), which is included in this investigation, is an example of a method 
using restriction enzymes to assess methylation levels, measuring methylation mainly at CGIs, 
which tend to be unmethylated [297]. Therefore, any detectable change would likely be an 
increase in methylation [265]. This measurement is better interpreted as a summary measure of 
the gene-specific methylation changes that are known to occur in association with 
carcinogenesis [297].  
Genome-wide hypomethylation is often associated with repetitive, transposable 
elements (TE) and thus, many surrogate assays for genome-wide methylation levels have been 
designed to target these sequences [265]. The most commonly investigated repetitive elements 
include Long Interspersed Nucleotide Element 1 (LINE1), short interspersed elements (SINEs, 
including Alu), and Satellite repeats (Sat2) [265]. LINE-1, the best understood TE, is also the 
most highly expressed TE in the human genome (with 500,000 copies, equivalent to 
approximately 17% of the human genome) [264, 298].  The Alu family of elements is also a 
common TE with 1.1 million copies [264]. Both Alu and LINE-1 tend to be highly methylated in 
normal tissue but hypomethylation of these elements has been detected in tumors [265]. Sat2 
are short, tandem repeated noncoding DNA regions [299]. The measurement of methylation at 
repetitive elements is the most convenient method for population-based studies and is 
considered a surrogate measure used to reflect genome-wide methylation levels [265]. 
However, the degree to which these surrogate measures truly reflect global methylation remains 
controversial [300, 301]. Reports suggest that global methylation may be tissue specific and not 
necessarily correlated [275, 302, 303].   
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Measurement of Gene Specific Promoter Methylation. Gene specific promoter 
methylation is typically measured in tissue or blood samples. One review suggested that there 
was a good concordance of 84% between tumor and blood samples from the same patients for 
gene-specific markers [281]. For example, blood hypermethylation of BRCA1 has been 
associated with an increased prevalence of BRCA1-methylated breast tumors, suggesting a 
functional link between blood methylation and disease histology [304-306]. However, a recent 
review concluded that CGIs are sometimes methylated in a tissue-specific manner [266].  
 Similarly to measurement of global methylation, a variety of methods have been used to 
ascertain gene-specific promoter methylation levels [266]. Bisulfite treatment of DNA and PCR 
or pyrosequencing methods are commonly used, as is the MethyLight assay [266]. More 
recently, array technologies such as the Illumina 450K array have also been used, and shotgun-
sequencing of bisulfite converted DNA [266]. Shotgun sequencing provides the most 
comprehensive coverage [266]. Gene-specific methylation can be also measured at different 
sites in the gene, although most research has focused on CGIs at transcriptional start sites 
[266]. An important and newly discovered limitation of studies using bisulfite-treated DNA is that 
bisulfite treatment does not distinguish between 5mC and 5-hydroxymethylcytosine (5-hmc) 
[307]. This same study also found that 5-hmc regions cause replication methods (such as PCR) 
to stall, which could result in bisulfite-based methylation analytic methods underestimating 
methylation levels in regions with large amounts of hydroxymethylation [307].  
 Summary.  Measurement of DNA methylation can be on a global scale or in specific 
gene regions and is usually evaluated in blood DNA [265]. Global DNA methylation is often 
quantified using a proxy measure of DNA methylation at transposable elements (TE) [265], in 
particular LINE-1 [265]. There are some other methods used to measure global methylation, 
such as the LUMA assay [265]. The LUMA assay, which is used in this investigation, utilizes 
restriction enzymes to assess methylation levels, mainly at CGIs, which tend to be 
unmethylated [297]. In contrast, gene-specific DNA methylation is more often measured in 
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tissue but can also be measured in blood [281]. Bisulfite treatment of DNA and subsequent PCR 
and/or pyrosequencing methods, or the MethyLight assay, are commonly used to quantify gene-
specific methylation [266]. Recently, array techniques and shotgun sequencing methods have 
been used to increase the number of CpG sites analyzed [266]. 
1.3.2 Global DNA Methylation 
Genome-wide, or global, hypomethylation is not completely understood. However, it is 
hypothesized that genome-wide hypomethylation may induce chromosomal instability, a 
potential tumorigenic event [265]. Chromosomal instability may increase the likelihood of 
mutations, genetic recombination, deletions or translocations that could be relevant to cancer 
[265, 283, 308].  In addition, hypomethylation may alter expression of genes relevant for cancer, 
including the transcription of noncoding RNAs [283].  More than a third of DNA methylation 
occurs in repetitive elements [275, 309], which together represent a large proportion of the 
human genome (LINE-1 and ALU together represent 30%) [310]. LINE-1 and Alu are commonly 
measured repetitive sequences that are used as proxies for global methylation levels. Genomic 
DNA methylation may vary based on specific white blood cell types [275, 311] and whether the 
DNA is from blood or tissue [275]. Global methylation has been predominately investigated in 
white blood cells [275]. 
Predictors of Global Methylation. There has been a lot of interest in identifying factors 
associated with genome-wide hypomethylation [273, 275, 312]. The 1-carbon metabolism 
pathway has been hypothesized to be important; insufficiency of dietary folate and other 1-
carbon metabolism-dependent micronutrients and germline or somatic mutations in 1-carbon 
metabolism pathway genes have been associated with hypomethylation in tumor, normal 
tissues and blood in some [267, 300, 313], but not all studies [296, 314-316].  Folate 
intervention studies have reported significant increases, decreases and no changes in 
methylation levels [312]. A randomized estrogen replacement therapy trial conducted among 
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postmenopausal women found those given equine estrogen had an increase in percentage of 5-
mC in peripheral mononuclear cells compared to women with placebos [317], suggesting that 
estrogen can directly impact DNA methylation levels.  
Blood DNA methylation alterations have been associated with exposure to 
environmental and lifestyle risk factors for cancer and thus it is hypothesized that blood 
methylation may provide a useful biomarker for cancer risk [273, 300]. Across demographic 
factors, there has been variability in global methylation associations with age, gender and race 
[275, 312]. For example, a combined analysis of five studies found age and alcohol to be 
inversely associated with Alu, but not LINE-1 [275]. This provides evidence that global DNA 
methylation changes may not occur homogenously across the human genome [275]. There 
have been many studies investigating changes in global methylation with behavioral risk factors 
for breast cancer, however there is not sufficient evidence to suggest a consistent pattern [312]. 
For example, studies have investigated global methylation in association with alcohol drinking 
[275, 296, 318-321], body size [275, 316, 318, 322] and physical activity [316, 323]. 
Environmental exposures, including benzene [324], persistent organic pollutants [318, 325], 
lead [326, 327], arsenic [328] and air pollution [329-331] have also been investigated in 
association with changes in global methylation but results have been generally inconsistent 
[312].  
DNA methylation is largely established in utero or in early life [272], and therefore early 
life may be a time of increased susceptibility to risk factors such as prenatal smoke exposure 
[275]. These early life factors, including prenatal smoke, famine and folate supplementation, 
suggest that exposure early in life may have associations with global methylation patterns 
decades later [275, 332-334].  Global methylation levels have also been found to be lower 
among girls with a family history of breast cancer [299, 335]. Early age at menarche, a known 
risk factor for breast cancer risk, has also been linked with increased global methylation, 
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measured by LUMA [336]. These results all underscore the importance of investigating 
exposures across the life course when considering DNA methylation.  
Global Methylation and Breast Cancer. It is unclear whether DNA methylation 
changes measured in white blood cells can be interpreted as an intermediate biomarker for 
breast cancer risk [265].  A recent meta-analysis of twenty-three publications that have reported 
blood genomic DNA methylation in relation to overall cancer risk (not specific to breast cancer) 
in population-based case-control studies reported a random effects OR of 1.39 (95%CI 0.91, 
1.97) [265]. The associations differed by the global methylation marker used, with the most 
consistently positive associations with cancer risk found in the five studies that measured global 
methylation using 5meC levels (OR=2.65, 95%CI 1.20, 6.09) [265]. Imprecise but positive 
associations were reported for Alu (OR=1.31, 95%CI 0.93, 1.68), Sat2 (OR=1.55, 95%CI 0.99, 
2.10) and LINE-1 (1.24, 95%CI 0.76, 1.72) [265]. 
Investigations of global DNA methylation with breast cancer risk have been limited. 
Associations have been reported between breast cancer and hypomethylation of the Sat2 
element [313, 337] and 5md-C levels [292], but not with Alu [305, 313]. LINE-1 hypomethylation 
has not been shown to have consistent associations with breast cancer, with most studies not 
reporting a significant association [292, 297, 301, 313, 337]. However, a recently published 
prospective cohort investigation did find an increased risk (lowest quartile compared to those in 
the highest quartile, HR=1.75, 95%CI 1.19, 2.59) [338]. LIBCSP found a null association 
between LINE-1 and breast cancer risk (quartile 5 vs quartile 1, OR=1.00, 95%CI 0.76, 
1.30)[297]. In contrast, LIBCSP also reported a strong positive (highest quintile vs. lowest 
quintile OR=2.41, 95%CI 1.83, 3.16) association between hypermethylation and breast cancer 
risk using the LUMA assay [297].  No other studies have reported global methylation measured 
with LUMA with breast cancer risk [265].  
Limitations. Many of the results for predictors and health outcomes in association with 
global methylation are limited by drawing inferences from cross-sectional studies [312], in which 
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it is difficult to determine temporality of the association. Those that were conducted 
prospectively may not have had a long enough follow-up time to see effects [312]. In addition, 
these studies have been limited in sample size [312]. As the sizes of the effect estimates may 
be expected to be modest [275], these could be easily obscured by the random error introduced 
in small studies   
Although studies report that some risk factors are associated with white blood cell 
methylation levels, there are few consistent patterns [312]. These patterns may be further 
obscured by the type of marker used and different sources of DNA.  In addition, repetitive 
element methylation levels are averages of methylation at different locations in the genome 
[275]. They are surrogate measures of total global methylation and may be influenced by 
different, simultaneous, hypo- and hyper- methylation processes that occur and thus, any effect 
may be obscured [275]. Despite the limitations addressed here, there is reasonable evidence to 
suggest that global DNA methylation is an important marker of genomic instability and may 
impact breast cancer incidence or susceptibility.   
Summary. It is hypothesized that genome-wide hypomethylation may result in 
chromosomal instability, a potential tumorigenic event [265], that increases the likelihood of 
mutations, genetic recombination, deletions or translocations [265, 283, 308]. Blood DNA 
methylation alterations have been associated with exposure to environmental and lifestyle risk 
factors for cancer and thus it is hypothesized that blood methylation may provide a useful 
biomarker for cancer risk [273, 300]. However, predictors of global DNA methylation have not 
been consistent, likely due to variable measurement methods, small sample sizes and cross-
sectional study designs [312]. LINE-1 hypomethylation has not been shown to have consistent 
associations with breast cancer with all [292, 297, 301, 313, 337], but one [338], not finding a 
strong association. In this study population, there was no association with LINE-1 and breast 
cancer risk but a strong association between hypermethylation and breast cancer risk using the 
LUMA assay [297].   
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1.3.3 Gene-Specific DNA Methylation 
Another method of measuring and evaluating DNA methylation is to focus on specific gene 
regions, with most studies focusing on gene-specific promoter regions [266]. Most CpG sites in 
the genome tend to be methylated under normal conditions except those sites within CpG 
islands that are located 5’ to the promoter and exon 1 [339]. DNA methylation patterns are 
important in maintaining tissue- and time-specific gene expression, as well as the establishment 
and maintenance of imprinted genes [340]. The disruption of these healthy, normal patterns of 
methylation has been found to be important in carcinogenesis [281]. Typically, studies report a 
shift towards increased, or hypermethylation, at CpG islands even in the context of an overall 
loss of methylation (hypomethylation) as discussed above [281]. In contrast to global 
methylation which is thought to result in chromosome instability, gene-specific promoter 
methylation is thought to play a role in carcinogenesis by directly altering gene expression [341]. 
DNA methylation can independently prevent binding of DNA polymerase and transcription 
factors or interact with histone modifications and chromosome remodeling mechanisms that 
lead to a gene being silenced [342].  
Gene promoter hypermethylation is a common event and appears to occur at least as 
frequently as genetic mutations in somatic cells [342]. Specifically, silencing of tumor 
suppressor genes by tumor hypermethylation is known to be a common event in 
carcinogenesis, hypothesized to provide a selective growth advantage to tumor cells [281]. 
Gene-specific methylation is often measured in tissue samples, but also can be measured in 
blood [312].  A review of four studies comparing methylation levels in tumor and blood samples 
from breast cancer cases show good concordance (average concordance of 84%) [281]. This 
research has led to the paradigm of considering hypermethylation to be associated with gene 
silencing [266]. However, methylation at non-CGIs and at other sites in the gene (enhancers, 
insulators, repetitive elements and gene bodies) has unknown effects on transcription [266]. 
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Gene-Specific Methylation in Non-Tumor Tissue. Studies reporting levels of 
methylation at promoter regions in non-diseased populations are limited.  In a healthy 
population, promoter methylation levels of genes measured in DNA from plasma samples 
reported in one study were as follows: APC (7%), CCND2 (22%), GSTP1 (2%), 
MGMT (9%), RARβ2 (29%)  and P16 (3%)[343]. Similarly, a study measuring methylation in 
fine-needle aspiration biopsies from a small sample of unaffected women (n=55) detected 
promoter methylation of RARβ2 (9%), APC (26%), H-cadherin (17%) and RASSF1A (37%) 
[287].  Gene specific promoter methylation has also been measured in the tissue of women 
without breast cancer using reduction mammoplasty tissue. For example, 47% of women 
undergoing reduction mammoplasty (n=15) displayed promoter methylation of p16; however, 
the methylation was differentially expressed in ductal and lobular tissue, but not in myoepithelial 
or stromal cells [344] consistent with the hypothesis that methylation differs across tissue types. 
In another study of women undergoing reduction mammoplasty, there was promoter 
hypermethylation in p16 (31%), BRCA1 (17%) and ER-α (9%)[345]. Therefore, a certain level of 
methylation even among tumor suppressor genes may be expected to maintain healthy cellular 
function.  
Predictors of Gene-Specific Methylation. The predictors of gene-specific methylation 
are not consistent or well-established [312]. Methylation of tumor suppressor genes in benign 
breast epithelium has been shown to increase with age [346]. The Sister Study reported 
approximately 28% of over 27,000 CpG sites measured in white blood cells were associated 
with age; many CpG sites were subsequently confirmed using other independent datasets and 
were also found to be hypermethylated in a variety of tumor types [347]. Gene-specific 
methylation has been associated with demographic factors, as well as environmental and 
lifestyle factors in white blood cells [312] and in plasma [343].  For example, gene-specific 
promoter methylation measured in white blood cells (WBC) has been associated with benzene 
exposure [324, 348], air pollution [329], arsenic [349, 350], cigarette smoking [351] and alcohol 
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drinking [321] . Similarly, alcohol and folate intake has been found to be independently 
associated with breast tumor DNA methylation profiles [352]. In addition to folate intake, a diet 
with high-fat intake has been associated with RARβ methylation in tissue [343].  
Gene-Specific Methylation and Breast Cancer. Research on gene-specific 
methylation with breast cancer has further supported the hypothesis that methylation is an early 
event in carcinogenesis. Gene-specific methylation is thought to occur at least as frequently as 
somatic mutations [342]. RASSF1a, CCND2, TWIST and HIN1 have been found to be 
methylated in adjacent non-tumor tissue, although levels were less than in tumor tissue [353]. 
This is consistent with other studies that have reported methylation in adjacent normal tissue 
[354]. Methylation has been detected in both lobular and ductal in situ carcinomas [353, 355] 
and in early stage (0 or I) breast cancer [356, 357]. One report found that women with benign 
breast disease lesion had an intermediate level of methylation (using a panel of RASSF1a, 
RARβ2, APC and CCND2) when compared to women with breast cancer and control women 
[287]. Similarly, Pu et al., [288] found an increased frequency of methylation of RARβ, 
RASSF1a, CCND2 when comparing benign and in situ tissue to invasive breast cancer. Studies 
have also reported that methylation progresses with stage [358].   
Studies have investigated the ability of methylation to differentiate between benign 
breast disease, which may be a precursor lesion, and breast cancer but results have been 
inconsistent [287, 288, 354]. Methylation has also been shown to increase with risk of breast 
cancer as calculated by the Gail model [287]. Studies have reported frequent methylation of 
genes involved in cell cycle regulation (p16(INK4A), p14(ARF), p15, CCDN2, DAPK), DNA 
repair (MGMT, hMLH1), detoxification (GSTP1), signal transduction (RARβ2, APC, ERB) and 
adhesion and metastasis (CDH1, CDH13) in breast cancer [281].  In the case of breast cancer, 
no single gene has been found to be consistently methylated across all breast cancers [281]; 
suggesting that to best understand DNA methylation and its impact on health outcomes requires 
using a panel of methylation sites. Different methylation sites may also act on carcinogenesis in 
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different ways and help to facilitate the novel capabilities a cell has to have to become 
cancerous [274]. For example, methylation at specific genes may influence the replicative 
potential of cells (p16ink4a, cyclin D2, GSTP1), the self-sufficiency of growth signals (ERa, ERb, 
PGR, RASSF1a), insensitivity to anti-growth signals (HIN1), the influence evasion of apoptosis 
(DAPK, TWIST) and invasion and metastasis (APC and E-Cadherin) [274].  
There is also evidence that methylation changes may be particularly associated with 
specific breast cancer tumors subtypes over others [359, 360]. For example, presence of 
methylated ESR1 has been associated with ER- tumors [360]. These results suggest that 
differential methylation may have a role that is heterogeneous across breast cancer tumor 
subtypes.  
The LIBCSP measured gene-specific promoter methylation in a panel of breast cancer-
related genes including ESR1, PGR, BRCA1, APC, p16/CDKN2a, HIN1, RASSF1a, DAPK1, 
GSTP1, CCND2, TWSIT1, CDH1 and RARβ. In the LIBCSP, many promoter methylation sites 
(GSTP1, TWIST, RARβ, BRCA1, APC and p16 ) were significantly associated with higher 
breast cancer-specific mortality [361-363]. In addition, GSTP1 and RARβ were significantly 
associated with higher all-cause mortality [363]. The number of methylated genes was also 
associated with breast-cancer specific mortality [363]. HIN1 and RASSF1a were significantly 
associated with having a positive ER and positive PR tumor subtype status as determined by 
immunohistochemistry [363]. RARβ was associated with negative PR status [363].  
Limitations. Previous research on the predictors and outcomes associated with gene-
specific methylation has had a number of limitations. The most significant of which is the lack of 
reproducibility of results. Even though a number of studies have been conducted investigating 
gene specific methylation, the lack of a standardization of methylation methods has resulted in 
relationships often not being reproducible [281]. Studies have used variable methods of DNA 
methylation assays, measured different genes or even different CpG sites within genes and 
relied on different sources of DNA (such as serum, plasma, tissue, tumor biopsy) [281]. In 
 54 
addition, many of these studies are cross-sectional [312] which complicates any interpretation of 
temporality between environment and lifestyle factors with DNA methylation and limits 
understanding of when these methylation changes are occurring. Finally, many studies have a 
modest sample size which may obscure findings [281]. However, even more so than with global 
methylation, there is sufficient evidence that gene-specific methylation is a common and likely 
early event in breast cancer and may be directly impacted by environmental exposures.  
Summary. DNA methylation patterns are important in maintenance of normal cell 
functioning and disruption of these patterns may contribute to cancer risk [340]. Studies tend to  
report a shift towards hypermethylation at CpG islands [281] which may directly alter gene 
expression [341]. Similar to global methylation, the predictors of gene-specific methylation are 
not consistent or well-established [312]. There is some evidence for aberrant DNA methylation 
in response to certain exposures, such as cigarette smoking [351]. Research with gene-specific 
methylation with breast cancer has further supported the hypothesis that methylation is an early 
event in carcinogenesis and may be associated with certain tumor types over others [359, 360] 
as well as differential all-cause and breast cancer-specific mortality [361-363] .  
1.3.4 DNA Methylation and Polycyclic Aromatic Hydrocarbons 
Both PAH and DNA methylation have been found to be individually important for breast cancer 
risk, however the relationship between these factors and the resulting impact on breast cancer 
risk has yet to be investigated. This section will consider the existing biological and 
epidemiological research that has investigated PAH exposure sources and DNA methylation 
which support the hypothesis of this dissertation that DNA methylation may play an important 
role in this association. The flexibility of the epigenome has generated a strong interest in 
evaluating the direct epigenetic alterations that result from environmental exposures [11], and 
thus, much of the research to date has focused on the impact of PAH exposure on methylation.   
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Biology of PAHs and DNA Methylation. An association between PAH and DNA 
methylation alterations is biologically plausible. B[a]P has been shown to result in changes in 
DNA methylation in vitro [364]. Interestingly, benzo[a]pyrene diolepoxide (B[a]PDE), the 
activated form of B[a]P) reacts preferentially (3-10 fold) with guanines that are followed by 5-
mC, suggesting a potential synergistic relationship [365, 366]. DNA methylation may promote 
spontaneous deamination, enhance DNA binding of carcinogens such as PAH, and increase 
ultraviolet absorption by DNA, all mechanisms that may result in increased DNA adduct 
formations and gene inactivation [367]. Thus, it is biologically plausible that PAH-DNA adducts 
and methylation may have a synergistic impact on breast carcinogenesis. In addition, a study of 
prolonged B[a]P exposure in mouse embryonic fibroblasts found global DNA hypermethylation 
to be associated with DNA-methyltransferase (DNMT) overexpression, the enzyme that 
catalyzes DNA methylation reactions [368]. Experimental research suggests that DNMTs bind to 
DNA lesions with high affinity when there are high levels of DNA damage [369], which might 
result in increases in methylation in association with PAH adduct levels.  
Adult PAH Exposure Sources and Aberrant DNA Methylation. Both global and gene-
specific aberrant DNA methylation have been demonstrated in occupationally and heavily PAH 
exposed individuals, such as coke-oven workers and firefighters. Among occupational-exposed 
workers, inconsistent results have been reported including both hyper- and hypo-methylation 
changes being measured in global markers [370, 371]. Occupational PAH exposure has also 
been linked with multiple gene-specific promoter methylation without a consistent direction of 
change [370, 372-375]. Although not an occupational source of PAH exposure, 
hypermethylation of the p16 gene was also observed in patients very highly-exposed to indoor 
unventilated-stove coal use in China [349]. 
Few studies have investigated associations between DNA-adducts and global DNA 
methylation changes and most were conducted in either special or highly exposed study 
populations. For example, a previous study found positive associations between global 
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methylation levels measured in infant cord blood and the presence of BaP adducts[376].  Other 
reports observed positive associations with global methylation markers and adduct levels in 
occupationally exposed workers [371, 377].  In the LIBCSP, we have found a positive 
association between PAH-DNA adducts and LINE-1 methylation among ambiently-exposed 
controls [378]. Our results contrast with another study that used a urinary metabolite of PAH as 
an exposure marker and found the metabolite to be negatively correlated with LINE-1 [370]. 
However, this biomarker likely reflects very recent exposure levels rather than biological 
susceptibility and DNA damage that is incorporated into the blood adduct measure [121].   
 For gene-specific methylation, a report has linked DNA adducts and RASSF1a  
hypermethylation measured in hepatocellular tumors [379] but not GSTP1 [380]. Bulky DNA 
adducts were associated with HIC1 methylation [374] and negatively correlated with p53 and IL-
6 methylation measured in peripheral blood samples [377]. Among cases in the LIBCSP, 
detectable PAH-DNA adducts were found to be significantly associated with HIN1 promoter 
methylation levels [378]. Therefore, any associations between adducts and gene-promoter 
methylation is likely site-specific.  
Cigarette smoking and air pollution, both ambient PAH sources, have been 
demonstrated to be associated with aberrant changes in DNA methylation. The air pollution and 
DNA methylation body of research has focused on associations with non-PAH components of 
air pollution, in particular particulate matter [312]. Studies investigating PAH exposure in the 
general population have predominately investigated the impact of cigarette smoke on blood 
DNA methylation [351, 374, 381-391].  However, results have been inconsistent with global 
methylation changes measured in WBC in association with adult active smoking with most 
studies reporting a null association [275, 292, 296, 314, 318, 320, 325, 392-394], but  two 
studies did report decreased global methylation in association with adult cigarette smoking [388, 
390]. There have been some reports of active smoking in association with gene-specific 
promoter methylation [395]  and increasingly more results with the use of array methylation 
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technology with more extensive CpG coverage [351, 382, 385, 387]. Cigarette smoking and 
exposure to ETS has also been associated with methylation changes in tumors of the bladder 
[396], esophagus [397], upper-aerodigestive tract [398] and lung [399, 400] as well as in oral 
tumors [401] and head and neck tumors [402]. More consistent methylation changes have been 
reported with more detailed exposure information on cigarette smoking, such as cumulative 
smoke exposure and time since quitting [381, 384, 391] and there has been some evidence of 
dose-response relationships [374, 389].   
DNA Methylation as a Modifier. There have been fewer studies investigating DNA 
methylation, environmental exposures and health outcomes using an effect-modification model 
[11] compared to the number of studies investigating direct associations with PAH exposure. As 
Bollati and Baccarelli state in their review, researchers ‘should apply epigene-environment 
interactions’ as they do with gene-environment interactions [11]. Similar to the effect 
modifications postulated for genetic polymorphisms, epigenetic differences could result in 
individuals being more vulnerable to environmental exposures [11].  
Although there has been some consideration of methylation interacting with air pollutants 
on respiratory outcomes [403] and protein levels [404], very few studies have considered that 
DNA methylation may interact with PAH exposure and cancer risk. The Spanish Bladder Cancer 
Study investigated global methylation levels using 5-mdC and interaction with smoking status. 
They found current smokers in the lowest methylation quartile had the highest risk compared to 
never smokers in the highest methylation quartile (OR=25.51, 9.61-67.76, P for interaction 0.06) 
[314]. A previous study by Choi and colleagues (2009), assessed a statistical interaction 
between ever/never smoking and global methylation measured using 5-mdC and found  the 
highest risk in never smokers with the lowest tertile of methylation (OR=6.02, 95%CI 2.229, 
15.78) compared to those in the highest tertile of methylation [292]. Women who were smokers 
and in the lowest teritle had a lower odds of breast cancer (OR=1.97, 95%CI 0.89-4.39) (P for 
interaction=0.08) [292]. However, in the LIBCSP the association between LUMA and breast 
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cancer risk did not differ by smoking status (ever/never) [297]. This discrepancy is likely due to 
the fact that LUMA is best interpreted as a summary of gene-specific methylation rather than 
global methylation levels.  
In this dissertation, I utilized both approaches suggested by Bollati and Baccarelli (2010) 
to better understand the environmental epigenetic changes that may be impacted by PAH 
exposure and their resulting association with breast cancer risk. I considered global DNA 
methylation as a modifier (AIM 2A) in the relationship between PAHs exposure patterns and 
breast cancer with the hypothesis that global DNA methylation may result in an increased 
susceptibility to PAH sources. For AIM 2B, I considered the direct associations between the 
PAH sources and gene-specific DNA methylation measured in the tumor tissue; with the 
hypothesis that PAH exposures may be directly altering the gene-specific methylation levels.  
Summary. DNA methylation may play an important role in the association between PAH 
and breast cancer. This hypothesis is supported by the fact that in vitro studies show that B[a]P 
has been shown to result in aberrant DNA methylation [364]. Epidemiologic studies of high PAH 
exposed individuals demonstrated that PAH may impact DNA methylation changes in humans 
[349, 370, 372-375]. Additionally, there has been evidence of associations between bulky DNA 
adducts and aberrant methylation [371, 377]. Among the general population, cigarette smoking 
and air pollution exposures have been found to be associated with DNA methylation levels[312]. 
While DNA methylation has often been investigated as a potential mediator between 
environmental exposures and health outcomes, it is not considered frequently as a modifier [11]. 
Evaluating methylation both as an outcome in association with PAH exposure as well as a 
modifier of the PAH-breast cancer relationship as advocated in a recent review [11] may provide 
a better understanding of the role DNA methylation plays in this association. 
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1.3.5 Summary and Conclusions 
DNA methylation, specifically, is the addition of a methyl group to cytosines within CpG 
dinucleotides and can result in some alteration of gene expression [266]. These changes are 
stable and heritable as cells replicate [11]. Gene methylation can be measured on a ‘global 
level’, often measured using methylation at repetitive transposable elements. In addition, 
methylation can be measured at specific genes and specific regions within a gene. DNA 
methylation may be largely determined by genetics and early life or in utero exposures [272]. 
However, DNA methylation at certain genes does appear to be influenced at least in part by 
environmental and lifestyle factors [273-277]. It hypothesized that genome-wide 
hypomethylation may induce chromosomal instability, whereas gene-specific DNA methylation 
at promoter regions are indicators of the gene being silenced. Both gene-specific and global 
methylation are thought to be an early, causative events in carcinogenesis [274, 285, 286] 
LINE-1 hypomethylation has not been shown to have consistent associations with breast 
cancer, with most studies not reporting a significant association [292, 297, 301, 313, 337], but 
one prospective study found a significant association [338]. LIBCSP found a null association 
with LINE-1 and breast cancer risk but a strong positive association between hypermethylation 
and breast cancer risk using the LUMA assay [297], although LUMA is better interpreted as a 
summary measure of gene-specific promoter methylation.  Inactivation of tumor suppressor 
genes by increased promoter methylation is a common epigenetic alteration in breast 
carcinogenesis, which has been observed in our own studies as well as others [274, 288, 405-
408] . LIBCSP has reported that several gene methylation levels are significantly associated 
with higher breast cancer-specific and all-cause mortality and differentially associated with 
hormone receptor status [363].  
The biological samples as well as the analytic methods used to measure DNA 
methylation vary widely across studies. As such, a significant limitation of this line of research is 
the lack of reproducibility of results. In the case of breast cancer, no single gene has been found 
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to be consistently methylated across all breast cancers [281], suggesting that to best 
understand DNA methylation and its impact on health outcomes will require using a panel of 
methylation sites. There is also evidence that methylation changes may be particularly 
associated with some specific breast cancer tumor subtypes over others [359, 360]. 
Experimental and epidemiologic studies suggest that PAHs may induce DNA 
methylation changes [312, 364], although epidemiologic research has been very inconsistent on 
the association between smoking and methylation [312]. However, it is also possible that DNA 
methylation profiles might result in an increased or decreased susceptibility to an environmental 
exposure and their impact on breast cancer risk [11, 314].  Only one previous study investigated 
an interaction between smoking and breast cancer risk [292]; and conclusions were limited by 
only considering global methylation and one single PAH source. This study investigated the role 
of global methylation (1) as a modifier of the association between PAH sources and breast 
cancer risk in cases and controls; and (2) the direct association between PAH exposure sources 
and gene-specific methylation among case women.  I am strongly poised to address this 
research question as I was able to incorporate multiple PAH exposure sources as well as utilize 
a panel of DNA methylation markers.  
1.4 Summary and Conclusions 
Breast cancer is the most commonly diagnosed cancer among women in the U.S. [5]. While 
many risk factors for breast cancer are known, many are not modifiable in an effort to reduce 
risk. Research suggests that established risk factors may vary by menopausal status and tumor 
subtype, suggesting differential etiology [98, 108, 409]. Environmental exposures are suggested 
by many as promising modifiable risk factors [52]. PAHs are formed from incomplete 
combustion of organic materials [66, 67] and are established carcinogens on the lung[68] and 
can induce mammary tumors in animal models [69]. Individuals in the general population are 
continuously exposed to ambient levels of PAHs. 
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Despite studies demonstrating associations between single PAH exposure sources 
(including tobacco smoke [72-79], grilled/smoked meat intake [230] and vehicular traffic 
emissions [83-86]) and breast cancer risk, the relationship between PAH and the human breast 
is not well understood. Progress has been hindered by inadequate exposure assessment, which 
has often relied on either short-term biomarkers or individual sources of PAHs. Although PAH 
biomarkers (i.e., PAH-DNA adducts) have been consistently linked to breast cancer [87-92], 
biomarkers cannot discern exposures that occurred in the distant past or during susceptible 
windows of exposure. No study has examined multiple PAH source exposures in association 
with breast cancer risk, which would better mimic the complexity of PAHs. Epigenetic changes, 
in particular DNA methylation, may be important for breast carcinogenesis [274].   
The hypothesis of this dissertation was that life course exposure to PAHs, evaluated 
using patterns of long-term exposure to PAHs from predominant sources (vehicular traffic, 
active smoking and environmental tobacco smoke, grilled/smoked food intake and residential 
use of indoor stoves/fireplaces), increases the risk of developing breast cancer.  Global 
methylation, a marker of genome stability [410], was hypothesized to be an effect measure 
modifier of the PAH and breast cancer relationship. Additionally, I investigated whether PAHs 
were directly associated with gene-specific methylation levels in the tumor. To address the first 
aim, I utilized an innovative approach of hierarchical regression, to estimate associations with 
exposure profiles of long-term PAH exposure. This dissertation was conducted using the case-
control resources from the LIBCSP, a population-based study with existing global and gene-
specific promoter methylation data and extensive, individual-level PAH exposure information 
over the life course assessed using an interviewer-administered questionnaire structured to 
maximize recall. 
PAHs are potentially modifiable breast cancer risk factors and exposure is complex and 
ubiquitous. Results from this study have the potential to identify subgroups of women whose 
exposure to PAHs might be most detrimental to their risk of breast cancer.  Due to the extensive 
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prevalence of PAHs, there are multiple major sources of PAHs that can be targeted by 
prevention strategies. The study aims are defined and described below.  
1.5 Research Aims, Hypotheses and Study Rational 
This dissertation examines the association between PAH sources incorporating the following: 
active smoking, environmental tobacco smoke, grilled/smoked meat intake, vehicular traffic and 
use of indoor stoves/fireplaces with breast cancer risk.  In addition, this dissertation investigated 
the role of gene-specific and global DNA methylation in the PAH-breast cancer relationship. 
Investigating multiple PAH exposures and incorporating DNA methylation aims to better explain 
the relationship of PAHs with breast cancer and result in an improved understanding of the role 
that DNA methylation plays in the association between PAH and breast cancer.   
Specific Aim 1: Long-term Ambient PAH Exposure and Breast Cancer 
Specific Aim 1.  Determine whether long-term exposure to PAH from multiple sources 
(active smoking, environmental tobacco smoke, indoor air pollution, vehicular traffic, and 
grilled/smoked foods) is associated with breast cancer incidence. 
 Hypothesis:  Profiles of high exposure levels across multiple PAH sources will be 
associated with breast cancer risk.  
 Rationale: PAHs are formed from incomplete combustion of organic materials [66, 67] 
and are a potential modifiable breast cancer risk factor. PAHs are established carcinogens on 
the lung [68] and can induce mammary tumors in animal models [69].  Individuals in the general 
population are continuously exposed to ambient levels of PAHs. Ambient PAH exposures are 
constant and originate from multiple sources, with the most predominant being traffic emissions 
[41], tobacco smoke [148], indoor stoves [262], smoked and grilled foods and leafy vegetables 
[67, 68, 240]. Despite studies, including those in this study population, demonstrating 
associations between single PAH exposure sources (including tobacco smoke [72-79], 
grilled/smoked meat intake [230], indoor air pollution from synthetic fire logs [175] and vehicular 
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traffic emissions [83-86, 192]) and breast cancer risk, the relationship between PAH and the 
human breast is not well understood. To the best of my knowledge, no previous study has 
examined multiple PAH source exposures, which would better mimic the complexity of 
exposure. 
Specific Aim 2: Long-term Ambient PAH Exposure and Breast Cancer: Exploration of 
DNA Methylation 
 Specific Aim 2A:  Determine whether the association between individual PAH sources 
and breast cancer incidence is modified by global methylation. 
 Hypothesis:  I hypothesized that global methylation, a marker of genome instability [410],  
will interact with PAH exposure sources that were previously found to have the strongest 
associations with breast cancer, to influence breast cancer risk.  
 Rationale: PAHs have been associated with global DNA methylation alterations in both 
animal and human studies [371, 373, 411]. However, it is also of interest to determine whether 
DNA methylation profiles result in subgroups more susceptible to environmental exposure [11].  
One study has investigated an interaction between global methylation and active smoking in 
respect to breast cancer risk and found an increase in risk among nonsmokers with the lowest 
level of global methylation [292]. In LIBCSP, no interaction was observed between active 
smoking and LUMA in respect to breast cancer risk [297]. However, no previous study has 
evaluated the hypothesis that global DNA methylation may interact with PAH exposure to 
influence breast cancer risk when taking into account multiple PAH sources.   
Specific Aim 2B: Explore whether individual PAH sources are associated with breast 
cancer incidence, when breast cancer subtypes are defined by methylation status of the tumor. 
 Hypothesis: I hypothesized that one or more gene-specific promoter methylation levels 
will be associated with sources of PAH exposure, when considering those previously found to 
have the strongest associations with breast cancer. 
 Rationale: Inactivation of tumor suppressor genes by promoter methylation is a common 
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epigenetic alteration in breast carcinogenesis, which has been observed in our own studies as 
well as others [274, 288, 405-408]. PAH exposure has also been associated with gene-specific 
DNA methylation alterations in animal and human studies [371, 373, 411]. However, no 
previous studies have investigated multiple PAH exposure sources in association with promoter 
DNA methylation. Because epigenetic effects are considered to be a result of both one’s 
inherent genetic profile as well as environmental influences on the genome [412], this could 
provide evidence on another mechanism by which PAHs may influence breast cancer risk.  
1.6 Potential Public Health Impact 
Breast cancer has a significant burden in this country, due to both high incidence and mortality 
[8]. PAHs are potentially modifiable breast cancer risk factors and exposure is complex and 
ubiquitous [4]. While individual PAH sources have been linked to breast cancer [4], without 
investigating across the many sources women are exposed to in daily life it is difficult to make 
an argument for ambient PAH reduction. Additionally, by examining the role of DNA methylation, 
the results of this dissertation may also provide evidence for an epigenetic mechanism which 
could also inform the biology of this, as well as other environmental risk factors and disease 
associations. Due to the extensive prevalence of PAHs [41], there are multiple major sources of 
PAHs that can be targeted by prevention strategies. If DNA methylation is found to have a 
significant role in this relationship, it is another potentially modifiable factor that could be used in 
screening programs or possibly public health strategies to remedy irregular but elastic DNA 
methylation patterns.  
  
 
6
5
 
 
Table 1.1 Previous epidemiologic investigations of PAH sources in association with breast cancer risk not in the LIBCSP 
study population 
PAH Source First Author Year Study Design Population 
Exposure 
Assessment Finding Comments 
Indoor Stove/ 
Fireplace Use N/A N/A N/A N/A N/A N/A 
        
Vehicular 
Traffic and 
other sources 
of airborne 
PAH 
Lewis-Michl 
[84] 1996 
Population-
based Case-
Control  
Female residents 
of 20+ years in 
Nassau and 
Suffolk counties, 
New York 
GIS using 1990-1992 
NYDT traffic data 
aggregated at 25km2 
grids to determine 
residential traffic 
density  
Elevated point estimates 
for high traffic density (top 
5%) in Nassau county only 
(premenopausal women 
OR=1.24, 95%CI 0.41, 
3.73; postmenopausal 
women OR=1.33, 95%CI 
0.80, 2.21) 
Same 
geographic 
location as  
current study 
Bonner [86] 2005 
Population-
based  Case-
Control  
The Western New 
York Exposures 
and Breast Cancer 
Study, Erie and 
Niagara Counties,  
New York 
Annual average total 
suspended 
particulates (TSP) at 
residences  
High TSP at birth was 
associated with 
postmenopausal breast 
cancer (OR=2.42 95%CI 
0.97-6.09). No consistent 
associations among 
premenopausal  
Considered early 
age at exposure  
Nie [85] 2007 
Population-
based Case-
Control  
The Western New 
York Exposures 
and Breast Cancer 
Study, Erie and 
Niagara Counties,  
New York 
Geographic traffic 
exposure model 
estimated PAH 
exposure using 
benzo[a]pyrene as a 
surrogate for total 
PAH at residences 
Exposure at menarche 
was associated 
premenopausal OR=2.05, 
(95%CI 0.92, 4.54); 
exposure at time of first 
birth was associated with 
postmenopausal 
(OR=2.57, 95%CI 1.16-
5.69) 
Exposure model 
similar to one 
used in current 
study. 
Considered early 
life exposure.  
Association 
found to be 
limited to lifetime 
nonsmokers 
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Crouse [83] 2010 
Hospital-
based Case-
Control  
Female residents 
of the greater 
Montreal area  
Ambient residential 
nitrogen dioxide 
concentrations as a 
proxy for traffic 
pollution using 
pollutant monitoring 
data and land-use 
regression models 
Positive but modest 
associations reported for 
higher concentrations of 
ambient nitrogen dioxide 
gas with postmenopausal 
breast cancer. 
Association 
stronger after 
adjustment for 
confounding and 
when limited to 
those who lived 
at the same 
address for at 
least 10 years 
Raaschou-
Nielsen [188] 2011 Cohort  
Diet, Cancer and 
Health Cohort 
study, residents of 
Copenhagen and 
Aarhus area 
Modeled 
concentrations of 
nitrogen oxides and 
amount of traffic at 
the residence 
(defined by crude 
variables indicating 
nearby traffic) 
Positive association 
reported with breast 
cancer risk, adjusted 
OR=1.15 (95%CI: 0.89, 
1.51). 
Estimate 
attenuated after 
adjustment for 
confounders.  
Chen [190] 2012 Ecological SEER 
Emission data for 
seven pollutants from 
the EPA at the USA 
national level.  
Correlation of breast 
cancer trend with NOx, an 
indicator of air pollution.  
Motor vehicles 
are the major 
source of NOx  
Wei [189] 2012 Ecological SEER 
Emission data from 
the EPA at the USA 
national level and 
state emissions of 
NOx. 
Multiple traffic-related 
pollutants were associated 
with the incidence of 
breast cancer.  
Higher incidence 
reported in 
metropolitan 
areas  
 Hystad[191] 2014 
Population-
based Case-
Control 
National 
Enhanced Cancer 
Surveillance 
System (Canada) 
Mean exposure 
levels to traffic-
related air pollution 
was derived from 
1975-1994. NO2 was 
used as a proxy for 
traffic exposure. 
Positive association using 
land-use regression 
models, with estimates 
more pronounced for 
premenopausal breast 
cancer risk.  
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Grilled/ 
Smoked/ 
Barbecued 
Meat 
Gertig [237] 1999 Cohort  
Nurses' Health 
Study 
FFQ, specifically 
asked about the 
frequency of cooking 
meat pan fried, 
roasted, barbecued, 
broiled and stewed.  
Intake of barbecued or 
charred meat was not 
associated with breast 
cancer risk.  
Exposure was 
evaluated for the 
past year.  
Delfino [236] 2000 
Hospital-
based Case-
Control  
Cases and 
controls were 
identified by 
suspicious breast 
mass 
Dietary intake 
questionnaire on type 
and frequency of 
meat intake and 
method of cooking  
No association for any 
type of meat intake or 
cooking method with 
breast cancer risk. 
Exposure was 
evaluated for the 
past year.  
Holmes [238] 2003 Cohort  
Nurses' Health 
Study 
FFQ, specifically 
asked about charred 
meat from 
barbecuing or broiling 
No increase in risk for 
intake of charred meat.  
Exposure was 
evaluated for the 
past year.  
Kabat [235] 2009 Cohort  
NIH-AARP Diet 
study 
Questionnaire on 
meat intake and 
usual cooking 
method 
No increase in risk for 
intake of grilled or 
barbecued meat.  
Intake was 
evaluated for the 
past year.  
Ferrucci [82] 2009 
Randomized 
Controlled 
Trial 
PLCO Cancer 
Screening Trial 
Diet was assessed 
using Diet History 
questionnaire and the 
NCI FFQ. 
Reported an increase for 
grilled meat (HR=1.10, 
95%CI 0.90, 1.34); for a 
combined exposure group 
of  grilled/pan 
fried/well/very well done 
meat (quintile 5 vs. quintile 
1, HR=1.20 95%CI 0.99-
1.45) 
Did not report an 
increase in risk 
for a B[a]P 
index.  
Fu [80] 2011 
Population-
based Case-
Control 
Nashville Breast 
Health Study 
Frequency of meat 
intake and cooking 
method was 
assessed by 
questionnaire  
Increase in risk for grilled 
meat  intake (quartile 4 vs. 
quartile 1, OR=1.6, 95%CI 
1.3-1.9), 
Did not report an 
increase in risk 
for a B[a]P 
index.  
Di Maso [81] 2013 
Hospital-
based Case-
Control 
Integrated series 
of Italian case-
control studies 
FFQ, with specific 
items on different 
cooking methods.  
Roasting or grilling meat 
was associated with an 
increase in risk of breast 
cancer OR=1.20 (1.32-
2.34) 
Association 
attenuated with 
other cooking 
methods.  
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 Mourouti[239] 2014 Case-control 
Women in Athens, 
Greece and 
surrounding areas 
FFQ, grilled meat 
intake in last year 
prior to diagnosis 
No association with grilled 
meat (data not shown). 
Intake was 
evaluated for the 
past year.  
        
Active 
Smokinga 
Gaudet [72] 2013 
Cohort/ Meta-
Analysis 
American Cancer 
Society Cancer 
Prevention Study 
II and Meta-
Analysis of 14 
other cohort 
studies 
Smoking history was 
collected by 
questionnaire, 
including average 
number of cigarettes 
per day, age when 
they started and 
duration 
Increase in risk for current 
(OR=1.12, 95%CI 1.08, 
1.16) and former smokers 
(OR=1.09, 95%CI 1.04, 
1.15).  Increase risk for 
initiating smoking <first 
birth (OR=1.21, 95%CI 
1.14, 1.28). 
Most recent 
meta-analysis on 
active smoking.  
Rosenberg 
[213] 2013 Cohort 
Black Women's 
Health Study 
Smoking history, age 
started, frequency 
and duration 
collected by 
questionnaires.  
Active smoking was 
associated with an 
increased risk for 
premenopausal (IRR=1.21, 
95%CI 0.90-1.62) and 
association was stronger 
for starting prior to 18 
years of age, 20+ years of 
smoking (OR=1.70, 95%CI 
1.05-2.75)  
Association was 
strongest for 
ER+ cancers 
Gao [214] 2013 
Population-
based Case-
Control Chinese women 
Questionnaire 
assessed personal 
smoking and smoking 
of husbands.  
Ever smokers had an 
increase in breast cancer 
risk (OR=3.55, 95%CI 
1.27, 9.91) 
Cotterchio 
[215] 2014 
Population-
based Case-
Control 
Ontario Women's 
Diet and Health 
Study 
Questionnaire on 
active  cigarette 
smoking history 
(years, pack-years, in 
relation to first 
pregnancy) 
increased premenopausal 
breast cancer risk was 
observed among current 
smokers (OR=1.42, 95%CI 
0.75, 2.69) and women 
smoking before first 
pregnancy (OR=1.44, 
95%CI 0.75, 2.69) 
A supplemental 
questionnaire on 
passive smoking 
was used, but 
no effect 
estimates for 
passive smoking 
were reported. 
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Catsburg 
[218] 2014 Cohort 
Canadian Study of 
Diet and Health 
Detailed tobacco 
history was assessed 
via questionnaire 
including current 
status, age at start 
and cessation, extent 
of inhalation, number 
of cigarettes/day and 
any cigar and pipe 
smoking 
Null associations reported 
between all characteristics 
of active smoking history 
and breast cancer risk. 
Authors had no 
information on 
ETS and 
therefore were 
unable to 
exclude ETS 
exposed 
individuals from 
the referent 
group.  
Kawai[217] 2014 
Population-
based Case-
Control 
Young women in 
Seattle-Puget 
Sound 
Metropolitan Area  
Questionnaire assed 
smoking history, 
including ages, 
duration, years since 
quitting 
Ever smokers had an 
increase in risk overall 
(OR=1.3, 95%CI 1.1, 1.7). 
Risk was highest among 
women with ER+ breast 
cancer, and current/past 
smokers with >10 pack-
year history (OR=1.6, 
95%CI 1.1, 2.4) 
Risk was also 
increased for 
smoking prior to 
first birth. 
        
ETSa 
Yang [220] 2013 Meta-analysis 
10 prospective 
cohorts 
Questionnaire 
assessment of 
passive smoke 
history 
Meta-analysis found a null 
association with ever  
passive smoking- 
combined RR=1.01, 
95%CI 0.96, 1.06  
Most recent 
meta-analysis on 
ETS.  
Rosenberg 
[213] 2013 Cohort 
Black Women's 
Health Study 
Passive smoke 
exposure was 
measured at home 
and work 
Women exposed to 
passive smoke had an 
increase in risk of premenp 
breast cancer (IRR=1.42, 
95%CI 1.09-1.85).   
Association was 
strongest for 
ER+ tumors 
Gao [214] 2013 
Population-
based Case-
Control Chinese women 
Questionnaire 
assessed personal 
smoking and smoking 
of husbands.  
Husband's ever smoking 
was also associated with 
an increase in breast 
cancer risk (OR=1.47, 
95%CI 1.18, 1.84) 
Increase risk 
with increased 
years and pack-
years of ETS 
  
 
7
0
 
 
Hu [222] 2013 
Hospital-
based Case-
Control Chinese women 
Questionnaire 
assessed hours/day 
of exposure to a 
smoking spouse in 
the home or in the 
workplace and years 
of exposure.  
Women exposed to 
passive smoking were at 
an increase in risk of 
breast cancer (OR=1.54, 
95%CI 0.94, 2.52) 
Dossus [216] 2014 Cohort EPIC  
Passive smoke 
exposure was only 
assessed in a portion 
of the cohort. 
Women exposed to 
passive smoke were  at an 
increase in risk of breast 
cancer HR=1.10, 95%CI 
1.01, 1.20) 
Pack-years 
smoked after 
menopause was 
not associated 
with breast 
cancer risk. 
 Tong [221] 2014 
Hospital-
based Case-
Control Chinese women 
Questionnaire 
assessment of 
passive smoke 
exposure.  
Women exposed to 
passive smoke were at an 
increased risk for breast 
cancer (OR=1.46, 95%CI 
1.05-2.03), risk increased 
with increasing pack-years  
Association was 
similar among 
ER+PR+ tumors.  
 Fu[225] 2015 
Hospital-
based Case-
Control Chinese Women 
Questionnaire 
assessment of 
passive smoke 
exposure.  
Women exposed to 
passive smoke were at an 
increased risk for breast 
cancer (OR=4.82, 95%CI 
2.63-8.85).  
 Wada[226] 2015 Cohort Japanese women 
Questionnaire 
assessment of 
passive smoke 
exposure. 
Non-smoking women 
whose husband’s smoked 
had an increase in breast 
cancer risk  (OR=1.98, 
95%CI 1.03-3.84).  
*For active smoking and ETS, most recent meta-analysis is included as well as any publications that were published after the meta-analysis.  
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Table 1.2 Evidence of estrogen and anti-estrogen activity of selected PAH compounds by 
PAH exposure source.  
a  Relevant PAH compounds selected from Gullet et al., 2003, Böstrom et al., 2002, Smith et al., 2000, 
Alomoirah et al., 2011  
bEvidence from Arcaro et al., 1999, Chaloupka et al., 1992, Vondracek et al., 2002, Fertuck et al., 2001, 
Gozgit et al., 2004, van Lipzig et al., 2004, Kummer et al., 2008.   
PAH Exposure Source 
Relevant PAH 
Compoundsa Estrogenicb Anti-estrogenicb 
Synthetic Log Burning chrysene/triphenylene + + 
benzo(e)pyrene - + 
retene no evidence no evidence 
Vehicular traffic benzo[g,h,i]perylene - -  
 benzo[a]pyrene + + 
pyrene - -  
fluoranthene + -  
phenanthrene - - 
Tobacco smoke benzo[a]pyrene + + 
naphthalene  no evidence no evidence 
pyrene - - 
fluoranthene + -  
Grilled/smoked meat benzo[a]pyrene + + 
phenanthrene - -  
pyrene - -  
  fluoranthene + -  
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Figure 1.1. Metabolism of polycyclic aromatic hydrocarbons in relation to breast cancer 
risk (adapted from Hecht 2002 [69])  
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Figure 1.2. The relationship between multiple PAH exposure sources and breast cancer 
risk as investigated by the Long Island Breast Cancer Study Project (LIBCSP) and other 
research groups. 
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CHAPTER II. MATERIALS AND METHODS 
The goals of this dissertation were to: (AIM 1) determine whether long-term exposure to PAH 
from multiple sources (active smoking, environmental tobacco smoke (ETS),  indoor air 
pollution, vehicular traffic, and grilled smoked meat) are associated with breast cancer 
incidence; (AIM 2A) determine whether the association between individual sources of long-term 
PAH and breast cancer incidence are modified by global methylation; and, (AIM 2B) explore 
whether individual sources of PAH are associated with breast cancer tumor subtypes defined by 
methylation status of the tumor. For the second aim, those individual PAH sources with the 
strongest associations with breast cancer identified in the first aim were used.  
To address these goals, this dissertation draws upon existing data from the parent study, 
the LIBCSP, a population-based study. Details of the case-control study methods are presented 
below, beginning first with the description of the source population and data collection methods, 
followed by a description of variable construction, statistical methods, and study power.  
2.1 Study Population and Design: The Long Island Breast Cancer Study Project (LIBCSP) 
The parent study for this dissertation is the case-control resources of the LIBCSP. The LIBCSP 
was initiated as a large population-based case-control study in response to federal legislation to 
identify environmental risk factors associated with breast cancer incidence on Long Island – 
specifically Nassau and Suffolk counties only. Extensive details of the LIBCSP case-control 
methods have been published [52]. The parent study received IRB approval from all relevant 
institutions, and all women gave written informed consent prior to study participation [52]. 
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2.1.1 Case Eligibility and Identification 
Eligible LIBCSP cases included English-speaking, adult female residents with no personal 
history of breast cancer and who were living in either Nassau or Suffolk counties on Long 
Island, New York. Women were diagnosed with a first primary in situ or invasive breast cancer 
between August 1, 1996 and July 31, 1997. Eligible cases were identified using rapid case 
ascertainment through either daily and/or thrice weekly review of the pathology records of all 
hospitals in the two study counties (28 hospitals), as well as three large tertiary care centers 
located in New York City, which is adjacent to the target study counties. Diagnosing physicians 
were contracted to confirm diagnosis, date of diagnosis and seek permission to contact the 
patient for participation in the study. A total of 2,271 women were identified as potential eligible 
cases and approximately 73% (n=2,030) were eligible based on study criteria and physician 
consent was obtained for 90.5% (1,837). Physician refusal to contact was primarily due to age-
related comorbidity. The average length of time between date of diagnosis and interview was 96 
days.  
2.1.2 Control Identification 
Eligible LIBCSP controls were adult female residents of the same two counties, without a 
personal history of breast cancer and were frequency matched to the expected distribution of 
the cases by 5-year age groups. LIBCSP controls were identified using random digit dialing 
(RDD) for women under age 65 years. RDD began July 1, 1996 and was conducted in eight 
waves over the course of 12 months. The response rate for the RDD telephone screener was 
77.9%. As the study was conducted prior to 2000, RDD was a valid method for control 
ascertainment [413]. For women who were age 65 years and older, Health Care Finance 
Administration rosters were used to identify potential controls. The overall response rate for 
controls, when considering the response rate of those who were age 65 years and older, was 
approximately 62.7%. The average time between control identification and interview date was 
167 days.  
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2.1.3 Study Interview 
Written, signed informed consent was obtained from participants prior to the case-control study 
interview. The case-control study interview consisted of an interviewer-assisted, structured 
questionnaire, a self-administered food frequency questionnaire, collection of home samples 
and a biologic (blood) sample which was conducted in the residence of the participant. Study 
interviews and blood collection were completed by a trained phlebotomist or nurse. In total, 
1,508 cases (82.1% of eligible case participants) and 1,556 controls (62.7% of eligible control 
participants) completed the case-control interview.   
Main Case-control Questionnaire. Information on potential risk factors, including 
several of the PAH sources, was obtained using a structured questionnaire that took on average 
101 minutes to complete. The case-control questionnaire collected detailed information on a 
range of variables across the life course including: demographic characteristics; lifetime 
residential history in Nassau and Suffolk counties (including use of indoor stoves/fireplaces); 
medical history (including family history of cancer); reproductive and menstrual history (including 
menopausal status); cigarette smoking (active and passive); lifetime alcohol consumption; body 
size and physical activity across the life-course; and lifetime intake of grilled and smoked foods 
[52].  
Residential Soil Sample Collection. The case-control interviewers also conducted 
residential sampling of outdoor soil among a subset of participants who had lived in their current 
Long Island residence for at least 15 years [52]. These were collected in order to validate the 
LIBCSP geographic model of traffic PAH exposure [52, 133]. Soil samples were collected and 
analyzed for benzo[a]pyrene and other PAH compounds using high-resolution gas 
chromatography/mass spectroscopy for 360 cases and 356 controls [52, 133].   
Biologic Sample Collection. At the time of the case-control interview, 73.1% of case 
participants (n=1,102 cases) and 73.3% of control participants (n=1,151) donated a non-fasting 
40mL blood sample. For cases, this was shortly after diagnosis and before the completion of the 
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first course of treatment for the majority of case participants (77.2% donated prior to 
chemotherapy) [52]. Blood samples were collected in EDTA-treated, lavender-top tubes and 
shipped overnight at room temperature and processed in the laboratory of Dr. Regina Santella 
at Columbia University in New York City. There, the blood samples were aliquoted into red 
blood cells, lymphocytes, granulocytes and plasma and were stored in -80°C freezers using 
preprinted bar code levels with the subject’s randomly assigned study identification numbers. 
This processing occurred for most blood samples within 24 hours of collection. Laboratory 
personnel were blinded to case-control status of the samples. Women who donated blood were 
more likely to be younger, white, and to have used oral contraceptives [52]. Blood samples were 
used to assay DNA methylation levels and evaluate PAH-DNA adducts in circulating 
mononuclear cells, as well as other biomarkers of interest [52, 89, 297]. Equal proportions of 
eligible cases and controls donated blood (approximately 73% which is comparable to other 
population-based studies) suggesting that blood samples are likely representative of the general 
population [52].  
Archived pathology blocks for the first primary breast cancer were obtained for 962 
women (63.8% of case participants) and of those, tumor tissue was available for 859 cases 
(89.3%) [414]. Formalin-fixed, paraffin-embedded tumor sections were revived by a trained 
pathologist and cancer tissue was separated manually [414]. Tumor tissue was utilized to define 
p53 mutations and to assess gene-specific promoter DNA methylation [414, 415]. Study 
participants with and without tumor tissue did not differ substantially by breast cancer risk 
factors [414].   
 Further extensive detail on the demographics of the study participants, previous 
published results, PAH exposure source assessment, tumor subtype outcome assessment, 
DNA methylation assays and other covariate assessment is described below.  
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2.1.4 Study Population Characteristics 
Demographic characteristics of the parent study, the LIBCSP, have been previously published 
[52] and are summarized in Table 2.1. Briefly, LIBCSP respondents ranged in age from 20 to 98 
years; approximately two-thirds were postmenopausal; and 94% were white, 4% black and 2% 
other, which is consistent with the racial distribution of Nassau and Suffolk residents during the 
timeframe of subject identification and recruitment[52]. Demographic distributions (age, race, 
education, income, religion and marital status) were similar for cases and controls [52].  
Previous LIBCSP published reports have found associations with established breast 
cancer risk factors among women on Long Island including positive associations with increasing 
body size (for postmenopausal breast cancer only) [416], average lifetime alcohol use [417], use 
of exogenous hormones [418], and age at first birth [95]. Inverse associations have been 
reported with increasing regular use of non-steroidal anti-inflammatory drugs [419], 
breastfeeding [95], and recreational physical activity (for postmenopausal breast cancer only) 
[38]. 
2.1.5 Results from Previous Analyses of PAH Sources  
The LIBCSP study team has previously reported modest 35-75% increases in breast cancer risk 
associated with sources of long-term PAH including environmental tobacco smoke 
exposure[74], grilled/smoked meat intake [230], vehicular traffic exposure based on 
geographical modeling estimates [133, 181, 192], and use of indoor stoves/fireplaces for 
burning of synthetic logs [175]. The magnitude of the associations observed between these 
PAH sources and breast cancer are reviewed in Figure 1.2 and discussed in more detail below. 
In addition to associations with PAH sources, LIBCSP has also reported modest, positive 
associations with the short-term biomarker PAH-DNA adducts [89, 92].  
Active Cigarette Smoking and ETS Exposure.  LIBCSP reported a positive 
association between breast cancer incidence and long-term ETS (OR=2.10, 95%CI 1.47, 3.02) 
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for nonsmoking women who were passive exposed to a spouse for over 27 years [74].  A null 
association was reported for active smoking only (OR=1.06, 95%CI 0.76, 1.48) and a 
suggested, although imprecise, increase was observed for women exposed to both ETS and 
active smoke (OR=1.15, 95%CI 0.90, 1.48) [74]. An elevated association was also reported 
among women exposed to both active smoke and ETS for hormone receptor-positive tumors 
(ER+PR+, OR=1.42, 95%CI 1.00, 2.00) as well as among premenopausal women (OR=1.43, 
0.93-2.21) [74]. Exposure to active smoking or ETS before first full-term pregnancy was not 
associated with an increase in breast cancer incidence [74].  Interactions have been reported 
between smoking and certain SNPs in DNA repair genes (XPD and XRCC1), but not in the 
oxidative stress gene OGG1, with breast cancer incidence in LIBCSP [420-422]. 
 Grilled/Smoked Meat Intake.  Lifetime total grilled or smoked meat intake was 
associated with postmenopausal, but not premenopausal, breast cancer incidence (intake 
highest vs. lowest tertile of total grilled/smoked meat; OR=1.47, 95%CI 1.12-1.92) [230]. 
Elevated ORs were also observed for intake of smoked beef, pork and lamb and 
grilled/barbecued beef, pork and lamb. This association was most evident among those with low 
fruit and vegetable intake (intake highest vs. lowest tertile of total grilled/smoked meat; 
OR=1.74, 95%CI 1.20-2.50), but did not substantially differ across tumor subtypes (ER/PR) 
[230]. Steck and colleagues did not find an increase in incidence with an index of 
benzo[a]pyrene intake from the diet among all women [230].  However, there was a potential 
association between the benzo[a]pyrene index and breast cancer among postmenopausal 
women with ER+PR+ tumors (OR=1.47, 95%CI 0.99-2.19)[230].  
 Indoor Stove/Fireplace Use. In the LIBCSP, ever use of an indoor stove/fireplace was 
significantly associated with breast cancer incidence [175]. However, when investigating this 
association by material burned in the stove or fireplace, women reporting ever burning synthetic 
logs in their homes had a 42% increased breast cancer risk (OR=1.42, 95%CI 1.11-1.84), but 
no increase was observed for ever burning wood (OR=0.93, 95%CI 0.77, 1.12) [175]. Odds 
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ratios were elevated in association with synthetic log burning, increasing after 7+ years of 
exposure, for exposures after age 20 years, and among those with ≥2 Glutathione S-transferase 
(GST) variants (OR=1.71, 95%CI: 1.09, 2.68) [175]. The odds ratios for any stove/fireplace use 
were slightly elevated for 21.7-30 years of exposure (OR=1.13, 95%CI 0.87, 1.51), which did 
not persist for exposures after 30 years [175]. There was little observed variation by breast 
cancer subtype defined by ER/PR and p53 mutation status [175].  
Vehicular Traffic.  Recent vehicular traffic exposure among the LIBCSP participants, 
was modestly and not significantly associated with breast cancer incidence (1995 estimates 
complete case analysis (CCA), top 5% vs. below the median, OR=1.14, 95%CI 0.80, 1.64)[192]. 
Effect estimates were stronger, but imprecise for long-term PAH exposures (1960-1990 
estimates with 20% multiple imputation, top 5% vs. below the median, OR=1.44, 95%CI 0.78, 
2.68) [192]. The strongest associations were reported for women with low fruit and vegetable 
intake (1995 estimates, CCA, 75th-95th percentile vs. <50th percentile, OR= 1.46, 95%CI 0.89, 
2.40, interaction p value=0.01) and among premenopausal women (1995 estimates, CCA, 75th-
95th percentile vs. <50th percentile, OR= 1.64, 95%CI 1.13, 2.38, interaction p value=0.02 )[192]. 
There was evidence of tumor heterogeneity with stronger odds ratios among hormone receptor-
negative tumors (1995 estimates, CCA, ER-PR- vs. other subtypes, ≥95th percentile vs. <50th 
percentile, OR=1.67, 95%CI 0.91, 3.05), but no tumor heterogeneity was observed by p53 
mutation status [192]. Additionally, results were most pronounced for in situ cases (1995 
estimates, CCA, ≥75th percentile vs <50th percentile 1.42 0.99, 2.02) compared to invasive 
breast cancer [192]. 
2.1.6 Summary and Conclusions 
This dissertation draws upon the case-control resources of the LIBCSP, a large, population-
based study that was designed to address research questions for environmental exposures. 
LIBCSP benefits from the large range of ages included in the study population (20-98 years). 
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DNA was obtained for most participants, which has been utilized for DNA methylation assays in 
both blood and tissue. Most importantly, LIBCSP has extensive measures of multiple PAH 
sources a feature that makes this study population unique and optimal for these research 
questions. The additional questionnaire data provides the ability to address potential 
confounding of the PAH-breast cancer association.   
2.2 PAH Exposure Assessment and Variable Definitions 
Five specific PAH exposure sources were assessed across the life course including: (1) active 
smoking history; (2) history of ETS; (3) grilled/smoked meat; (4) indoor stove/fireplaces; and (5) 
vehicular traffic.  Measures of active smoking and ETS exposure history, grilled/smoked meat 
intake, and indoor stove/fireplace use were derived using responses from the structured case-
control questionnaire. Active smoking and ETS exposure were considered as separate 
exposure sources. Vehicular traffic estimates were derived using a GIS model specifically 
designed for LIBCSP. These measures will be discussed in more detail below.  
Active smoking. Active smoking history was defined as smoking at least 1 cigarette a 
day for 6 months of longer. Age at which the participant began and quit smoking was 
considered, as were any periods of 1 year or more not spent smoking, to calculate pack-years. 
Current active smoking was defined as smoking within 12 months prior to reference date. Active 
smoking (ever, never), current smoking (ever, never) and smoking prior to first pregnancy (yes, 
no) were considered the active smoking variables for my primary analysis. For a sensitivity 
analysis, I also considered continuous versions of total active smoking (pack-years) and current 
active (pack-years).   
Environmental Tobacco Smoke. To define exposure to residential ETS, responses 
from the main questionnaire were utilized where participants were asked whether they had a 
member of their household (across the life course) at any point smoke in their presence. The 
relationship of that person, the age of first and last exposure and the number of years exposed 
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to ETS was recorded.  Over half of cases and controls were exposed to ETS from a spouse, 
[731 cases (60.6%) and 670 controls (54.6%)]. I considered ever residential ETS (yes, no) and 
ever residential ETS from a spouse (yes, no) in the primary analysis. In a sensitivity analysis, I 
also considered continuous versions of the residential ETS variables, using months of passive 
tobacco smoke exposure and months of exposure from a spouse.  
 Grilled/Smoked Meat. Frequency of intake of grilled/smoked meat was assessed over 6 
decades of life (<20 years, 20-29 years, 30-39 years, 40-49 years, 50-59 years, 60+ years) 
across 4 different groups of PAH containing meat including grilled or barbecued poultry or fish, 
smoked beef, lamb and pork; grilled or barbecued beef, lamb and pork; smoked poultry or fish. 
The average intake over the six decades (or fewer depending on the age at diagnosis) was 
calculated to determine the average lifetime consumption of grilled/smoked meat.  
 Derived average values for intake of grilled/smoked meat were missing for 9-10% of the 
study participants due to small amounts of missing across the numerous groups (6 decades of 
consumption x 4 food groups); many of which were concentrated within a single decade 
(although not the same decade for all participants) [230]. Under the direction of Dr. Bruce Levin, 
chair of the Department of Biostatistics at Columbia University, imputation from multiple 
regression was used to predict the missing values based on the women who had complete 
values [230]. This imputation strategy reduced the proportion missing of the variable to 
approximately 3%-5% across the four groups of meat intake [230]. The final imputed results did 
not substantially differ from a complete case analysis, when missing values were removed from 
the analysis [230]. The multiple imputation did not appear to affect the observed ORs, so the 
imputed data was used in the previous LIBCSP report by Steck et al., [230] was used in this 
dissertation.  
For this study, total grilled/smoked food intake (<33% vs ≥33% percentile or <55 
servings/year, 55+ servings/year), grilled/barbecued beef, pork and lamb (<33% vs ≥33% 
percentile or <14, 14+ servings/year); and smoked beef, pork and lamb (<50th percentile, ≥50th 
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percentile or <22, 22+ servings/year). were considered as average servings consumed per year 
based on quantile distributions of intake in controls and as previously published by Steck et al., 
[230]. Dichotomization was based on observed associations with breast cancer risk for each 
grilled/smoked meat variable of interest [230]. Continuous versions of the grilled/smoked meat 
intake variables were considered as a sensitivity analysis.   
  Indoor Stove/ Fireplace Use.  Information on the use of an indoor stove/fireplace 
(burning wood, coal or synthetic logs) at a residence in Nassau and Suffolk counties where a 
participant resided for at least 1 year was self-reported in the questionnaire. The study 
participants were asked if there was an indoor stove/fireplace at this residence that was used at 
least 3 times per year.  If yes, they were asked whether they burned wood, coal, gas or 
synthetic logs; participants could select multiple responses. The date and/or ages of participants 
at time of living in each residence was recorded, which was used to calculate exposure 
duration.  Exposure frequency or exposures to indoor air pollution at non-residences or 
residences outside of Long Island were not captured in this set of questions. Indoor 
stove/fireplace use regardless of material burned (ever, never), wood burning (ever, never) and 
synthetic log burning (ever, never) was considered.  
 Vehicular Traffic.  The questionnaire assessed information about lifetime residential 
history on Nassau and Suffolk counties on Long Island. Residences that subjects resided at for 
one year or more were recorded. Addresses were geocoded using BLR software (BLR Data, 
Inc., Lebanon, NH). A total of 8,321 residential addresses were obtained from study interviews, 
of which 6,189 residences have been geocoded successfully (Dr. Jan Beyea, personal 
communication). Most study participants had at least one address that successfully geocoded to 
at least street level detail.  
A historical model of residential PAH exposure from vehicular traffic (years 1960–1995) 
was developed for the LIBCSP by Dr. Beyea, a physicist and modeler at Consulting in the 
Public Interest [133, 181, 423] in collaboration with the LIBCSP study team. Using the geocoded 
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residential history data on subject addresses, the geographic model incorporates historical US 
vehicular PAH emissions data, information on traffic and transportation patterns in the New York 
metropolitan area, Long Island meteorological variables, and pollutant dispersion factors [133, 
181, 423].  Historical tailpipe emission parameters were based on PAH measurements 
conducted in road tunnels across multiple locations in the United States and further validated 
using individual vehicles run on dynamometer test beds [181]. Transportation network of the 
New York metropolitan area was evaluated for historical traffic count and average US tailpipe 
emissions under cruise condition, incorporating emission variability from cold-engine emission 
and acceleration and deceleration at intersections [133, 423]. Standard meteorological and 
deposition variables were used to estimate residential ambient concentrations[133]. For homes 
within 100 meters from a road, B[a]P concentrations were calculated using highway line-source 
models and for homes farther than 100 meters, using Gaussian plume models with Briggs 
dispersion parameters which incorporate dispersion factors including wind speed and direction, 
rain washout, decay and particle deposition [133, 423].  PAH exposures from traffic were at first 
calculated beginning in 1960 [423] and ended in 1995, right before LIBCSP started recruitment 
in 1996-1997 [52].  
As reviewed in Beyea et al. [133], PAH levels in residential soil samples were chosen to 
validate/calibrate the geographic model because PAH deposition is proportional to airborne 
concentrations above the soil, and because respirable particles in outdoor air are known to 
penetrate indoors efficiently, and have been found to dominate indoor respirable PAH 
concentrations in a number of studies. Additionally, the model was validated against PAH-DNA 
adduct levels in circulating lymphocytes among women with detectable adducts [133].    
 For the exposure years 1960-1990, multiple imputation was used to impute 20% 
missing data [423]. The validated geographic model produces exposure at residences whose 
location is accurately known; otherwise multiple imputation is carried out based on modeled 
exposures before and after the time that a residence location is missing [424].  A woman's total 
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accumulated exposure is the summation of exposures at different residence locations over the 
1960-1990 period. A woman is included in an imputed set of data for analysis, only if the 
percentage of her total accumulated exposure coming from missing residences is less than 20% 
of the total. For an optimal sample size (see Table 2.4), vehicular traffic data for the year 1995 
was used  (<95th, ≥95th) which was previously determined using cubic smoothing splines to best 
represent associations with breast cancer incidence [192].  A sensitivity analysis was completed 
using the historical vehicular traffic estimates from 1960-1990, for which exposure levels/effect 
estimates were higher.  
2.3 Outcome Assessment  
Breast cancer diagnosis was identified through daily/weekly contact with hospital pathology 
departments, and then confirmed by the diagnosing physician and by the medical record. There 
were 1,506 cases enrolled in the study.  
2.4 DNA Methylation Assessment and Variable Definitions 
Both global and gene specific promoter methylation were previously assessed in the LIBCSP in 
the laboratories of Dr. Regina Santella at Columbia University and Dr. Jia Chen at Mt. Sinai 
School of Medicine. Two methods were used to assess global methylation levels: (1) the 
analysis of LINE-1 and (2) LUMA. For gene-specific methylation levels, methylation-specific 
PCR [361, 425] was used to measure the promoter methylation for ESR1, PGR and BRCA1. 
The MethyLight assay was used for determining the methylation status of the following genes: 
APC, CCND2, CDH1, DAPK1, GSTP1, HIN1, p16, RARβ, RASSF1A and TWIST [426, 427]. 
The methods used to determine methylation levels have been previous published for the parent 
study and are briefly described below [297, 415].  
2.4.1 Global DNA Methylation Assessment  
Global DNA methylation, a form of epigenetic regulation, is hypothesized to confer genomic 
stability and integrity. In order to assess global DNA methylation, surrogate assays have been 
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developed that are hypothesized to reflect genome-wide methylation levels [428]. Many of these 
surrogate global methylation assays target repetitive transposable elements (TE) such as LINE-
1, Sat2 and short interspersed elements (SINEs) (e.g. Alu).  Of these, LINE-1 is the most highly 
expressed TE in the human genome, with 500,000 copies which is approximately 17% of the 
human genome [265, 298, 429]; it is also the most commonly measured marker in association 
studies with cancer [265]. High methylation at repetitive elements is proposed to protect against 
expression of these transposable elements [264, 265, 430].  
 LUMA measures levels of 5-mC in the sequence CCGG [431]. The LUMA assay for 
surrogate genome-wide methylation relies on DNA cleavage using restriction endonucleases 
followed by a polymerase extension assay using a pyrosequencing assay [431]. LUMA 
measures methylation predominately at CpG Islands (CGI), which are regions of high CpG 
density, which tend to be unmethylated [265]. LUMA is also a surrogate measure of genome-
wide methylation but because it measures across CGI it will likely differ from methylation of TEs, 
such as LINE-1. The advantages of LUMA include the assay being quantitative and rapid, with 
an internal control for DNA input and the ability for high throughput for large-scale studies.  
 In LIBCSP, global DNA methylation was measured using the LUMA assay and 
pyrosequencing of LINE-1 in blood samples donated at the time of interview and stored as 
described previously. Pelted mononuclear cells were separated from whole blood by Ficoll 
(Sigma Chemical Co., St. Louis, MO) and washed twice with phosphate-buffered saline (PBS) 
[52].  Pelleted cells were frozen at -80°C and DNA was isolated using standard methods of 
extraction using followed by treatment with RNAse and proteinase K treatment followed by 
phenol and chloroform isoamyl alcohol extraction [52, 420].  
LUMA Assay Methods. 200ng of genomic DNA was digested for 4 hours by the 
restriction enzymes HpaII + EcoRI or MSPI + EcoRI in 2 separate 20µl reactions in a 96-well 
plate. Next, 15 µl of annealing buffer (20mM Tris acetate and 2mM Mg-acetate pH 7.6) were 
added to the product of the digestion reaction and samples were then analyzed by PyroMark 
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Q24 (Qiagen, Valencia, CA, USA) using the following dispensation order: GTGTCACATGTG.  
This method has been previously validated using samples with known DNA methylation [432]. 
Cases and controls were assayed at the same time and laboratory personnel were 
blinded. Randomly selected samples were replicated to examine potential batch effects and to 
determine any variation between different runs and the percent corresponding variability (CV) 
was less than 1%. 5-Aza-dC demethylated and CpG methylated Jurkat genomic DNAs (New 
England Biolabs, Ipswhich, MA, USA) were used as unmethylated and methylated controls in 
the assay. LUMA methylation level is expressed as a percentage obtained using the following 
equation [432]: 
ℎ	
 % =  
1 − II ∑G/∑T
I ∑G/∑T
∗ 100 
LUMA methylation assays were completed on 2,100 peripheral blood samples donated 
as described above by cases and controls in LIBCSP [297].  The mean methylation level of the 
LUMA assay was 57.3% for 1055 cases and 52.4% the 1101 controls.[297] 
LINE-1 Assay Methods. The LINE-1 assay was completed using a pre-validated 
pyrosequencing assay to assess 4 CpG sites in the promoter of LINE-1 at EpigenDx 
(Worcester, MA, USA). 500ng of genomic DNA was bisulfite treated and purified with Zymo 
DNA methylation kits (Zymo Research, Irvine, CA, USA) and eluted in 20µl of elution buffer. The 
50µl PCR reaction contained 10x PCR buffer, 3.0 mM MgCl2, 200 µM dNTPs, 0.2 µM primers, 
1.25 U DNA polymerase (HotStar; Qiagen) and approximately 10ng of bisulfite-converted DNA.  
The PCR reaction as completed as follows: DNA polymerase was activated by incubation at 
95°C for 10 minutes, followed by 34 cycles of the following: 95°C for 15 seconds, 45°C for 30 
seconds and 72°C for 30 seconds. The reaction then extends for 5 minutes at 72°C. A universal 
biotinylated primer was used in the initial PCR reaction to allow for isolation of the amplicon, 
followed by denaturation and release of a single-strand product that can then be used for 
pyrosequencing. The 10µl PCR products were sequenced using the Pyrsoequencing PSQ96 
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HS System (Qiagen). Methylation status at each of the 4 CpG loci was analyzed individually as 
a T/C single nucleotide polymorphism (SNP) using QCpG software (Qiagen). Methylation status 
data at all 4 loci were averaged to provide an overall percent 5meC status.  
The LINE-1 methylation assays were also completed on ~2,100 peripheral blood 
samples donated as described above by cases and controls in LIBCSP [297] . For LINE-1, the 
mean level of methylation was 78.8% (range: 69.0-89.2%) among 1064 cases and 78.8% 
(range: 66.0-94.4%) among 1100 controls [297]. 
2.4.2 Gene-Specific Promoter Methylation Assessment  
Promoter hypermethylation of cancer-related genes, often tumor suppressor genes, is a 
hallmark of tumor cells[266]. To address possible differential methylation of gene specific 
promoter regions, multiple genes were selected. The panel of 13 genes (ESR1, PGR, APC, 
BRCA1, CCND2, CDH1, DAPK1, GSTP1, HIN1, p16, RARβ, RASSF1a and TWIST), previously 
shown to be relevant for breast carcinogenesis, are described in full in Table 2.3 [415].  
Briefly, estrogen receptor 1 (ESR1), progesterone receptor (PGR) and retinoic acid 
receptor beta (RARβ) are steroid hormone receptors. Other genes selected are tumor 
suppressor genes, including breast cancer 1, early onset (BRCA1), adenomatous polyposis coli 
(APC),  cyclin-dependent kinase inhibitor 2a (p16/CDNKN2a), secretoglobin, family 3a, member 
1 (HIN1/SCGB3A1), Ras association domain family member 1 (RASSF1a), death-associated 
protein kinase 1 (DAPK1), E-cadherin (CHD1), many of which are  relevant for cell cycle control. 
Cyclin D2 (CCND2) is an oncogene that regulates CDK kinases. Twist homolog 1 (TWIST) is a 
transcription factor that functions in cell lineage determination and differentiation. Glutathione S-
transferase pi 1 (GSTP1) is a detoxification gene that is important for xenobiotic metabolism, 
including the detoxification of PAH active intermediates [261, 415].  
Archived pathology blocks were obtained and processed as described previously [414]. 
After processing, tissues for 859 cases (89.3%) were considered sufficient for the methylation 
assays [415]. There were few differences in demographic and clinico-pathologic features 
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between cases with and without tumor blocks used for methylation analysis. Cases with 
methylation data tended to be slightly older (mean age 59.6 compared to 57.9 years), 
postmenopausal (70.07 vs. 64.6%) and had a greater percentage of invasive tumors (87.8 vs. 
80.1%) [361, 414, 415].   
Tissues were incubated overnight at 56°C in 30µl of the digestion buffer containing 150µl 
of the proteinase K (10 mg/ml), 850µl of 0.5% Tween 20, 1mM EDTA, pH 8.0, and 50mM Tris, 
pH 8.5. The next day, 10µl of proteinase K solution was added and the samples were incubated 
for 4 to 6 hours at 56°C. Proteinase K was then inactivated using an incubation of 100°C for 10 
minutes. DNA samples were stored at -80°C [361]. Two methylation assays were used to 
assess gene-specific promoter methylation, methylation-specific PCR and the MethyLight 
assay. 
Methylation-specific PCR Methods. Promoter methylation of ESR1, PGR and BRCA1 
was determined by methylation-specific PCR [361, 425], which generated a dichotomous 
methylation outcome.  DNA underwent bisulfite-conversion, which converts unmethylated 
cytosine residues to uracil, using CpGnome DNA Modification Kit (Chemocon International, 
Purchase, NY).  PCR was performed on a total volume of 20µl containing 0.5 U of Amplitaq 
Gold II (Roche, Nutley, NJ, USA). Each PCR reaction began with denaturation at 95°C for 10 
minutes, followed up by 40 cycles of the following: 30 seconds at 94°C, 30 seconds at 55°C and 
then 30 seconds at 72°C, and ending with a final 10 minute extension at 72°C. PCR products 
were analyzed using electrophoresis on a 2% agarose gel, stained with ethidium bromide and 
visualized using UV transillumination. DNA was considered methylated if PCR product is yielded 
using the methylation-specific primers. Bisulfite-modified universal methylated DNA (Chemicon 
International, NY) was used as a positive control and distilled water as a negative control in the 
assay [361, 425]. 
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MethyLight Assay Methods. The MethyLight assay was used for determining the 
methylation status of the remaining genes [426, 427].  Sodium bisulfite conversion of genomic 
DNA was completed (6). Genomic DNA is then amplified by fluorescence-based, real-time 
quantitative PCR (11, 12). Bisulfite-converted genomic DNA is amplified using locus-specific 
PCR primers flanking an oligonucleotide probe with a 5’ fluorescent reported day (6FAM) and a 
3’ quencher dye (TAMRA) (13). The 5’ to 3’ nuclease activity of Taq DNA polymerase cleaves 
the probe and releases the reporter, whose fluorescence can then be detected by the laser 
detector of the ABI Prism 7700 Sequence Detection System (Perkin-Elmer, Foster City, CA). 
After crossing a fluorescence detection threshold, the PCR amplification results in a fluorescent 
signal proportional to the amount of PCR product generated. Initial template quantity can be 
derived from the cycle number at which the fluorescent signal crosses a threshold in the 
exponential phase of the PCR reaction. References samples are included on each assay plate 
to verify plate-to-plate consistency. Plates are normalized to each other using these samples. 
PCR amplification is performed using a 96-well optical tray and caps with a final reaction 
mixture of 25 µl, with 600nM of each primer, 200nM probe, 200uM each dATP, dCTP and 
dCTP, 500uM dUTP, 3.5mM MgCl2, 1xTaqMan Buffer A containing a reference dye, and 
bisulfite-converted DNA or unconverted DNA at the following conditions: 50C for 2min, 95C for 
10min followed by 40 cycles of 95C for 15s and 60C for 1 minute.  PCR primers and probes, 
designed for bisulfite converted DNA sequences were used. The percentage methylation was 
calculated using the 2-ΔΔCT method and the following equation:  
ΔΔCT =  , "#$%& −  ,'(&)*+",-.% − / , "#$%& −  ,'(&)*012..3 ,%&43."&%5 67' ∗ 100 
Samples with greater than or equal to 4% methylation were considered methylated, and 
samples with less than 4% methylation were considered to be unmethylated. There was some 
missing data because of limited DNA methylation as a template for the PCR reaction which 
predominately occurred as a result of small tumor sizes.  
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2.5 PAH-DNA Adducts Assessment 
PAH-DNA adducts were used for calibration of the vehicular traffic model. As described above, 
73.0% of cases and 73.3% of controls who completed the questionnaire donated nonfasting 
blood samples. DNA was extracted from blood samples and was used to assess PAH-DNA 
adduct levels in whole blood by competitive enzyme-linked immunosorbent assay (ELISA) [141] 
in the laboratory of Dr. Santella. The antibody in ELISA recognizes PAH diol epoxide adducts 
that form at the N2 position of the guanine base. Laboratory assays of the PAH-DNA adduct was 
successfully completed for 873 cases and 941 controls [92].  
2.6 Other Covariate Assessment 
As previously described covariate information for the LIBCSP was collected with structured 
questionnaires with trained interviewers [52].  Most cases and controls completed a self-
administered and validated Block FFQ [52, 433, 434]. 
Directed acyclic graphs (DAGs, Figure 2.1) were utilized as conceptual models to 
determine which variables would be evaluated as potential confounders in this ancillary study 
analysis for the risk of developing breast cancer. Confounders investigated (and their 
corresponding variable definitions) in this analysis include: age (five-year groupings), 
socioeconomic status (SES) using pre-tax annual household income for the year prior to 
reference date  (<$34,999, $35,000-$69,999, ≥$70,000); and educational attainment (high 
school graduate or less, some college, college graduate), age at menarche (≤12, >12 years), 
parity (nulliparous, parous), total energy intake (kcal, continuous), religion (none, Protestant, 
Catholic, Jewish, other), alcohol intake (average lifetime intake), and marital status (never, 
ever).  All of these LIBCSP variables were assessed using the main LIBCSP case-control 
questionnaire, with the exception of total energy intake, which was derived from the FFQ. There 
was a minimally sufficient adjustment set identified from the DAG (Figure 2.1), which includes 
the covariates education, income, age, alcohol use, age at menarche, and parity.  
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2.7 Statistical Analysis 
The first specific aim (AIM 1) of this dissertation was to simultaneously consider multiple long-
term PAH sources (active cigarette smoking, environmental tobacco smoke, grilled/smoked 
meat intake, indoor stove/fireplace use and vehicular traffic) and associations with breast cancer 
incidence utilizing existing case-control resources from the LIBCSP, conducted in Long Island, 
New York. The second aim incorporates DNA methylation: AIM 2A is to determine effect 
measure modification of the PAH sources and breast cancer association by global DNA 
methylation and AIM 2B to explore the association between PAH sources and breast cancer 
when tumor subtype is defined by gene-specific DNA methylation measured in the tumor.  
Evidence supporting an association between long-term PAH exposure and breast 
cancer incidence, may provide crucial evidence for a relationship between PAH exposure and 
breast cancer.  By investigating potential effect measure modification by global DNA methylation 
and associations with gene-specific DNA methylation, results from this study provides 
information relevant to how PAH influences breast cancer risk and the role of epigenetics in this 
relationship. Details of the statistical analyses that were used to address these aims are 
discussed below.  
2.7.1 Descriptive Statistics 
Data analysis began with an examination of the distributions of the participant characteristics 
(including all PAH source exposure variables and potential confounders). By case-control 
status, the distributions were calculated as means and standard deviations (SDs) for continuous 
variables and as frequencies (n) and relative frequency (%) for categorical variables. PAH 
exposure variables were coded as described above, all as dichotomous indicators to facilitate 
adequate scaling in the hierarchical analysis. Overlaps in the distributions of PAH exposure 
variables within source by case-control status are displayed in Table 2.2. This analysis was 
completed using SAS 9.3 (Cary, NC).  
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2.7.2 Long-term PAH Exposure in Association with Breast Cancer Risk 
Hierarchical regression models were used to estimate ORs and 95%CIs for the PAH sources 
and PAH exposure profiles on breast cancer incidence (AIM 1A).  
 To examine the effect of the main PAH sources and routes of exposure on breast cancer 
risk, 12 PAH exposure variables were considered. For the primary analysis, they were  
characterized into five main exposure sources: (1) active smoking:  any active smoking, current 
active, smoking prior to first pregnancy; (2) ETS: any ETS, ETS from spouse; (3) vehicular 
traffic:  1995 vehicular traffic; (4) indoor stove and/or fireplace use: any stove/fireplace use, 
wood burning, synthetic log burning; (5) diet: total grilled/barbecued and smoked meats, 
smoked beef, pork and lamb and grilled/ barbecued beef, pork and lamb.  
A single exposure model, a multivariable model and a hierarchical model were used to 
calculate odds ratios (ORs) and corresponding 95% credible intervals (CI) as shown in a 
previous LIBCSP publication [435]. Both the single exposure model and the multivariable 
models modeled the risk of breast cancer using logistic regression.  
logit (Pr(Y=1 ∣ X,W, β, γ)) = α +  Xβ + Wγ 
where Y is the outcome (case status), X denotes the 12 individual PAH exposures and 
W is the matrix of confounders. β represents the effect (ln(OR)) of the individual PAH sources 
on breast cancer risk. For the single exposure model, each PAH variable was modeled alone. 
For the multivariable model, all 12 exposures were included in the same model.  
Hierarchical regression builds on this first-level model by including a second-level model that 
incorporates the information on the PAH sources. The second level of the hierarchical 
regression for the logistic coefficient β is: 
β=Zπ + δ 
where Z is the second-stage design matrix (the Z matrix has rows corresponding to each 
β and columns responding to an exposure source)), which includes our prior information about 
the PAH exposure variables and their respective sources, π is the vector of coefficients 
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corresponding to the effects of the second stage covariates on breast cancer (i.e., the effect of 
each PAH exposure source on breast cancer risk) and δ is the vector of random errors of each 
PAH exposure variable which is assumed to be normally distributed with a mean=0 and a 
variance=τ2. 
The columns in the Z matrix represent each of the groups of PAH exposure sources of 
interest (active smoking, ETS, indoor stove/fireplace, grilled/smoked meat intake). If the PAH 
exposure variables contribute to the source they were scored as 1 and 0 if they did not 
contribute to that source of exposure.   
Combining equations 1 and 2 provides posterior estimates of the association between 
each PAH variable, according to the source, and breast cancer risk: 
logit (Pr(Yi=1 ∣ X,Z, W)] = α + XZπ+X δ+ Wγ 
where the X,Z and W matrices are the same as previously described, the π and γ are 
fixed effects and the δ coefficient is random with a mean=0 and variance=τ2.   
A Bayesian Markov chain Monte Carlo approach was used for the three different 
models, the single exposure, multivariable and the hierarchical regression[436, 437].  For the 
intercept, the PAH variables and the PAH sources, a minimally-informative normally-distributed 
prior was used. For τ, a uniform prior from 0.01 to 100 was used. A missing data logistic 
regression model was specified within the hierarchical model for 1995 vehicular traffic (which 
had approximately 15% missing data), imputing missing data using the covariates income, 
education and age [438, 439]. Missing data was due primarily to lack of geocoding matches by 
the software. The covariates income, education and age were included in the missing data 
model because these variables were associated with vehicular traffic levels; however, because 
there were no correlations observed between the higher order PAH sources, these other PAH 
variables were not included in the model to impute the missing data. Trace plots were visually 
examined to evaluate Markov chain convergence.  
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From the hierarchical model, OR and 95%CI for PAH exposure profiles of interest 
relative to women who had low PAH exposure were estimated by calculating linear 
combinations of the relevant β coefficients. The odds ratios for the profiles, and their respective 
95% credible intervals, are estimated within the original hierarchical regression model.  The 
PAH exposure profiles of interest were defined as (1) the referent, low PAH exposure (non-
smokers, no ETS, low intake of grilled/smoked foods, low vehicular traffic emissions and no 
stove/fireplace use); (2) tobacco smoke (current, active smokers who started prior to first 
pregnancy and were exposed to ETS from a spouse); (3) ingested PAHs (high intake of overall 
grilled/smoked foods, grilled/barbecued beef, pork and lamb and smoked beef, pork and lamb); 
(4) indoor stove/fireplace users (indoor stove/fireplace users who burned both wood and 
synthetic logs); (5) inhaled PAHs (active smokers, ETS,  high vehicular traffic, stove/fireplace 
users); (6) indoor source PAHs (active smokers, ETS from spouse, high overall grilled/smoked 
foods and stove/fireplace users); (7) five PAH sources (active smokers, ETS, high overall 
grilled/smoked foods, stove/fireplace users and top 5% of vehicular traffic exposure).  Posterior 
probability density distributions were estimated for the low PAH and indoor source PAHs.  
2.7.3 Interactions  
A statistical interaction is the departure from additivity or multiplicativity of effects on an outcome 
[440]. Evidence of a biological interaction between two exposures may be inferred from 
measures of statistical interaction as calculated in a regression model. While additive 
interactions on the risk scale may be more applicable to biological interactions, multiplicative 
interactions may be more relevant to a multistage disease such as breast cancer [440].   
A frequentist approach was used for the analysis of Aim 2. Potential interaction was assessed 
for global DNA methylation markers, LINE-1 and LUMA (AIM 2A). Multiplicative interactions was 
assessed with a cross-product term in the model between the hypothesized effect measure 
modifier and each single source PAH variable. The model fit was evaluated using a likelihood 
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ratio test (LRT), which is the difference of the two -2LogLikelihood values of the logistic models 
calculated with and without the interaction terms. An a priori alpha level of 0.05 was used for 
testing effect measure modifiers.  
 For additive interaction, I calculated an ICR, or RERI (Relative Excess Ratio Interaction), 
and 95% CIs [440, 441].  ICR values less than zero indicates less than additive joint effects, ICR 
values of zero suggest no interaction on the additive scale and ICRs greater than zero suggest 
more than additive interaction [440].  
2.7.4 Tumor Heterogeneity  
For AIM 2B, I assessed tumor heterogeneity of the PAH source-breast cancer associations 
when defining the tumor by gene-specific DNA methylation. Tumor subtypes were defined as 
methylated vs. nonmethylated. A case-case approach and logistic regression were used to 
determine the OR for being methylated versus not methylated[442, 443].  
2.7.5 Sensitivity Analyses 
Vehicular Traffic.  For AIM 1, there was a sensitivity analyses conducted where all aspects 
of the modeling effort described for AIM 1 were repeated, substituting the higher 1960-1990 
traffic exposure estimates for the lower 1995 estimates. A sophisticated multiple imputation 
approach was previously used for this long-term vehicular traffic data in this study population 
[423], but the approach was not compatible with the Bayesian hierarchical model used here. 
Power was reduced by using the 1960-1990 estimates due to missing data, but the effect 
magnitude could have been stronger because PAH exposure levels were higher in earlier years. 
Continuous variables.  Continuous scaled (divided by 2 standard deviations) coding of 
active smoking, residential ETS, and grilled/smoked meat variables were considered [444].  
Alternative Z-matrix (ingestion versus inhalation). Another Z-matrix configuration was 
evaluated, where the second-level model included two routes of exposure, ingestion versus 
inhalation.  
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Restriction to postmenopausal, ER+ women.  The statistical analysis for both Aim 1 and 
2 were repeated, limiting to postmenopausal women and cases with ER+ tumors.  
Correction for multiple comparisons using False Discovery Rate adjustment (FDR).  
For Aim 2, the potential issue of multiple comparisons was addressed using the FDR, as it is 
easily implemented and is less conservative than other methods. A p-value was determined to 
be statistically significant when the following expression was met: raw p-value(i) ≤ (0.05i)/m 
where, i=p-value rank and m=total number of statistical comparisons [445].  
2.8 Strengths and Limitations 
2.8.1 Strength and Limitations of the Study Design 
The large population-based design of the parent study provides good study power to 
simultaneously include the PAH sources in a single model and to examine the main effects of 
PAH exposure profiles on breast cancer risk. I was also able to assess interactions with global 
DNA methylation due to the high proportion of study participants with available DNA for 
methylation assays (see Table III).  
Study concerns include the differences in participation rates between cases and controls 
(82.1% vs 62.7%), with lower participation rates observed among older control women [52]. 
Long Island is also a homogenous study population and it is composed of predominately white, 
postmenopausal women [52]. This limits the generalizability of the study results, which may not 
be applicable to all U.S. women.  Also, the ability to investigate tumor subtype, which is known 
to vary by race [12], is also limited. However, having a homogenous population can also be 
considered as an advantage; homogeneity improves internal validity and decreases the 
likelihood of residual confounding. The results of this dissertation are applicable to the women 
with the highest risk of breast cancer in the U.S.: white, postmenopausal women [106].  
As with many case-control studies, the LIBCSP relied on self-reported data in order to 
establish life course exposure and errors in reporting by case/control status have the potential to 
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bias study results. The questionnaire was administered by a trained interviewer, who was 
educated and trained to collect study data in a systematic manner [52], in order to minimize this 
bias. Also, in the mid-1990s when the data was collected, it is unlikely that women were aware 
of our hypothesis that PAH exposures may differentially affect breast cancer risk. Further, in the 
case-only analysis, any error is lessened as it is unlikely that reporting will differ by tumor 
subtype or by DNA methylation.   
 Breast cancer is a rare disease and thus, a case-control study is the most efficient study 
design. An alternative design would be to conduct a cohort study to investigate PAH sources 
across the life course with breast cancer. However, this would be inefficient and incredibly time-
intensive to assess the major PAH exposure sources across the life course. This dissertation is 
practical and a cost-efficient utilization of extensive, existing resources as the PAH source 
information, DNA methylation and confounder data has been previously collected.   
The study team used extensive quality control procedures for questionnaire data (data 
range/logic checks and re-interviewing a random sample of 20% of study participants) and the 
laboratory components (re-running random samples of DNA methylation assays). This study 
also had extensive information on a wide range of variables including demographic and lifestyle 
variables, PAH exposure variables, reproductive history, dietary data and tumor characteristics. 
These resources allowed for controlling for potential confounding, describing effect measure 
modification by DNA methylation and heterogeneity by tumor subtype.  
2.8.2 Strength and Limitations of the PAH Exposure and DNA Methylation Assessment 
To the best of my knowledge, the LIBCSP is the only population study with extensive PAH 
exposure information from multiple sources and assessment of global and gene-specific 
promoter methylation data. The LIBCSP parent study has been a leader in previous research on 
the impacts of PAHs on breast cancer risk [4]. This is a unique opportunity to ascertain 
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individual-level exposure information for multiple PAH source exposures and to investigate 
multiple exposures simultaneously. 
This dissertation is thus an efficient use of existing resources; the long-term PAH 
exposure assessments, the demographic and other risk factor information, and biologic 
specimens for consideration of tumor subtypes and assessment of methylation have already 
been collected through the parent study. The detailed exposure information on multiple PAH 
sources allowed for exploring exposure across sources, a question that has not yet been 
addressed previously. The life course nature of exposure data is beneficial for assessing breast 
cancer risk factors as breast cancer is known to develop over many years [446].   
While active smoking, ETS exposure, stove/fireplace use and grilled/smoked meat 
intake was self-reported, ascertaining these over the life course by any other method would be 
incredibly challenging and time-intensive. For active smoking history in particular, self-report has 
been shown to be an accurate measure [207].  The LIBCSP vehicular traffic model has many 
strengths and is considered to be a state of the art exposure model, using PAH-specific vehicle 
emissions data, PAH-specific dispersion parameters which were validated and calibrated 
against residential soil PAH levels and PAH-DNA adduct levels measured in lymphocytes [133].  
However, there are some limitations to the exposure ascertainment.  The LIBCSP did 
not collect residential history information outside of Nassau and Suffolk counties or for 
addresses within Nassau or Suffolk counties at which a participant resided for less than one 
year [52]. This impacts our stove/fireplace information use as well as the vehicular traffic model; 
therefore any exposure outside for these residences would not be captured.  Nonresidential 
traffic exposures, stove/fireplace use and environmental tobacco smoke outside of the home 
(i.e. the work place) would not be included in our exposure assessment [74]. Finally and 
importantly, all of these PAH exposure sources are proxy measures for total PAH exposure and 
contain a large number of non-PAH chemicals, some of which are confirmed carcinogens [41, 
68, 252]. It is important to note that these measurements have been previously useful in 
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identifying important relationships between PAH exposure sources and breast cancer risk [74, 
175, 192, 230]. Similarly, the effect estimates reported by the Long Island study are similar to 
other associations reported by other investigators [85, 86, 212, 234]. Using these proxy 
measures of PAH exposure is the most efficient way to estimate the PAH-breast cancer 
association over the life course and across multiple PAH sources.  
 There were extensive quality control techniques implemented with the methylation data 
[297, 363, 415]. Equal proportions of cases and controls donated blood samples [297]. Tumor 
DNA was not available for all LIBCSP cases and therefore the case-only analysis with gene-
specific methylation was limited to those cases with tumor DNA available [415]. However, due to 
the population-based nature of the study, differences between those with and without tumor 
DNA can be quantified – which is useful in better characterizing any bias if it is present. 
Although this study contains multiple methylation markers that are known to be relevant to 
breast cancer [415], there could be some important methylation sites that were not considered 
in this analysis and therefore this study may be missing some possible biologically relevant 
associations.  
2.8.3 Strength and Limitations of the Data Analysis 
Hierarchical analysis is a useful approach to investigate multiple environmental exposures with 
breast cancer risk and is optimal for this research question to examine the relationship with 
these different PAH sources. While multiple comparisons is a consideration given the number of 
statistical tests in this dissertation, there was minimal use of p-values and all of these 
comparisons are biologically driven [447].  As such, I avoided using any correction for multiple 
comparisons.  
2.8.4 Strength and Limitations of the Data Interpretation 
We expected to find a 30-70% increase in the odds ratios for breast cancer incidence for the 
perceived ‘high’ exposure profiles of long-term PAH measure across the life course. We 
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expected these findings to vary by global DNA methylation markers and to see differential 
findings by breast cancer subtype. This dissertation did not rely heavily on significance testing in 
order to interpret the patterns of the PAH-breast cancer incidence associations. The precision of 
confidence intervals, the magnitude of effect estimates, and overall patterns of associations 
were taken into account when interpreting results. Additionally, results from this dissertation 
were carefully interpreted with consideration of the study limitations and strengths. 
 Identifying factors that influence an individual’s susceptibility to environmental 
exposures, in particular epigenetic markers included in this study, may help to uncover biologic 
pathways that are relevant to breast cancer. The relationship between tumor and peripheral 
blood DNA methylation levels has not yet been established. However, this was the first study to 
examine the direct associations of multiple long-term PAH sources on breast cancer risk, and to 
consider the role of both global and/or gene-specific DNA methylation biomarkers in this 
association. The results of this study may help to better inform the genes that are used for future 
studies of PAH sources. However, interpretation of the DNA methylation findings is challenging, 
given there is very little consistent data on DNA methylation, particularly for global DNA 
methylation, and breast cancer [312, 448]. While DNA methylation is believed to be an early 
step in carcinogenesis [449], it is unknown whether this association would exist prior to 
malignancy and if so, at what point these changes arise. The association between breast cancer 
and tumor DNA methylation is more consistent than it is with the more accessible surrogate 
biomarkers such as those in the peripheral blood [281]. However, biomarkers in the peripheral 
blood are of increasing interest as they would be more useful as a population-based screening 
tool to identify those at greatest risk [265].  
In sum, to address these significant study aims focused on a ubiquitous exposure, long 
term PAH exposure, and the most commonly occurring cancer among American women, this 
research study utilized a novel research strategy, a sophisticated hierarchical analysis approach 
and capitalized upon the existing resources of the LIBCSP. Efforts have been incorporated into 
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the approach to minimize potential biases, particularly with regard to measurement error of the 
PAH source components that will contribute to understanding associations with profiles of long-
term PAH exposure.  
2.9 Summary and Conclusions 
The LIBCSP is a large, population-based study with a comprehensive, life-course assessment 
of multiple PAH sources and has both global and gene-specific epigenetic markers. Additionally, 
LIBCSP has extensive data on a number of breast cancer risk factors that may act as 
confounders of this association. Using a case-control approach, I utilized hierarchical regression 
analysis to estimate associations across multiple long-term PAH sources (active cigarette 
smoking, ETS exposure, vehicular traffic, indoor stove use, and grilled/smoked food intake) and 
examine the association of these sources, and groups of sources, of PAH exposure with breast 
cancer incidence (AIM 1). Additional goals of this research included investigating the role of 
global (AIM 2A) and gene-specific DNA methylation (AIM 2B) in the PAH sources and breast 
cancer association, which may provide clues to the epigenetic mechanisms. I expected this 
study to find that high PAH exposure profiles are associated with an increase in the odds ratios 
for breast cancer incidence, and that those PAH sources that are most strongly associated with 
breast cancer incidence may interact with, or be associated with, aberrant DNA methylation.  
 PAHs are ubiquitous environmental carcinogens that women are exposed to from 
multiple sources, across the life course. No previous epidemiologic research has evaluated 
multiple PAH sources with respect to breast cancer risk. Previous population studies have been 
limited by relying on short-term biomarkers or single long-term PAH exposure measures, when 
in reality PAH exposures occur across the life course, and thus the PAH sources and their joint 
subsequent impact may vary over time. This dissertation addresses, in a cost-efficient manner, 
these novel research questions, because it draws upon the resources of the only existing 
epidemiologic study with extensive life course assessments of multiple long-term PAH sources 
and blood and tumor-based DNA methylation biomarkers. Using hierarchical analysis provides a 
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better understanding of the associations with breast cancer across PAH sources and identifies 
groups of PAH sources that would be most useful to target to reduce breast cancer risk. The 
findings, if confirmed, could be used to implement policies to decrease ambient PAH exposures 
to reduce breast cancer incidence.   
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Table 2.1 Study participant characteristics (n[%]) for the Long Island Breast Cancer 
Study Project, Long Island, New York, 1996-1997 (from Gammon et al., 2002 [52]) 
Factor  Cases 
(n = 1,508) 
Controls 
(n = 1,556) 
Age at 
reference    
 <35 39 (2.6) 45 (2.9) 
 35-44 181 (12.0) 245 (15.7) 
 45-54 397 (26.3) 423 (27.2) 
 55-64 372 (24.7) 403 (25.9) 
 65-74 365 (24.2) 310 (19.9) 
 75-84 134 (8.9) 112 (7.2) 
 85+ 20 (1.3) 18 (1.2) 
 Missing 0 0 
    
Race White 1411 (93.8) 1429 (91.8) 
 African-American 69 (4.6) 85 (5.5) 
 Other 25 (1.7) 42 (2.7) 
 Missing 3 0 
    
Education <High school 183 (12.2) 150 (9.7) 
 High school graduate 538 (35.8) 526 (33.9) 
 Some college 360 (24.0) 415 (26.7) 
 College graduate 191 (12.7) 236 (15.2) 
 Post college 230 (15.3) 225 (14.5) 
 Missing 6 4 
Marital Status    
 Ever Married 1443 (95.8) 1486 (95.5) 
 Never Married 64 (4.2) 70 (4.5) 
 Missing 1 0 
    
Income  <$20,000 188 (12.5) 169 (10.9) 
 $20,000-34,999 343 (22.8) 337 (21.7) 
 $35,000-49,999 243 (16.2) 264 (17.0) 
 $50,000-69,999 252 (16.8) 288 (18.5) 
 $70,000-89,999 190 (12.6) 210 (13.5) 
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 ≥$90,000.00 288 (19.2) 286 (18.4) 
 Missing 4 2 
    
Menopausal 
status Premenopausal 468 (31.7) 500 (33.5) 
 Postmenopausal 1010 (68.3) 993 (66.5) 
 Missing 30 63 
    
Age at 
menarche ≤12 years 671 (44.5) 686 (44.1) 
 >12 years 837 (55.5) 870 (55.9) 
 Missing 13 9 
    
Parity Nulliparous 198 (13.1) 171 (11.0) 
 Parous 1310 (86.9) 1385 (89.0) 
Lactation 
(parous) Never 841 (64.2) 840 (60.7) 
 <2 months 118 (9.0) 124 (9.0) 
 2-5 months 103 (7.9) 128 (9.2) 
 6-13 months 146 (11.2) 140 (10.1) 
 ≥14 months 102 (7.8) 153 (11.1) 
 Missing 0 0 
    
Body mass 
index at 
reference  <22.3 kg/m2 341 (22.9) 382 (25.0) 
 22.3-25.1 kg/m2 367 (24.6) 391 (25.60) 
 25.2-29.2  kg/m2 391 (26.2) 376 (24.61) 
 ≥29.2 kg/m2 392 (26.3) 379 (24.8) 
 Missing 17 28 
    
Alcohol use Never  588 (39.0) 593 (38.1) 
 Ever 920 (61.0) 963 (61.9) 
 Missing 0 0 
    
First degree 
family history of No   1166 (79.8) 1321 (87.0) 
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breast cancer 
 Yes 295 (20.2) 197 (13.0) 
 Missing 37 22 
    
Oral 
contraceptive 
use Never 848 (56.4) 840 (54.0) 
 Ever 657 (43.7) 715 (46.0) 
 Missing 3 1 
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Table 2.2 Overlap of PAH exposure variables by PAH source and case status.                                                  
Summary PAH 
variables PAH variables 
Controls 
 
Cases 
N %a 
 
N %a 
Any Active Smoking 855 100 833 100 
Current active smoking 291 34.0 649 43.0 
Smoking before first 
pregnancy 698 81.6 711 61.2 
Any ETS 1180 100 1162 100 
Any ETS from spouse  643 54.5 711 61.2 
High total 
Grilled/Smoked 
Meat Intake  944 100 991 100 
High grilled/bbq beef, pork 
and lamb 802 87.9 847 85.5 
High smoked beef, pork 
and lamb 629 66.6 660 46.5 
Fireplace Users 768 100 747 100 
Synthetic Logs 202 26.3 246 32.9 
Wood 699 91.02 674 90.2 
aPercentage is a function of the summary PAH variable   
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Table 2.3 Genes selected for methylation analysis and their putative functions (from Xu 
et al. 2011 [415])                                                  
Gene Full name Group Function 
Assayed 
sample N 
Methylated 
samples 
(%) 
ESR1 
estrogen 
receptor 1 
steroid 
hormone 
receptor 
hormone binding, 
DNA binding and 
activation of 
transcription 851 44.8 
PGR 
progesterone 
receptor 
steroid 
hormone 
receptor 
mediates the 
physiological effects 
of progesterone 851 11.9 
BRCA1 
breast cancer 
1, early onset 
tumor 
suppressor 
maintaining genomic 
stability 851 59.0 
APC 
adenomatous 
polyposis coli 
tumor 
suppressor 
an antagonist of the 
Wnt signaling; 
Defects cause 
familial adenomatous 
polyposis 800 48.4 
p16/CDKN2A 
cyclin-
dependent 
kinase inhibitor 
2A 
tumor 
suppressor cell cycle control 777 3.6 
HIN1/SCGB3A1 
secretoglobin, 
family 3A, 
member 1 
tumor 
suppressor 
growth-inhibitory 
cytokine, regulates 
epithelial cell 
differentiation. 765 62.9 
RASSF1A 
Ras association 
domain family 
member 1 
tumor 
suppressor 
involved in cell cycle 
control 765 85.2 
DAPK1 
death-
associated 
protein kinase 1 
tumor 
suppressor 
a positive mediator 
of gamma-interferon 
induced programmed 
cell death 765 14.1 
GSTP1 
glutathione S-
transferase pi 1 Detoxification 
xenobiotic 
metabolism 765 27.8 
CCND2 cyclin D2 Oncogene 
regulators of CDK 
kinases 765 19.6 
TWIST1 twist homolog 1 
transcription 
factors 
cell lineage 
determination and 
differentiation 765 15.3 
CDH1 E-cadherin 
tumor 
suppressor 
cell proliferation, 
invasion and/or 
metastasis 765 5.8 
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Gene Full name Group Function 
Assayed 
sample N 
Methylated 
samples 
(%) 
RARβ 
retinoic acid 
receptor, beta 
steroid 
hormone 
receptor 
mediates cellular 
signalling in 
embryonic 
morphogenesis, cell 
growth and 
differentiation 765 27.6 
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Table 2.4 LIBCSP participants with data on: (1) PAH sources for patterns of exposure; (2) 
DNA methylation measures (*with variable N as shown in TABLE 2.2) and (3) key 
covariates to define susceptibility. 
LIBCSP DATA RESOURCES     Available for Dissertation Control 
N 
Case 
 N 
                                                                  Total LIBCSP Study 
Population 
1556 1508 
(1.) Patterns of PAH Sources Components   
Active Smoking 1553 1508 
Passive Smoking 1383 1356 
Grilled/Smoked Foods 1518 1485 
Indoor Stove Use 1549 1502 
1995 Vehicular Traffic Exposure Estimates (CCA) 1334 1274 
1960-1990 Vehicular Traffic Exposure Estimates (20% MI) 552 558 
(2.) DNA Methylation Measures   
Global Methylation 1101 1055 
Gene-specific Tumor Methylation N/A 765-851* 
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Figure 2.1. Directed acyclic graph (DAG) to evaluate confounding for the association 
between PAH exposure and breast cancer risk. 
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CHAPTER III. EXPOSURE TO MULTIPLE SOURCES OF POLYCYCLIC AROMATIC 
HYDROCARBONS AND BREAST CANCER INCIDENCE  
3.1 Introduction 
Breast cancer is the most commonly diagnosed cancer among women in the U.S. [7]. Whether 
environmental exposures contribute to breast cancer incidence remains unclear. Experimental 
research suggests that polycylic aromatic hydrocarbons (PAHs) induce mammary tumors [68], 
but associations in women are understudied. Women are exposed to PAHs across the life 
course from multiple sources, including cigarette smoking, environmental tobacco smoke (ETS), 
diet, indoor and outdoor air pollution [41]. PAHs are formed from the incomplete combustion of 
organic material and are confirmed carcinogens to the human lung [68].  
Previous population studies have observed positive associations between short-term 
blood and tissue-based PAH biomarker concentrations (including those from PAH-DNA 
adducts) and breast cancer incidence [88, 90, 92]. However, it is unclear from biomarker studies 
which PAH sources are the predominant contributors to these associations. As long-term 
exposure to potential carcinogens is considered to be most relevant for carcinogenesis, other 
studies have considered single, isolated PAH exposure sources and have found consistent 
increases in breast cancer incidence in association with active cigarette smoking [72], long-term 
residential ETS [73, 74, 227], indoor air pollution from burning synthetic logs [175], outdoor air 
pollution [83-86, 188, 192] and intake of grilled and smoked foods [80, 81, 230].   
Women are exposed to multiple PAH sources and estimation of the association with 
breast cancer risk may be improved if these multiple sources are considered together. The 
relative contribution of PAH sources to an individual’s exposure is unknown [41]. Active smoking 
is likely the largest contributor [131], but diet is the predominant source among non-smokers 
 113 
 
[41]. However, carcinogenic potency is hypothesized to vary by route of exposure [131], 
metabolic pathway and type of PAH [41]. Thus, it is unclear whether certain sources, groups of 
sources, or all PAH sources should be targeted for breast cancer risk reduction. 
 The study reported here aims to consider, in a single hierarchical regression model, the 
impact of multiple long-term PAH sources on breast cancer incidence. Variables from the same 
exposure source (for example, different measures of grilled/smoked meat intake) are highly 
correlated. A hierarchical regression approach permits estimation of odds ratios (ORs) for a 
disease outcome considering multiple PAH source exposures in a single multivariable model, 
while accounting for similar sources of the PAH exposures. Additionally, by using a single 
statistical model we are able to estimate the OR for groups of PAH sources, or PAH exposure 
profiles, based on contrasting a priori defined exposure groups of interest across the main 
sources.  
3.2 Methods 
The study reported here builds upon the population-based case-control resources of the Long 
Island Breast Cancer Study Project (LIBCSP), for which extensive methods have been 
previously published [52]. IRB approval was obtained from all relevant institutions. Written 
signed informed consent was obtained from all participants.  
 Study Population. The cases are English-speaking female residents of Nassau or Suffolk 
counties on Long Island, New York who had been diagnosed with their first primary in situ or 
invasive breast cancer between August 1st, 1996 and July 31st, 1997. Cases were identified 
using rapid case ascertainment with study personnel contacting the pathology departments of 
28 hospitals on Long Island and three tertiary care hospitals in New York City on a daily or 
weekly basis. Controls were women without a history of breast cancer who resided in the same 
two source counties as the cases and were frequency matched on the expected 5-year age 
distribution of the cases. Controls were identified using random digit dialing for those less than 
 114 
 
65 years of age and by using Health Care Finance Administration Rosters for those 65 years of 
age and older.  
PAH Exposure Sources Assessment.  Five binary PAH exposure sources were 
assessed across the life course. Active smoking, residential ETS, grilled/smoked meat intake, 
and indoor wood-burning stove/fireplace use were assessed by structured questionnaire [74, 
175, 230] with a trained interviewer, and vehicular traffic exposure was assessed using a 
validated historical geographic model [133, 192].  Exposure coding decisions were based on 
previous published LIBCSP results [74, 175, 192, 230]. Continuous variables required 
categorization because associations with breast cancer were non-linear nor log-linear and were 
dichotomized in order to facilitate interpretation and scaling in the hierarchical regression across 
PAH sources.  
Active smoking (ever, never) was defined as smoking at least 1 cigarette per day for 6 
months or longer, and current active smoking (yes, no) was defined as smoking within the last 
12 months prior to diagnosis or referent date for controls (=date of identification).. Smoking prior 
to first birth (yes, no) was determined by using age at first birth and age at which participant first 
starting smoking. Participants were asked if they had lived with a smoker to determine ETS 
exposure (yes, no) and their relationship to that person to evaluate if they lived with a smoking 
spouse (yes, no). Indoor stove/fireplace use was defined as having used a stove/fireplace in a 
Long Island residence for at least 3 times per year (yes, no) and whether or not participants 
burned wood (yes, no) and/or synthetic logs (yes, no).   
Continuous variables for the PAH sources were dichotomized using cutpoints that best 
reflected previous associations observed with breast cancer incidence [192, 230]. Frequency of 
intake of grilled/smoked meat was assessed for six decades across the life course, or fewer 
depending on age at diagnosis. Lifetime intake was defined as the average servings consumed 
per year based on quantile distributions of consumption in the controls, as follows: for total 
grilled/barbecued and smoked meats (<33% vs ≥33% percentile or <55 servings/year, 55+ 
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servings/year); grilled/barbecued beef, pork and lamb (<33% vs ≥33% percentile or <14, 14+ 
servings/year); and smoked beef, pork and lamb (<50th percentile, ≥50th percentile or <22, 22+ 
servings/year). The geographic model for vehicular traffic exposure incorporated historical U.S. 
vehicular PAH emissions data, information on traffic and transportation patterns, Long Island 
meteorological variables and pollutant dispersion factors to determine vehicular traffic exposure 
in 1995, the year prior to LIBCSP recruitment (low risk= <95th percentile, high risk= ≥95th 
percentile). Previously, we found the association with breast cancer to be limited to the top 5% 
of those exposed to vehicular traffic [192]. 
Confounder Assessment.   A directed acyclic graph was used to identify a minimally 
sufficient set to control for confounding [450]. The effect estimates were adjusted for the 
following covariates, which were assessed by structured questionnaire [52]: age at menarche 
(≤12, >12 years); parity (nulliparous, parous); lifetime alcohol intake (non-drinkers, <15g/day, 
15g-30g/day, ≥30 g/day); education (high school graduate or less, some college, college or 
post-college); income (<$34,999, $35,000-$69,999, ≥$70,000); and the frequency matching 
factor, 5-year age group.  
Statistical Analysis. To examine the associations between the main PAH sources and 
PAH groups and breast cancer incidence, 12 binary PAH exposure variables were considered. 
For our primary analysis, these 12 variables were characterized according to five exposure 
sources: (1) active smoking: ever active smoking, current active, smoking prior to first 
pregnancy; (2) residential ETS: any residential ETS, residential ETS from spouse; (3) indoor 
stove and/or fireplace use: any stove/fireplace use, wood burning, synthetic log burning; (4) diet: 
total grilled/barbecued and smoked meats, smoked beef, pork and lamb and grilled/ barbecued 
beef, pork and lamb; and (5) vehicular traffic. Estimating associations with the PAH exposure 
variables by these five exposure sources facilitates understanding which of these sources to 
prioritize for reduction from a public health standpoint.  
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All models were specified in a Bayesian framework and we calculated posterior means 
for the ORs and corresponding 95% posterior credible intervals (CrI, the Bayesian analog to a 
confidence interval) [451]. The risk of breast cancer was specified using logistic regression.  
logit[Pr(Y=1 ∣ X,W, β, γ)] = α +  Xβ + Wγ 
where Y is case status, X denotes the individual PAH exposures, and W is a vector of 
confounders. The β coefficient represents the association [ln(OR)] of the individual PAH sources 
with breast cancer.  
Hierarchical regression builds upon this first-level model by specifying a second-level 
model that incorporates information on the PAH sources that may explain the individual PAH-
exposure associations [74, 175, 192, 230]. The second level of the hierarchical regression for 
the logistic coefficient β is: 
β=Zπ + δ 
where Z is the second-stage design matrix (Table A.1) with each row corresponding to a β from 
the first-stage model and each column corresponding to an exposure source, which encodes 
our prior information about the PAH exposure variables and their respective sources. The 4x1 
coefficient vector π corresponds to the associations between the second stage covariates (PAH 
exposure source) and the log-OR with breast cancer and δ is assumed to be normally 
distributed with a mean=0 and a variance=τ2.  
For our analysis, the columns of the Z matrix represent the four groups of PAH exposure 
sources of interest: active smoking, residential ETS, indoor stove/fireplace, grilled/smoked meat 
intake. This approach accounts for a degree of similarity of PAH exposures that come from 
similar sources while allowing some residual variation (δ) associated with these effects. If the 
PAH exposure variables were thought to be related to a particular source they were scored as 
1, otherwise were coded as 0. As only one variable was available for vehicular traffic, there was 
no column in the Z-matrix for it and thus, it effectively serves as its own source.     
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Combining these equations allows for estimation of the association between each PAH 
variable, according to PAH source, and breast cancer: 
logit[Pr(Y=1 ∣ X,Z, W)] = α + XZπ+X δ+ Wγ, 
where, from this mixed-model specification, the π and γ correspond to fixed effects of 
the PAH sources and confounders, respectively, and δ contains the random exposure-level 
effects [451-453]. 
For the intercept (α), and covariate coefficients (π and γ), a relatively non-informative 
normally-distributed prior was used (mean=0, variance=1000). For τ, a uniform prior from 0.01 
to 100 was used. We specified an additional model to account for the approximately 15% of the 
1995 vehicular traffic data that were missing. Missing data are easily accommodated in a 
Bayesian framework by specifying a distribution for the variable with missing data [438, 439]. In 
this case, the indicator of high vehicular traffic level was modeled from a logistic regression with 
covariates income (<$34,999, $35,000-$69,999, ≥$70,000), education (high school graduate or 
less, some college, college or post-college) and age (5-year age groups), with relatively non-
informative normal priors on their coefficients (mean=0, variance=1000). In addition to this 
hierarchical model, for comparison, we also estimated single exposure and multivariable models 
(only estimating α, β and γ from the first stage model without specifying a second-stage model), 
including the missing data model for 1995 vehicular traffic. For the single exposure model, each 
PAH variable was modeled alone; for the multivariable model, all individual exposures were 
included simultaneously. These models correspond to common analytical methods employed in 
similar analyses [435, 454].  
From the hierarchical model, the posterior mean of the OR and corresponding 95%CrI 
for PAH exposure profiles of interest relative to women who had low PAH exposure were 
estimated by calculating linear combinations of the relevant β coefficients (Table A.2). These 
profiles were predetermined to facilitate interpretation by considering typical or potentially 
informative patterns of exposure across the 12 PAH measures. The profiles that span across 
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PAH sources were chosen in part based on classifications that had sufficient numbers of cases 
and controls to estimate associations. The PAH exposure profiles of interest were defined as: 
(1) the referent of low PAH exposure (non-smokers, no residential ETS, low intake of 
grilled/smoked foods (<55 servings/year total grilled/barbecued and smoked meats, <14 
servings year of grilled/barbecued beef, pork and lamb, <22 servings year of smoked beef, pork 
and lamb), low risk vehicular traffic (<95th percentile), and no stove/fireplace use); (2) tobacco 
smoke (current, active smokers who started prior to first pregnancy and were exposed to 
residential ETS from a spouse); (3) ingested PAHs (high intake of overall grilled/smoked foods 
(55+ servings/year), grilled/barbecued beef, pork and lamb (14+ servings/year), and smoked 
beef, pork and lamb (22+ servings/year)); (4) indoor stove/fireplace users (indoor stove/fireplace 
users who burned both wood and synthetic logs); (5) inhaled PAHs (active smokers, residential 
ETS, high risk vehicular traffic (top 5th percentile), stove/fireplace users); (6) indoor source 
PAHs (active smokers, residential ETS from spouse, high overall grilled/smoked foods (55+ 
servings/year), and stove/fireplace users); (7) five PAH sources (active smokers, residential 
ETS, high overall grilled/smoked foods (55+ servings/year), stove/fireplace users and high risk 
vehicular traffic exposure (top 5th percentile)). Sample sizes of cases and controls that were 
classified as exposed to each profile were determined. Posterior probability density functions for 
being a breast cancer case were estimated for the low PAH and the indoor source PAH profiles 
in order to visualize the differences in the probability of being a case between those two groups. 
To estimate posterior probabilities, confounders were specified at their modal values (age: 50-
54 years; income: $35,000-$69,999; education: high school or less; parity: parous; alcohol 
intake: <15g/day; age at menarche: >12 years) and PAH sources not specified in the definition 
of the profiles were set to the referent category.    
Sensitivity Analyses.  The hierarchical model was also fit 5 times using 5 separate 
datasets with multiple imputed historical 1960-1990 vehicular traffic estimates (up to 20% 
missing data imputed) to compare results across the 5 datasets and from the model fit only with 
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the 1995 estimates [423]. Continuous scaled (divided by 2 standard deviations) coding of active 
smoking, residential ETS, and grilled/smoked meat variables were considered [444]. Another Z-
matrix configuration was evaluated, where the second-level model included two routes of 
exposure, ingestion versus inhalation.  
Posterior means and credible intervals (CrI) of the model parameters were estimated by 
sampling from their joint posterior distribution through Gibbs sampling [455] conducted using 
JAGS [456] and the package R2jags [457] through the R language (R Foundation for Statistical 
Computing, Vienna, Austria). The 95% CrI represents the 2.5th and 97.5th percentiles from the 
estimated posterior distribution for each parameter. R code for the hierarchical Bayes analysis is 
included in the supplement. Trace plots were visually examined to evaluate convergence. 
3.3 Results 
Women in this population-based sample from Long Island NY were heavily exposed to PAHs 
across multiple sources (Table 3.1). Approximately 20% were current smokers; almost 80% had 
at one time or another lived in a home with a smoker; and almost half used stove/fireplaces in 
their home. Most women consumed at least 1 serving/week of grilled/barbecued/smoked meats.   
ORs for breast cancer incidence were elevated for residential ETS from a spouse 
(OR=1.20, 95%CrI=1.03, 1.40), total grilled/smoked foods (OR=1.16, 95%CrI=0.97, 1.38), 
vehicular traffic (OR=1.25, 95%CrI=0.85, 1.76) and synthetic log burning (OR=1.29, 
95%CrI=1.06, 1.57) in the hierarchical model (Table 3.2). The hierarchical analyses, 
incorporating second-stage information about the PAH exposure source, resulted in more 
precise estimates than the multivariable analyses as demonstrated by the smaller credible limit 
ratios (CrLRs). These hierarchical results were slightly attenuated from the single exposure 
estimates when modeling each PAH source individually. Results from the single exposure 
models are similar to, but differ slightly from results published previously [74, 175, 192, 230] due 
to changes in variable characterizations, analytic approach and adjustment set. In the 
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multivariable analysis, most of the estimates for the PAH variables remained similar although 
some estimates were attenuated in comparison to the single exposure estimates.  
 The overall fixed estimates for the PAH sources (2nd level estimates for active smoking, 
residential ETS, diet, stove/fireplace use and 1st level estimate of vehicular traffic) from the 
hierarchical model showed little evidence of an association with breast cancer incidence, with 
estimates close to null or imprecise (Table 3.3). An OR of 1.25 was observed in the hierarchical 
regression for vehicular traffic, although the credible intervals are wide and include the null 
value (OR=1.25, 95%CrI=0.85, 1.76).  
Less than 2% of women were characterized as having a low PAH exposure profile (n=26 
cases and n=21 controls) (Table 3.4). Very few women were considered exposed across all five 
PAH sources or by all the sources of inhalation (<1%), whereas about 10% of cases and 
controls were exposed across the indoor sources of PAH (active smoking, residential ETS, high 
overall grilled/smoked foods and stove/fireplace users).  
The OR for the association between breast cancer incidence and the indoor exposure 
source profile of PAH was elevated by 1.45 (OR=1.45, 95%CrI 1.02, 2.04; CrLR=1.99) (Table 
3.4, Figure A.1 and A.2).  Among women who were highly exposed to PAH via ingestion, the 
effect estimate was elevated by 1.44 (OR=1.44, 95%CrI 1.16, 1.78; CrLR=1.53). The OR for the 
PAH inhalation profile was 1.29, but the credible intervals included the null value (active 
smokers, residential ETS, top 5% of vehicular traffic, and stove/fireplace use; OR=1.29, 
95%CrI=0.77, 2.02; CrLR=2.61). Estimates were elevated for women who used stove/fireplaces 
in their home, burning both wood and synthetic logs (OR=1.29, 95%CrI=1.03, 1.59). Exposure 
profiles that included vehicular traffic exposure were imprecise due to the small number of 
people who were classified as highly exposed. For example, the OR for exposure from all five 
PAH sources was 1.50 (active smokers, residential ETS, top 5% of vehicular traffic, 
stove/fireplace users, grilled/smoked meat intake; OR=1.50, 95%CrI 0.87, 2.38; CrLR=2.74), but 
the credible intervals included the null value.  
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A sensitivity analysis was conducted with long-term exposure to vehicular traffic from 
1960-1990 included in the model, as estimates for long-term exposure have been found to be 
more strongly associated with breast cancer incidence in this study population [192]. Inclusion 
of long-term vehicular traffic did not strengthen the fixed-effects for vehicular traffic exposure 
(data not shown). The large amount of missing data for exposures in the distant past and few 
women who were categorized as being highly exposed for long-term vehicular traffic precluded 
this PAH source from being included in the primary analysis. Long-term exposure to vehicular 
traffic is highly correlated with 1995 exposure and thus, 1995 estimates may be a sufficient 
proxy for long-term vehicular traffic [192]. Estimates remained similar when using scaled 
continuous coding of the active smoking, residential ETS and grilled/smoked meat intake 
variables (data not shown). Therefore, the indicator coding model was used as it is more easily 
interpreted. When considering an alternative Z-matrix specification with a second-level model 
comprised of ingestion and inhalation, second-level estimates were similar (ingestion OR=1.13, 
95%CrI=0.95, 1.34; inhalation OR=1.07, 95%CrI=0.96, 1.18) (Table A.3).  The ORs for single 
PAH variables were also very similar after applying the alternative Z-matrix although the 
estimate for vehicular traffic was more precise (Table A.3; OR=1.12, 95%CrI 0.90 1.39; 
CrLR=1.54).  
3.4 Discussion 
Women in this population-based sample from Long Island NY were exposed to PAHs across 
multiple sources and very few were classified as having a low PAH exposure profile, 
underscoring the ubiquitous nature of PAH exposure. Exposure across indoor sources of PAH 
(active smoking, residential ETS from spouse, grilled/smoked meat intake, stove/fireplace use) 
was associated with a 1.45 increase in breast cancer incidence. For other PAH profiles, in 
particular ingestion and indoor stove/fireplace use, the OR for breast cancer were also elevated 
by 1.3 to 1.5.   
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The results reported here are consistent with laboratory evidence [68] and the existing 
epidemiologic literature on PAH sources and breast cancer incidence [72, 73, 81, 83-86, 227]. 
Consideration of all main PAH exposure sources concurrently in a single model provided effect 
estimates that better reflect the exposure complexity of multiple long-term PAH sources on 
breast cancer risk. All of the predominant PAH sources, tobacco smoke, indoor and outdoor air 
pollution and diet are modifiable breast cancer risk factors that can be reduced. The findings 
here suggest that all of the PAH sources considered contribute notably to breast cancer risk, in 
particular the sources included in the indoor PAH exposure profile. Similar findings were found 
for PAH profiles of ingestion and inhalation. Thus, one exposure route may not necessarily be 
more important for breast cancer risk than the other.  
Vehicular traffic is often considered to be the largest source of PAHs in outdoor air 
pollution, particularly in urban locations [177] Among our population-based sample of women on 
Long Island NY, vehicular traffic was associated with an elevated, but also very imprecise, OR 
for breast cancer risk. Despite this, vehicular traffic did not notably increase PAH profile 
estimates (e.g., when comparing estimates for indoor sources of PAH to all five sources) likely 
due to the fact that only the top 5% were considered exposed. This may not be the case in 
geographic locations where vehicular traffic exposure is higher and thus impacts more women. 
Although in our Long Island sample exposure levels were increased for historical exposure to 
vehicular traffic, 1995 vehicular traffic exposure is strongly correlated with long-term vehicular 
traffic exposure and thus may be considered a sufficient proxy [192]. We were unable to 
consider historical traffic exposure (1960-1990) due to the large amount of missing data in the 
distant past although it was more strongly associated with breast cancer incidence, as shown in 
our previous report [192].  In our sensitivity analyses, long-term vehicular traffic exposure did 
not notably change the second-level fixed effects for vehicular traffic, but the inclusion of that 
variable in our profile estimates may have resulted in more pronounced associations for women 
with high levels in both 1960-1990 and in 1995.  
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Our study reported here has many strengths, in particular the population-based design. 
Additionally, this study has uniquely collected information on life course exposure to the main 
PAH sources. The use of Bayes hierarchical analysis to model these main sources concurrently, 
and their profile-level associations, is useful to better understand the impact of multiple sources 
of interest. Our results were only slightly attenuated when comparing single and hierarchical 
models, thus, these results are encouraging that at least in the case of these PAH sources, 
modeling them individually may produce acceptable results.  
Several issues may impact interpretation of the study findings reported here. For 
example, self-reported exposure to the PAH sources could result in bias due to misclassification 
error in the PAH exposure markers. However, self-reported active cigarette smoking and ETS 
have been previously found to be a valid measurement [207]. Whether cases and controls 
reported these exposures differentially is unknown; however, at the time of LIBCSP data 
collection in the mid-1990s, most media attention in the Long Island NY area focused on the 
potential adverse effects of other environmental contaminants, including exposure to pesticides 
and electromagnetic fields, but not PAH sources [52]. Estimating vehicular traffic exposure was 
dependent upon each participant recalling her residential history, and the accuracy of the 
participant reporting this information is unlikely to be associated with her case-control status. 
Thus, any misclassification error associated with this exposure is likely to be non-differential. 
Yet, the OR associated with high vehicular traffic exposure was stronger in magnitude but with 
wide credible intervals in the hierarchical model.  
Importantly, the PAH sources characterized here also contain other chemicals, some of 
which may also be relevant to carcinogenesis [68]. However, PAHs have a strong biological 
rationale with breast cancer incidence and we hypothesize that PAHs are a large part of the 
underlying biologic mechanism [4]. Residential information was available only for Long Island 
residences based on the design of the study questionnaire. Therefore, if a woman used a 
stove/fireplace at any home not on Long Island, information on that source, or on vehicular 
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traffic exposure, would not have been included in this study [175]. The small number of women 
who were classified as low PAH exposure precluded us from considering associations by tumor 
subtype and potential effect measure modifiers. It is possible that PAH sources may be 
differentially associated with specific tumor subtypes and we were unable to address that. 
Patterns of exposure to the main PAH sources also has likely changed since the time of 
LIBCSP data collection (1996-1997), most significantly with the general decrease in tobacco 
use.[458] Finally, findings in this Long Island-based study population may not be generalizable 
to all women, since these women were predominately white and postmenopausal at diagnosis. 
However, these are women at the highest risk of breast cancer in the United States [7]. 
In conclusion, this epidemiologic study reports that experiencing a number of common 
PAH exposure sources is associated with a 30-50% increase in breast cancer incidence. The 
indoor sources of exposure (active/passive smoking, grilled/smoked food intake, indoor 
stove/fireplace use considered together) had the strongest association with breast cancer and 
are among the most common sources of long-term PAH exposures identified in our population-
based sample of women on Long Island, NY. This study provides support for existing public 
health strategies to reduce cigarette smoking and vehicular traffic exposure, as well as targeting 
other PAH sources in an effort to reduce a woman’s risk of developing breast cancer. 
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Table 3.1 Distribution of demographic characteristics and PAH exposure measures for 
study participants, by case-control status, LIBCSP 1996-1997.  
 Controls 
(N=1,556) 
Cases 
 (N=1,508) 
  N (%) N (%) 
Age Groupa 
<35   45 (2.9) 39 (2.6) 
35-44 245 (15.7) 181 (12.0) 
45-54 423 (27.2) 397 (26.3) 
55-64 403 (25.9) 372 (24.7) 
65-74 310 (19.9) 365 (24.2) 
75-84 112 (7.2) 134 (8.9) 
85+   18 (1.2) 20 (1.3) 
Incomea 
< $34,999 506 (32.6) 531 (35.3) 
$35,000-$69,999 552 (35.6) 495 (32.9) 
$70,000+ 496 (31.9) 478 (31.8) 
Educationa 
High school grad or less         676 (43.6) 721 (48.0) 
Some College            415 (26.7) 360 (24.0) 
College or Post-college 461 (29.7) 421 (28.0) 
Lifetime Alcohol Intakea 
Non-drinkers               605 (39.0) 598 (39.7) 
lifetime intake <15g/day   735 (47.3) 691 (45.8) 
lifetime intake 15-30g/day 119 (7.7) 147 (9.7) 
lifetime intake => 30g/day 94 (6.1) 72 (4.8) 
Parity     
Nulliparous 171 (11.0) 198 (13.1) 
Parous 1,385 (89.0) 1,310 (86.9) 
Age at menarche     
≤12 686 (44.1) 671 (44.5) 
>12 870 (55.9) 837 (55.5) 
Ever Active Smokingb 
Never 698 (44.9) 675 (44.8) 
Ever 855 (55.1) 833 (55.2) 
Missing 3  0  
Current Active Smokingb 
No 1262 (81.3) 1218 (80.8) 
Yes 291 (18.7) 290 (19.2) 
ETSb 
Never 328 (21.6) 301 (20.5) 
Ever 1188 (78.4) 1170 (79.5) 
ETS from spouseb 
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Never 865 (57.1) 752 (51.2) 
Ever 650 (42.9) 716 (48.8) 
Smoking before first 
pregnancyb 
No 855 (54.9) 859 (57.0) 
Yes 701 (45.1) 649 (43.0) 
Grilled/barbecued/smoked 
meat intakec 
≤54 servings/year 500 (34.6) 427 (30.1) 
55+ servings/year 944 (65.4) 991 (69.9) 
Grilled/barbecued beef, 
pork and lambc 
≤13 servings/year 569 (37.5) 523 (35.2) 
 14+ servings/year 949 (62.5) 962 (64.8) 
Smoked beef, pork and 
lambc 
≤21 servings/year 774 (50.4) 717 (48.4) 
22+ servings/year 762 (49.6) 763 (51.6) 
Vehicular traffic 1995d 
<95th percentile  1267 (95.0) 1197 (94.0) 
=>95th percentile 67 (5.0) 77 (6.0) 
Fireplace usee 
Never 781 (50.4) 757 (50.3) 
Ever 768 (49.6) 747 (49.7) 
Wood burninge 
Never 850 (54.9) 830 (55.2) 
Ever 699 (45.1) 674 (44.8) 
Synthetic log burninge     
Never 1347 (87.0) 1258 (83.6) 
Ever 202 (13.0) 246 (16.4) 
a previously published in Gammon et al., 2002 
b previously published in Gammon et al., 2004 
c previously published in Steck et al., 2007 
d previously published in Mordukhovich et al., 2015 
e previously published in White et al., 2014
  
 
1
2
7
 
 
Table 3.2. Adjusted odds ratios (OR), 95% credible intervals (CrI) and credible limit ratios (CrLR) for multiple long-term PAH 
source exposures and breast cancer incidence using single exposure, multivariable and hierarchical analyses, LIBCSP 
1996-1997a. 
Single Exposure c Multivariable Analysis  Hierarchical Analysis 
PAH Source 
(π) PAH Variables (β)b   OR (95%CrI) CrLR   OR (95%CrI) CrLR   OR (95% CrI) CrLR 
Active Smoking 
Ever active smoking 1.04 (0.89, 1.22) 1.37 1.03 (0.75, 1.37) 1.83 1.01 (0.83, 1.21) 1.45 
Current active smoking 1.15 (0.93, 1.40) 1.51 1.15 (0.91, 1.44) 1.57 1.09 (0.91, 1.30) 1.43 
Smoked before first pregnancy 1.01 (0.85, 1.18) 1.39 0.94 (0.68, 1.26) 1.85 0.97 (0.79, 1.17) 1.47 
Residential ETS 
Ever residential ETS 1.08 (0.90, 1.30) 1.44 0.92 (0.74, 1.15) 1.55 1.00 (0.82, 1.19) 1.45 
Ever residential ETS from 
spouse 1.27 (1.07, 1.48) 1.38 1.28 (1.07, 1.54) 1.44 1.20 (1.03, 1.40) 1.36 
Diet 
Total grilled/bbq and smoked 
meats 1.34 (1.13, 1.59) 1.41 1.21 (0.94, 1.51) 1.61 1.16 (0.97, 1.38) 1.42 
Grilled/bbq beef, pork and lamb 1.27 (1.07, 1.49) 1.39 1.13 (0.91, 1.38) 1.51 1.14 (0.96, 1.34) 1.39 
Smoked beef, pork and lamb 1.19 (1.02, 1.38) 1.35 1.07 (0.89, 1.28) 1.43 1.09 (0.95, 1.26) 1.33 
Vehicular traffic 
1995 vehicular traffic 1.20 (0.81, 1.70) 2.10 1.26 (0.86, 1.76) 2.06 1.25 (0.85, 1.76) 2.07 
Stove/fireplace 
use 
Ever any stove/fireplace use 1.09 (0.93, 1.27) 1.37 1.06 (0.70, 1.51) 2.16 1.03 (0.85, 1.24) 1.47 
Ever synthetic log burning 1.46 (1.18, 1.82) 1.58 1.47 (1.15, 1.86) 1.62 1.29 (1.06, 1.57) 1.49 
  Ever wood burning   1.05 (0.90, 1.23) 1.37   0.92 (0.62, 1.31) 2.05   0.98 (0.80, 1.17) 1.47 
a adjusted for age at menarche, parity, lifetime alcohol intake, education, income and the matching factor, 5-year age group. 
b See Table I for PAH variable cutpoints 
c estimates do not exactly conform to previously published results, because of changes in variable definition and confounder 
adjustment  (Gammon  et al., 2004, Steck et al., 2007, White et al., 2014, Mordukhovich et al., 2015) 
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Table 3.3. Fixed effects odds ratios (OR) and 95% credible intervals (CrI) from 
hierarchical logistic regression models for the association between long-term PAH 
exposure, grouped by exposure sources, and breast cancer incidence, LIBCSP 1996-
1997a. 
 
PAH Exposure Sources 
(π) OR (95% CrI) 
 Active smoking 1.02 (0.85, 1.23) 
Residential ETS 1.10 (0.86, 1.40) 
Diet  1.13 (0.93, 1.36) 
Vehicular trafficb 1.25 (0.85, 1.76) 
Indoor stove/fireplace use 1.09 (0.90, 1.31) 
a adjusted for age at menarche (≤12, >12), parity (nulliparous, parous), lifetime alcohol intake 
(non-drinkers, <15g/day, 15g-30g/day, ≥30 g/day), education (high school graduate or less, 
some college, college or post-college), income (<$34,999, $35,000-$69,999, ≥$70,000) and the 
matching factor, 5-year age group. 
b vehicular traffic estimate is derived from first-level of hierarchical model because there is only 
one variable within that PAH source  
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Table 3.4. Odds ratios (OR) and 95% credible intervals (CI) from hierarchical regression 
models for the association between PAH exposure profiles and breast cancer incidence, 
LIBCSP 1996-1996a 
 
Cases 
 (N=1,508) 
 
Controls 
(N=1,556) 
PAH Exposure Profilesb N %   N % OR (95%CrI) 
       Low PAH exposurec 26 1.7% 21 1.3% 1.00 (referent) 
Tobacco smoke (active and 
ETS)d 123 8.2% 124 8.0% 1.26 (0.94, 1.67) 
Ingested PAHse 531 35.2% 504 32.4% 1.44 (1.16, 1.78) 
Indoor stove/fireplace usef 206 13.7% 168 10.8% 1.29 (1.03, 1.59) 
Inhaled PAHsg 18 1.2% 15 1.0% 1.29 (0.77, 2.02) 
Indoor source PAHs h 160 10.6% 166 10.7% 1.45 (1.02, 2.04) 
Five PAH sourcesi 9 0.6%   9 0.6% 1.50 (0.87, 2.38) 
aadjusted for age at menarche (≤12, >12), parity (nulliparous, parous), lifetime alcohol intake 
(non-drinkers, <15g/day, 15g-30g/day, ≥30 g/day), education (high school graduate or less, 
some college, college or post-college), income (<$34,999, $35,000-$69,999, ≥$70,000) and the 
matching factor, 5-year age group. ORs and 95%CrI are derived from hierarchical regression, 
not directly from sample sizes shown above.  
b See Table I for PAH variable cutpoints and Supplemental Table II for profile definitions.  
c non-active smoker, no residential ETS, low intake of grilled/smoked foods, low vehicular traffic 
emissions, no stove/fireplace use 
d current, active smokers who started prior to first pregnancy and were exposed to residential 
ETS from spouse 
e high intake of overall grilled/smoked foods, grilled/barbecued beef, pork and lamb and smoked 
ham, pork and lamb 
f  indoor stove/fireplace users, burned both wood and synthetic logs 
g active smokers, residential ETS, top 5% of vehicular traffic, stove/fireplace users 
h active smokers, residential ETS spouse, high overall grilled/smoked foods and stove/fireplace 
users 
i active smokers, residential ETS, high overall grilled/smoked foods, stove/fireplace users and 
top 5% of vehicular traffic exposure 
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CHAPTER IV.  SOURCES OF POLYCYCLIC AROMATIC HYDROCARBONS ARE 
ASSOCIATED WITH GENE-SPECIFIC PROMOTER METHYLATION IN WOMEN WITH 
BREAST CANCER 
4.1 Introduction 
Polycyclic aromatic hydrocarbons (PAHs) are established carcinogens to the lung [68], but their 
relationship with breast cancer is not as well studied. There have been associations with breast 
cancer incidence reported in several epidemiological studies of PAH biomarkers, which tend to 
reflect recent exposure [2-6]. In support of this, PAHs induce mammary tumors in laboratory 
animals [69]. PAHs are ubiquitous pollutants that form as a combustion by-product of organic 
material [41]. The major sources of PAH in the general population are indoor and outdoor air 
pollution, tobacco smoke and diet [41]. Elevated associations with breast cancer incidence have 
been observed with the main sources of PAH exposure, including active cigarette smoking [72], 
long-term environmental tobacco smoke (ETS) [73, 74, 77, 227], indoor air pollution from 
burning synthetic logs [175], outdoor air pollution [83-86, 188, 190, 192], and intake of grilled 
and smoked foods [80-82, 230].    
Aberrant DNA methylation, an epigenetic modification, plays an important role in breast 
carcinogenesis [292, 297, 415]. Higher levels of methylation at promoter regions can silence 
tumor suppressor genes [266]. Our research team has reported that methylation at promoter 
regions of specific genes in breast tumor tissue is associated with breast cancer 
clinical/pathological factors and mortality in a population-based sample [363]  In contrast, lower 
levels of global methylation may confer genomic instability and increased mutation rates [265]. 
Although the associations between cancer and global methylation have been inconclusive [265], 
our research group has previously reported an association with breast cancer for luminometric
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methylation assay (LUMA), but not for methylation of long interspersed elements-1 (LINE-1) in 
white blood cells [297]. DNA methylation may be altered in response to environment and 
lifestyle factors and be a potential biologic mechanism for disease [11].Other investigators have 
found that exposure to the PAH sources tobacco smoke and air pollution may be associated 
with changes in DNA methylation patterns [370, 381, 459].   
For the current study, we first aimed to examine whether five individual PAH sources, 
previously found to be modestly associated with breast cancer incidence (current active 
cigarette smoking [74], long-term residential ETS [74], total grilled/smoked food intake [230], 
residential burning of synthetic logs [175] and high vehicular traffic exposure [192]), were also 
associated with promoter methylation status in a panel of 13-breast cancer related genes 
measured in the tumor tissue of a population-based sample of women with breast cancer. We 
also aimed to investigate whether these same PAH sources were associated with global 
methylation in a population-based sample of women without breast cancer, using two 
independent global methylation markers, LINE-1 and LUMA, measured in peripheral blood 
DNA.  
4.2 Materials and Methods 
Our study builds upon population-based resources from the Long Island Breast Cancer Study 
Project (LIBCSP).  The parent LIBCSP methods have been previously published in detail [52].  
Institutional Review Board approval was obtained from all relevant institutions.  
Study Population. Study participants included 1,508 breast cancer cases and 1,556 
controls who were English-speaking women residing in Nassau and Suffolk counties on Long 
Island, New York. Written informed consent was obtained from all study participants. 
Cases were women who had been recently diagnosed with a first primary in situ or 
invasive breast cancer between August 1st, 1996 and July 31st, 1997, and were residents of 
Nassau or Suffolk counties on Long Island, New York (NY).  There were no age or race 
restrictions for case eligibility. Cases were identified using rapid case ascertainment from the 
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pathology departments of all 28 hospitals on Long Island and three tertiary care hospitals in 
New York City. Diagnoses were confirmed by the physician or the medical record.  
Controls had no prior history of breast cancer and were frequency matched in 5-year 
age groups to cases based on the expected age distribution of case women. Controls were 
identified in 1996-1997 from among adult female residents of Nassau and Suffolk counties in 
NY using random digit dialing for those who were less than 65 years of age, and for those who 
were 65 years of age and greater, using the Health Care Finance Administration rosters.   
Study participants ranged in age from 20 to 98 years, and most cases and controls were 
postmenopausal (68.1% and 66.3%, respectively) and identified themselves as white (93.8% 
and 91.8%, respectively); the racial distribution of our population-based sample reflects that of 
Nassau and Suffolk counties at the time of data collection [52]. Cases and controls had similar 
distributions of education and income [52], and the median age at menarche was also similar 
(12.6 years, standard deviation (SD)=1.67; and 12.6 years, SD=1.65, respectively). On average, 
controls were more likely to be parous than cases (89.0% versus 86.9%, respectively) [52]. 
Some 10% of cases and 8% of controls reported drinking 1-2 glasses per day (15-30 grams) of 
alcohol, on average across the life course [23].  
PAH Exposure Sources Assessment.  Five PAH exposure sources were assessed. 
Current active smoking, residential ETS, grilled/smoked meat intake, and synthetic log burning 
were assessed by a trained interviewer using a structured questionnaire [74, 175, 230]; and 
vehicular traffic exposure was assessed by a validated historical geographic model [133, 192].  
Detailed LIBCSP PAH source assessment methods have been previously published [74, 175, 
192, 230].  The PAH variable definitions and total sample sizes used in the study reported here 
are described below. 
Current active smoking (yes, no) was defined as smoking within the 12 months prior to 
the reference date, which was date of diagnosis for cases and date of identification for controls 
(n=1,553 controls/1,508 cases) [74]. Participants were asked if they had lived with a smoking 
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spouse to determine residential ETS exposure (yes, no) (n=1,515 controls/1,468 cases) [74].  
Frequency of grilled/smoked meat intake was assessed for each of six decades across the life 
course, or fewer depending on age at diagnosis [230]. Lifetime intake was defined as the 
average servings consumed per year based on quantile distributions in the controls (<33% vs 
≥33% percentile or <55 servings/year, 55+ servings/year) (n=1,515 controls/1,468 cases) [230].  
Residential stove and fireplace use was defined as using a stove/fireplace in a Long Island 
residence for at least 3 times per year and whether or not participants burned synthetic logs 
(yes, no) (n=1,541 controls/1,501 cases) [175]. A geographic model estimated vehicular traffic 
exposure for the study participant’s residence in 1995 by incorporating historical United States 
(U.S.) vehicular PAH emissions data, information on traffic and transportation patterns, Long 
Island, NY meteorological variables and pollutant dispersion factors (<95th percentile, ≥95th 
percentile) (n=1,334 controls/1,274 cases) [192]. This cutpoint was previously found to best 
represent the association with breast cancer incidence [192]. 
Gene-specific promoter DNA methylation assessment.  Promoter methylation status was 
measured in tumor tissue for a panel of 13 breast cancer-related genes (APC, BRCA1, CCND2, 
CDH1, DAPK1, ESR1, GSTP1, HIN1, CDKN2A, PGR, RARβ , RASSF1A and TWIST1). These 
genes are known to play an important role in breast carcinogenesis and their promoter regions 
are frequently methylated in breast tumor tissues [415]. The methods used to determine gene-
specific promoter methylation status have been previous published and are briefly described 
below [297, 415].  
DNA was extracted from tumor blocks as described in previously published methods 
[361]. To determine methylation levels for ESR1, PGR and BRCA1, methylation-specific PCR 
was used [361, 425]. The gene was determined to be methylated or not methylated based on 
whether PCR product was obtained using methylation-specific primers. Thus, ESR1, PGR and 
BRCA1 are dichotomous variables (methylated vs. unmethylated) as determined by the assay. 
The MethyLight assay was used to measure the methylation status of the remaining 10 genes 
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[426, 427]. Bisulfite-converted genomic DNA was amplified using a fluorescence-based, real-
time quantitative PCR which results in a percentage methylated [460, 461]. Continuous values 
were dichotomized (<4%, ≥4% methylated) to be consistent with previous published reports by 
our study team and others [415, 427]. This ≥4% cutpoint for the MethyLight assay has been 
previously reported to distinguish between malignant and normal tissues and is indicative of 
repressed gene expression [462, 463]. Number of case samples completed and percent 
methylated for each promoter in LIBCSP have been previously reported (n=765-851 and 
percent methylation 3.6% -62.9%) [415]. 
 Global Methylation Assessment.  Two methods were used to assess global methylation 
levels in DNA extracted from blood samples, LINE-1 and LUMA (1,055 cases/1,101 controls) 
[297]. The LINE-1 assay, which represents methylation at repeated elements, was completed 
using a prevalidated pyrosequencing assay to assess 4 CpG sites in the promoter of LINE-1 at 
EpigenDx (Worcester, MA, USA) as described previously [297].  Methylation status at each of 
the 4 CpG loci was analyzed individually as a T/C single nucleotide polymorphism (SNP) using 
QCpG software (Qiagen). Methylation status data at all 4 loci were averaged to provide an 
overall percent 5-mC status.  The LUMA assay approximates 5-mC levels at all “CCGG” 
sequences and is expressed as a percentage obtained using the following equation [432]: 
methylation (%) = ((1-(HpaII∑G/∑T)/ (MspI∑G/∑T) * 100)).   
Hormone receptor subtype.  Breast cancer subtype for the first primary was defined by 
estrogen/progesterone receptor status (ER/PR) obtained from the medical record, and was 
available for 65.6% of cases (n=990) [52].   
Statistical Analysis.  All analyses were completed using SAS 9.3 (Cary, NC). To 
investigate whether the five PAH sources, considered separately, were associated with 
methylation levels, we used unconditional logistic regression to estimate odds ratios (ORs) and 
corresponding 95% confidence intervals (CIs) [464].  Multiplicative interaction was assessed by 
comparing multivariable models with and without cross-product terms to denote the interaction 
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using an a priori alpha level of 0.05 [464]. 
For examining gene-specific promoter methylation, we used a case-case approach to 
determine whether PAH source exposures were associated with methylation in tumor tissue. 
Tumor subtypes were defined as methylated versus non-methylated. If the gene-specific 
promoter sample size within a stratum was less than 5, it was no longer included in the analysis. 
We explored whether the association between sources of PAH and gene-specific promoter 
methylation varied by hormone receptor status by testing for a multiplicative interaction between 
the PAH source, gene-promoter methylation and ER/PR status of the tumor.  
For examining global methylation, we first used a controls-only approach to assess 
whether PAH sources were associated with LINE-1 or LUMA measured in control blood 
samples. LINE-1 and LUMA levels were dichotomized based on the distribution in the controls 
as neither LINE-1 nor LUMA were normally distributed before or after natural log transformation. 
We subsequently utilized a case-control approach to assess whether the relationship between 
PAH sources and breast cancer incidence was modified by LUMA and/or LINE-1, on a 
multiplicative scale. For the study reported here, global methylation assay results among cases 
are based on blood samples donated prior to chemotherapy (n=79%).  Additionally, in order to 
compare our results with previous research [465, 466], we conducted a sensitivity analysis to 
determine if LUMA was associated with wood-burning in the controls and if ever smoking was 
associated with gene-specific methylation in the tumor of cases.   
Confounders were identified using a directed acyclic graph [450] and included age at 
menarche (<12, ≥12); parity (nulliparous, parous); lifetime alcohol intake (non-drinkers, 
<15g/day, 15-30g/day, ≥30g/day); education (high school graduate or less, some college, 
college graduate); income (<$34,999, $35,000-$69,999, ≥$70,000); and the frequency matching 
factor, 5-year age group.  
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4.3 Results 
Gene-specific promoter methylation in tumor tissue 
 Results for the associations between each individual source of PAH exposure and the 
13 gene-specific methylation markers are shown in Tables 4.1-4.5, respectively. ORs greater 
than 1 indicate increased odds of methylation and ORs less than 1 indicate decreased odds of 
methylation. There were similarities in associations between the gene-specific DNA methylation 
measured in tumor tissue and the PAH sources (Tables 4.1-4.5).  For example, ORs for CCND2 
methylation were reduced for residential ETS (Table 4.2; OR=0.65, 95%CI=0.44-0.96) and 
perhaps for high grilled/smoked meat intake (Table 4.1; OR=0.69, 95%CI=0.46-1.06), although 
confidence intervals for the latter included the null value. ORs for RARβ methylation were 
elevated in association with burning of synthetic logs (Table 4.4; OR=1.80, 95%CI=1.16-2.78) 
and for high grilled/smoked meat intake (Table 4.1; OR=1.39, 95%CI=0.94-2.08). ORs for 
BRCA1 were reduced, indicating hypomethylation in association with synthetic logs use 
(OR=0.44, 95%CI=0.30-0.66), and perhaps with current active smoking (OR=0.74, 95%CI= 
0.52-1.07), although the confidence intervals for the latter included the null value (Tables 4.3 
and 4.4, respectively).  
Additionally, current active smoking was associated with lower odds of DAPK 
methylation (OR=0.53, 95%CI=0.28-0.99) (Table 4.3) although no other associations with DAPK 
were evident. Lower odds of ESR1 methylation was observed in association with residential 
ETS (OR=0.74, 95%CI= 0.56-0.99) (Table 4.2). Synthetic log use was associated with elevated 
odds of HIN1 methylation (OR=2.14, 95%CI= 1.34-3.42) and CDH1 methylation (OR=2.26, 
95%CI= 1.06-4.79) (Table 4.4). Vehicular traffic was associated with higher odds of TWIST1 
methylation (OR=2.79, 95%CI=1.24-6.30) (Table 4.5).  
Ever active smoking, while not included in our a priori exposures of interest, was 
additionally found to be associated with decreased odds of methylation of ESR1 (OR=0.69, 
95%CI 0.52-0.92) and  HIN1 (OR=0.66, 95%CI 0.48-0.91) (Table A.4). We did not observe any 
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evidence of effect measure modification of the association between PAH sources and gene-
specific methylation by hormone receptor status of the tumor (data not shown).  
Global methylation in peripheral blood 
Synthetic log use in the home was associated with hypomethylation of LINE-1 in controls 
(OR=0.59, 95%CI=0.41-0.86) and suggestively associated with a pattern of hypomethylation in 
the LUMA assay (OR=0.75, 95%CI=0.52-1.09) (Table  A.5). None of the other PAH sources, 
including indoor wood burning in a stove or fireplace (data not shown), were associated with 
either LINE-1 or LUMA. We did not observe any evidence of effect measure modification of the 
association between the PAH sources and breast cancer incidence by global methylation 
markers (Table A.6 and A.7), or tumor heterogeneity considering hormone receptor status of the 
tumor (data not shown).  
4.4 Discussion 
The sources of PAH exposure examined here were associated with a number of methylation 
sites in both the gene-specific tumor of cases and the blood of controls supporting the 
hypothesis that DNA methylation may be one of the potential biologic mechanisms for the 
association between PAH sources and breast cancer. We considered sources of PAH 
exposure, and classifications of exposure, based on our previous studies [74, 175, 192, 230] 
and others [72, 80, 191, 212], with breast cancer incidence. Thus, many of the associations with 
DNA methylation observed among our population-based sample of women with breast cancer 
are biologically plausible and relevant for breast carcinogenesis. For example, we observed 
decreased methylation in the tumor of CCND2, an oncogene, in association with residential 
ETS. Lower methylation at some CpGs in CCND2 is correlated with increased mRNA 
expression in The Cancer Genome Atlas (TCGA) breast tumor data [467]. Conversely, we 
observed increased methylation for RARβ, HIN1 and CDH1 in association with the sources of 
PAH exposure. Both HIN1 and CDH1 are tumor suppressor genes, and increased methylation 
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levels are associated with decreased expression of these genes in TCGA data [467].  
Decreased expression of RARβ, a steroid hormone receptor that is important for maintaining 
normal cell growth and regulation, has also been found to play a role in breast carcinogenesis 
[466]. Thus, PAH sources may be both increasing expression of oncogenes and repressing 
expression of tumor suppressor and other genes important for normal cell functioning.  
We observed that PAH sources were associated with DNA methylation in similar 
directions at certain gene promoter regions, despite differences in exposure source or even 
route of exposure. For example, we reported decreased ORs for methylation at CCND2 for both 
residential ETS and grilled/smoked meat intake. This pattern of findings is supportive of similar 
biologic mechanisms across the exposure sources. We observed either increased or decreased 
ORs for methylation across different genes, which is consistent with other epidemiologic studies 
of active smoking in healthy individuals that have found associations with both increases and 
decreases in methylation that are site-specific [351, 382, 385, 387, 395]. Similarly, a study in 
breast cancer cell lines found that treatment with the PAH compound benzo[a]pyrene (BaP) 
induces both hyper- and hypomethylation at different sites [468]. Although the mechanisms for 
the association between PAHs and DNA methylation are not completely understood, there are a 
number of possible mechanisms by which PAHs may disturb DNA methylation patterns resulting 
in both increases and reductions in methylation levels. There is evidence that a BaP metabolite, 
benzo(a)pyrene diolepoxide (BPDE), has enhanced binding to DNA at methylated CpG sites 
[365, 366] and that DNA methyltransferase bind to DNA lesions with high affinity when there is 
DNA damage such as that from carcinogenic adducts [369]. Additionally, BPDE can inhibit the 
function of methyltransferase enzymes resulting in a loss of methylation [469]. It is also possible 
that methylation may be lost during the repair of carcinogenic adducts from PAH exposure via 
the nucleotide excision repair pathway [470]. Repair of these damaged regions could lead to 
hypomethylation if methylation is not regained prior to DNA replication [468].  
 In addition to our findings with gene-specific methylation, exposure to burning synthetic 
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logs was found to be associated with LINE-1 hypomethylation in the peripheral blood among our 
population-based sample of women without breast cancer. LINE-1 hypomethylation in the 
peripheral blood, hypothesized to indicate chromosomal instability and increased likelihood for 
mutations, has been found to be associated with breast cancer in a prospective cohort [338], 
although such an association was not observed in the LIBCSP [297]. BaP has also been found 
to decrease global methylation in vitro [364]. In contrast to our null findings reported here for the 
LIBCSP population, a study conducted in Warsaw, Poland reported an inverse association 
between indoor air pollution measured by wood and coal burning with peripheral blood global 
methylation measured by LUMA [465]. However, the investigators of the Polish study did not 
consider synthetic log burning which is likely less commonly used in their study population.  
Several issues regarding our PAH source measures may impact our study interpretation. 
We selected the PAH source variables included here because each was previously reported to 
be most relevant to breast cancer incidence in our study population [74, 175, 192, 230]. 
However, other PAH source classifications (e.g., ever or former smokers) may also be relevant 
for methylation alterations [381]. We were unable to consider a multi-PAH source model, or 
develop a combined PAH source index, to examine associations with DNA methylation. This 
was primarily due to the pattern of ambient PAH source exposure in our study population, where 
few women were very highly exposed (<1%) and very few were low exposed (<2%) to all five 
main PAH sources [471]. Given this, we were unable to consider a single combined measure of 
PAH exposure further stratified by methylation status. Additionally, as PAH potency may vary by 
source types and by exposure route [41], it is likely not informative to incorporate them all into a 
simple, single index.  Further, because our study design limited our ability to isolate specific 
PAH carcinogens, we were unable to determine carcinogenic potencies of the PAH sources. 
Moreover, the PAH exposure sources considered here contain other chemicals [68] that could 
be relevant to DNA methylation changes and may be a reason for some discrepancy in patterns 
across methylated sites among studies and PAH sources [472].  
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 In our population-based sample of women, who were ambiently exposed to PAH from 
multiple sources, we were able to consider both gene-specific and global methylation with a 
number of PAH exposure sources, specifically focusing on those which our study team has 
previously found to be associated with breast cancer. We were also able to evaluate potential 
heterogeneity by hormone receptor subtype, as methylation level at a given locus may be 
particularly associated with specific breast cancer tumor subtypes over others [359]. 
Consideration of tumor subtype did not alter our conclusions, possibly because the LIBCSP 
study population is predominately women with hormone receptor positive tumors and therefore, 
power to assess associations in receptor negative tumors was limited [74]. 
 Few previous studies have considered associations between tobacco smoke and DNA 
methylation in breast cancer tissue; one study found ever smoking to be associated with ESR1 
hypermethylation in breast tissue of Iranian women (n=137)  [466], which we did not observe 
when we considered ever active smoking, which we specifically examined in order to try and 
replicate this finding. Differences in active smoking exposure history due to geographic and 
cultural difference between studies may, at least in part, explain this discrepancy. Methylation 
levels may reflect both long-term and recent exposures, so it is biologically plausible for 
variables reflecting different time periods to both be relevant [381]. Ever active smoking and 
current active smoking were associated with different methylation markers in this study, 
suggesting that methylation may change after stopping smoking[473] or that current smokers 
may represent those with a higher intensity or longer duration of tobacco use and thus may 
have different methylation patterns for that reason. Other studies have focused on white blood 
cell methylation in healthy individuals, although inconsistent associations between air pollution 
and smoking with both gene-specific and global methylation have been observed [312]. 
However, it is unclear whether global methylation measures accurately reflect that of the target 
tissue [281].  Thus, as compared with previous investigations, our study expands the specific 
research questions addressed and the study approach, by utilizing a larger population-based 
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study population as well as broadening the scope of the relevant PAH sources and DNA 
methylation targets considered.  
 We used a panel of a priori genes, and thus, this study cannot rule out that there are 
other methylation sites which could be relevant to PAHs and breast cancer. We did not adjust 
for multiple comparisons [474]; all comparisons made were driven by biologically plausible 
hypotheses and we did not rely on statistical significance for interpretation of measures of 
association and focused on evaluating trends [447]. However, we cannot rule out that some of 
these associations may be due to chance, because in our study there are some instances of low 
prevalence of methylated genes and small within stratum sizes that produced imprecise 
estimates and may have resulted in over fitting of the models.  
Regarding generalizability, the women in the LIBCSP are predominately white and 
postmenopausal [52], and therefore our results may not be applicable to all women. However, in 
the U.S., white postmenopausal women are at the highest risk of developing breast cancer [7].   
 In this first population-based study to report on gene-specific methylation in association 
with current active smoking, residential ETS, synthetic log burning, grilled/smoked meat intake 
and vehicular traffic, we identified biologically plausible associations with aberrant DNA 
methylation in the tumor tissue. DNA methylation represents a potential biologic mechanism for 
environmental chemicals, such as PAH, to influence breast cancer risk.  
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Table 4.1 Odds of gene specific promoter methylation in tumor of cases in association with average lifetime intake of 
grilled/barbecued/smoked meat intake, LIBCSP 1996-1997a 
 
Low grilled/barbecued/smoked average intake 
 (0-54 servings) 
 High grilled/barbecued/smoked average intake  
(55+ servings) 
Genes 
Unmethylated 
(N) 
Methylated 
(N) OR (95%CI)   
Unmethylated 
(N) 
Methylated 
(N) OR (95%CI) 
ESR1 122 106 1.00 (reference) 315 250 0.90 (0.65, 1.25) 
PGR 204 25 1.00 (reference) 509 63 1.00 (0.59, 1.69) 
BRCA1 99 130 1.00 (reference) 225 347 1.12 (0.81, 1.57) 
APC 118 102 1.00 (reference) 273 261 1.12 (0.80, 1.57) 
CDKN2A 204 8 1.00 (reference) 498 21 1.03 (0.42, 2.51) 
HIN1 71 128 1.00 (reference) 197 329 0.94 (0.65, 1.34) 
RASSF1a 26 173 1.00 (reference) 83 443 0.85 (0.51, 1.40) 
DAPK1 169 30 1.00 (reference) 450 76 1.07 (0.65, 1.75) 
GSTP1 145 54 1.00 (reference) 377 149 1.03 (0.70, 1.52) 
CCND2 147 52 1.00 (reference) 436 90 0.69 (0.46, 1.06) 
TWIST1 162 37 1.00 (reference) 451 75 0.77 (0.48, 1.22) 
CDH1 185 14 1.00 (reference) 498 28 0.74 (0.37, 1.50) 
RARβ 150 49 1.00 (reference)   377 149 1.39 (0.94, 2.08) 
a adjusted for age at menarche (<12, ≥12 years), parous (nulliparous, parous), lifetime alcohol intake (non-drinkers, <15g/day,  
15g-30g/day, ≥30 g/day), education (high school graduate or less, some college, college or post-college), income (<$34,999, 
$35,000-$69,999, ≥$70,000) and the matching factor, 5-year age group.
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Table 4.2 Odds of gene specific promoter methylation in tumor of cases in association with long-term residential 
environmental tobacco smoke (ETS), LIBCSP 1996-1997a 
 
No residential ETS Residential ETS 
Genes 
Unmethylated 
(N) 
Methylated 
(N) OR (95%CI)   
Unmethylated 
(N) 
Methylated 
(N) OR (95%CI) 
ESR1 210 195 1.00 (reference) 241 173 0.74 (0.56, 0.99) 
PGR 358 51 1.00 (reference) 369 48 1.00 (0.64, 1.56) 
BRCA1 166 243 1.00 (reference) 174 243 1.03 (0.77, 1.39) 
APC 203 183 1.00 (reference) 199 192 1.01 (0.75, 1.36) 
CDKN2A 364 13 1.00 (reference) 361 16 0.97 (0.44, 2.14) 
HIN1 130 226 1.00 (reference) 142 244 1.02 (0.74, 1.41) 
RASSF1a 48 308 1.00 (reference) 63 323 0.83 (0.53, 1.28) 
DAPK1 309 47 1.00 (reference) 329 57 1.05 (0.67, 1.62) 
GSTP1 255 101 1.00 (reference) 281 105 0.91 (0.65, 1.28) 
CCND2 279 77 1.00 (reference) 318 68 0.65 (0.44, 0.96) 
TWIST1 298 58 1.00 (reference) 329 57 0.89 (0.58, 1.36) 
CDH1 335 21 1.00 (reference) 364 22 0.86 (0.45, 1.67) 
RARβ 254 102 1.00 (reference)   283 103 0.86 (0.61, 1.21) 
a adjusted for age at menarche (<12, ≥12 years), parous (nulliparous, parous), lifetime alcohol intake (non-drinkers, <15g/day,  
15g-30g/day, ≥30 g/day), education (high school graduate or less, some college, college or post-college), income (<$34,999, 
$35,000-$69,999, ≥$70,000) and the matching factor, 5-year age group. 
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Table 4.3  Odds of gene specific promoter methylation in tumor of cases in association with current active smoking, 
LIBCSP 1996-1997a 
 
No current active smoking Current active smoking 
Genes 
Unmethylated 
(N) 
Methylated 
(N) OR (95%CI)   
Unmethylated 
(N) 
Methylated 
(N) OR (95%CI) 
ESR1 369 309 1.00 (reference) 91 74 0.94 (0.66, 1.35) 
PGR 601 84 1.00 (reference) 148 18 0.94 (0.54, 1.66) 
BRCA1 269 416 1.00 (reference) 78 88 0.74 (0.52, 1.07) 
APC 333 306 1.00 (reference) 80 81 1.09 (0.76, 1.57) 
CDKN2A 598 24 1.00 (reference) 149 6 0.81 (0.30, 2.14) 
HIN1 224 338 1.00 (reference) 60 93 0.81 (0.55, 1.20) 
RASSF1a 86 526 1.00 (reference) 27 126 0.70 (0.42, 1.15) 
DAPK1 517 95 1.00 (reference) 140 13 0.53 (0.28, 0.99) 
GSTP1 329 173 1.00 (reference) 113 40 0.82 (0.53, 1.24) 
CCND2 491 121 1.00 (reference) 124 29 1.12 (0.69, 1.81) 
TWIST1 517 95 1.00 (reference) 132 21 0.96 (0.56, 1.65) 
CDH1 578 34 1.00 (reference) 143 10 1.07 (0.50, 2.34) 
RARβ 442 170 1.00 (reference)   112 41 0.94 (0.62, 1.44) 
a adjusted for age at menarche (<12, ≥12 years), parous (nulliparous, parous), lifetime alcohol intake (non-drinkers, <15g/day,  
15g-30g/day, ≥30 g/day), education (high school graduate or less, some college, college or post-college), income (<$34,999, 
$35,000-$69,999, ≥$70,000) and the matching factor, 5-year age group. 
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Table 4.4  Odds of gene specific promoter methylation in tumor of cases in association with residential burning of synthetic 
logs, LIBCSP 1996-1997a 
 
No synthetic log use Synthetic log use 
Genes 
Unmethylated 
(N) 
Methylated 
(N) OR (95%CI)   
Unmethylated 
(N) 
Methylated 
(N) OR (95%CI) 
ESR1 381 325 1.00 (reference) 79 56 0.80 (0.55, 1.19) 
PGR 625 87 1.00 (reference) 121 15 0.82 (0.45, 1.50) 
BRCA1 270 442 1.00 (reference) 75 62 0.44 (0.30, 0.66) 
APC 347 322 1.00 (reference) 65 64 1.04 (0.70, 1.55) 
CDKN2A 624 25 1.00 (reference) 121 5 1.03 (0.37, 2.87) 
HIN1 256 394 1.00 (reference) 28 86 2.14 (1.34, 3.42) 
RASSF1a 101 549 1.00 (reference) 12 102 1.68 (0.87, 3.24) 
DAPK1 559 91 1.00 (reference) 97 17 1.13 (0.63, 2.03) 
GSTP1 473 177 1.00 (reference) 78 36 1.30 (0.83, 2.03) 
CCND2 523 127 1.00 (reference) 91 23 1.20 (0.72, 2.03) 
TWIST1 551 99 1.00 (reference) 97 17 1.03 (0.58, 1.85) 
CDH1 617 33 1.00 (reference) 103 11 2.26 (1.06, 4.79) 
RARβ 480 170 1.00 (reference)   73 41 1.80 (1.16, 2.78) 
a adjusted for age at menarche (<12, ≥12 years), parous (nulliparous, parous), lifetime alcohol intake (non-drinkers, <15g/day,  
15g-30g/day, ≥30 g/day), education (high school graduate or less, some college, college or post-college), income (<$34,999, 
$35,000-$69,999, ≥$70,000) and the matching factor, 5-year age group. 
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Table 4.5 Odds of gene specific promoter methylation in tumor of cases in association with vehicular traffic exposure, 
LIBCSP 1996-1997a 
Low vehicular traffic (<95th percentile) High vehicular traffic (≥95th percentile) 
Genesb 
Unmethylate
d (N) 
Methylated 
(N) OR (95%CI)   
Unmethylated 
(N) 
Methylated 
(N) OR (95%CI) 
ESR1 354 310 1.00 (reference) 24 18 0.74 (0.38, 1.45) 
PGR 594 77 1.00 (reference) 37 5 0.90 (0.30, 2.65) 
BRCA1 273 398 1.00 (reference) 20 22 0.72 (0.38, 1.40) 
APC 327 307 1.00 (reference) 18 18 1.11 (0.54, 2.25) 
HIN1 221 376 1.00 (reference) 13 25 1.35 (0.65, 2.80) 
RASSF1a 88 509 1.00 (reference) 8 30 0.60 (0.26, 1.42) 
DAPK1 515 82 1.00 (reference) 33 5 0.94 (0.34, 2.57) 
GSTP1 431 166 1.00 (reference) 26 12 1.18 (0.56, 2.15) 
CCND2 482 115 1.00 (reference) 32 6 0.66 (0.24, 1.78) 
TWIST1 520 77 1.00 (reference) 28 10 2.79 (1.24, 6.30) 
RARβ 433 164 1.00 (reference) 32 6 0.49 (0.20, 1.23) 
a adjusted for age at menarche (<12, ≥12 years), parous (nulliparous, parous), lifetime alcohol intake (non-drinkers, <15g/day,  
15g-30g/day, ≥30 g/day), education (high school graduate or less, some college, college or post-college), income (<$34,999, 
$35,000-$69,999, ≥$70,000) and the matching factor, 5-year age group. 
b CDKN2A and CDH1 had cell sizes less than 5 and odds ratios were not estimated  
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CHAPTER V.  DISCUSSION 
This dissertation aimed to investigate exposure across multiple PAH sources in association with 
breast cancer incidence and to explore the role of DNA methylation in the PAH and breast 
cancer association. To investigate these innovative aims, I utilized hierarchical regression 
analysis to allow for the inclusion of all of the predominant PAH exposure sources within a 
single statistical model. By focusing on the PAH sources that were identified in Aim 1 to have 
the most notable association with breast cancer risk (current active smoking, environmental 
tobacco smoke (ETS) from a spouse, 1995 vehicular traffic, synthetic log burning in the home, 
and total grilled/smoked foods) in association with global and gene-specific DNA methylation, 
this study concentrated on the most biologically plausible associations. This ancillary study 
utilized a large, population-based case-control study with long-term exposure assessment 
across the main sources of PAH exposure and available methylation data in both blood and 
tissue. Chapter V summarizes the results reported in Chapters III and IV, discusses study 
strengths and limitations, and concludes with the public health impact of my dissertation findings 
along with possible future research directions. 
5.1 Summary of Results 
Participants in the LIBCSP were highly exposed across multiple PAH sources. Approximately 
50% were ever active smokers and 20% were current smokers at time of enrollment. About 80% 
had lived in the home with a smoker at some point and for about half of the study participants 
their spouse smoked. Half of the study population used an indoor wood-burning stove or 
fireplace in a Long Island residence and over two-thirds consumed on average more than 1 
serving/week of grilled/smoked foods.  Positive associations were observed between multiple 
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PAH sources, when considered singly and as groups, or profiles, in association with breast 
cancer incidence. Most notably, exposure to the indoor sources of PAH (including: active 
smoking, residential ETS from a spouse, grilled/smoked meat intake and stove/fireplace use) 
was associated with a 46% increase in breast cancer incidence. Elevated odds ratios were also 
observed for high PAH exposure through ingestion and among those who burned both wood 
and synthetic logs in their indoor stove/fireplaces. Similar effect estimates were observed when 
considering estimates by exposure route, inhalation and ingestion, although results were much 
more precise for PAH exposure from ingestion.  
 In the Aim 1 hierarchical regression mode, I selected a single PAH exposure variable 
within each of the five main sources (active smoking, ETS, grilled/smoked meat intake, 
vehicular traffic and stove/fireplace use) that had the highest odds ratio with breast cancer risk 
to use in the DNA methylation analyses. Therefore, for Aim 2, I evaluated associations with both 
global and gene-specific DNA methylation and (1) current active smoking, (2) ETS from a 
spouse, (3) total grilled/smoked meat intake, (4) burning synthetic firelogs and (5) 1995 
vehicular traffic, respectively. Burning synthetic logs was associated with decreased odds, or 
hypomethylation, of LINE-1 in the blood of controls. LINE-1 is a global methylation marker, and 
decreased methylation is hypothesized to be indicative of increased chromosomal instability and 
likelihood of DNA mutations [265]. Effect measure modification on either additive or 
multiplicative scales was not observed between these five single PAH sources and global 
methylation markers with breast cancer incidence. Although I had hypothesized that global DNA 
methylation may act as an effect measure modifier, there was no evidence to support that LINE-
1 or LUMA were modifying the associations between the PAH sources and breast cancer or 
when considering tumor subtype (ER/PR status). Rather, these results corroborate the 
hypothesis that PAH sources may be associated with alterations in DNA methylation levels as a 
potential intermediate step to cancer [11].   
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Similar patterns of aberrant gene-specific methylation in tumor tissue were observed 
across many of these sources. For example, residential ETS and high grilled/smoked meat 
intake were associated with decreased odds of CCND2 methylation. Burning synthetic logs and 
high grilled/smoked meat intake were both associated with increased odds of methylation at the 
RARβ gene. Decreased odds of methylation, or hypomethylation, of BRCA1 was observed in 
association with both synthetic log use and current active smoking. However, confidence 
intervals for some of these estimates did include the null value. It is biologically plausible that 
these associations are relevant to breast carcinogenesis, as these genes were selected for the 
methylation panel based on important roles in breast carcinogenesis and tumor progression 
[415]. For example, the observed decreased odds of methylation at the CCND2 oncogene, and 
increased odds or methylation at steroid hormone or tumor suppressor genes, in association 
with the PAH sources suggests exposure to these PAH sources may indicate increased 
expression of CCND2 as well as silencing via increased methylation at RARβ and other sites. 
Associations were observed with other methylation markers but patterns were not consistent 
across PAH sources. The associations between sources of PAH exposure and gene-specific 
DNA methylation were not found to vary when considering hormone receptor subtype (ER/PR 
status) of the breast tumor.   
5.2 Strengths and Limitations 
The two source counties that the LIBCSP sampled from for this population-based study are 
relatively homogeneous in terms of race and ethnicity [52]. This homogeneity of the study 
sample is both a limitation and a strength of this dissertation. Study population homogeneity 
improves internal validity and may result in little residual confounding, but may hamper external 
validity. As such, because this study population is predominately white [52], their PAH exposure 
patterns may not be the same as women of other racial and ethnic groups within the U.S., or 
among women outside of the U.S. Additionally, the LIBCSP women were diagnosed with a first 
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primary breast cancer in the mid-1990s and PAH exposure prevalence, particular that of both 
active smoking and ETS, have decreased during these women’s lifetimes [458]. A woman 
diagnosed with breast cancer today would be much less likely to be a smoker herself or live with 
a smoking spouse, which were two highly prevalent PAH sources in this study population, for 
which the magnitude of the odds ratio for the association with breast cancer incidence was 
elevated. PAH exposure from vehicular traffic declined over time on Long Island and the 
increase in the odds ratio for breast cancer was limited to the top 5% of those exposed [192]. 
Thus, if this study was conducted in a geographic location where vehicular traffic levels are 
higher (for example, China) this may be a more important PAH exposure source than it was 
found to be in the LIBCSP study population.  
 Another consequence of a largely white and postmenopausal study population is that 
there is little variability of hormone receptor status and most women had hormone receptor 
positive tumors, which is the most common breast cancer subtype among American women 
regardless of race [105, 475]. We were unable to detect any variation by hormone receptor 
status in our methylation analyses and were likely limited by the few women who had hormone 
receptor negative tumors. However, these findings are applicable to women at greatest risk for 
breast cancer in the U.S., white postmenopausal women [7].  
 A sensitivity analysis was conducted, repeating the analysis but limiting to women who 
were postmenopausal and had ER+ tumors (data not shown). Results remained similar, 
although estimates of associations with breast cancer incidence (Aim 1) were elevated for 
grilled/smoked meat intake which is consistent with a previous LIBCSP publication that reported 
associations to be more pronounced in postmenopausal women [230]. Also, when limiting to 
postmenopausal women with ER+ tumors, the elevated but imprecise OR with vehicular traffic 
in my primary analysis was null. The LIBCSP previously reported this association for vehicular 
traffic to be more pronounced in women with hormone receptor negative tumors [192], so the 
results of my sensitivity analysis are also not surprising. Results remained similar, but less 
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precise, when considering both global and gene-specific DNA methylation. The limited 
differences observed in this sensitivity analysis is consistent with laboratory evidence that PAHs 
may exhibit both weak estrogen and antiestrogen properties [117].  
 Very few women were classified as having low exposure across the PAH sources, and 
conversely, very few women were highly exposed across all five of the PAH sources. This 
resulted in this study being unable to consider potentially important effect measure modifiers 
including fruit and vegetable intake and any heterogeneity by menopausal status at diagnosis 
and tumor subtype. Similarly, I was unable to consider the role of DNA methylation within the 
hierarchical model and thus, selected the most promising PAH exposure sources to evaluate 
individually. A small sample size is also often an important concern in epigenetic epidemiologic 
investigations. However, this study sample is large relative to similar breast cancer studies that 
have measured methylation in the tumor [466] as well as blood [465] in association with PAH 
exposure sources. For some of the methylation markers, we had a low prevalence of 
methylated genes in our study population [415] which made estimation of some of these 
associations difficult in particular when considering exposure to vehicular traffic. We also cannot 
rule out the possibility the measurement of methylation could have been influenced by copy 
number changes in some of these genes. 
 A number of quality control measures were used to minimize measurement errors in the 
DNA methylation assays. The assays were validated and included both unmethylated and 
methylated controls [297, 363]. Laboratory personnel were blinded to case-control status of 
global methylation samples [297]. Randomly selected samples were replicated to examine 
potential batch effects and to determine any variation between different runs and the percent 
corresponding inter-individual variability (CV) was less than 1% [297]. 
 Recall error is always a potential concern in epidemiologic studies, in particular in case-
control studies when participants may be asked to remember exposures over long periods of 
time and when recall has the potential to vary by case-status. Self-report of smoking and ETS 
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has been previously found to be a valid exposure assessment [207]. Findings from Long Island 
on active smoking, ETS and grilled/smoked meat intake and breast cancer incidence [74, 230] 
have been confirmed in other studies [72, 82, 216] suggesting that self-report may be a valid 
measurement. The possibility that women who were cases were more likely to report these PAH 
exposures cannot be ruled out. However, at the time the study was conducted, women on Long 
Island were more concerned about pesticides and electric fields than they were PAH sources 
[52]. Vehicular traffic exposure was not self-reported, but based on a woman’s recall of her 
homes on Long Island, which likely was not associated with case-control status.  
 It is also important to note that these PAH sources are mixtures of different PAHs as well 
as non-PAH carcinogens. Although other chemicals in the PAH sources may be relevant to 
breast cancer, there is a strong biologic rationale that PAHs have a role in breast 
carcinogenesis [4, 69, 476]. Other carcinogens that are prominent in these PAH sources include 
polychlorinated biphenyls (PCBs)[159], particulate matter [159], aromatic and heterocyclic 
aromatic amines [78, 234], N-nitrosamines [78], dioxins [477] and benzene [3]. PCBs may have 
both positive and inverse associations with breast cancer depending on the specific compound 
[478, 479] although evidence is based on few studies and not consistent [476, 480]. The 
association between dioxins and breast cancer incidence has been inconsistent [477, 481]. 
Research on the health effects of benzene has historically focused on occupationally-exposed 
men [3]. However, a study in New York did find an association among women who were likely to 
have moderate to high exposure based on job-exposure matrices [125] and an association was 
observed with ER-PR- tumors in the California Teacher’s Cohort study [482]. Particulate matter 
is often used as a proxy measure of air pollution, but particulate matter not been widely 
hypothesized to be a potential biologic mechanism for the association between air pollution and 
breast cancer incidence although a few studies have considered a role with survival after breast 
cancer [483, 484]. Occupational exposure to aromatic amines has been found to be associated 
with up to a 10-fold increase in breast cancer risk [485]. Interactions between smoking and 
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genetic polymorphisms in N-acetyltransferase enzymes, which function to metabolize amines, 
support the role of these chemicals in breast cancer incidence [486]. While evidence exists to 
support possible associations with other carcinogens, particularly PCBs, dioxins, benzene and 
aromatic amines with breast cancer incidence, findings have not been as consistent as those for 
PAHs. Additionally, these compounds are not present in all of the environmental exposure 
sources included in this study; instead, the common thread is PAH.  
 A strength of this study is that it considers simultaneously the main sources of PAH 
exposure in the general population and used long-term exposure assessment methods. 
However, a limitation of the PAH exposure assessment included here was the lack of 
occupational exposure data. This may particularly be relevant for ETS exposure if the women 
worked in professions with high exposure to tobacco smoke, such as working in a restaurant or 
bar. Additionally, exposure assessment for stove/fireplace use and vehicular traffic was limited 
to Long Island residences. It has been previously reported that limiting the analyses to only 
long-term residents (>15 years) did not alter the association with stove/fireplace use in this 
study population [175].  For vehicular traffic exposure, estimates from the year prior to diagnosis 
were used and therefore study participants were likely living on Long Island in that year per the 
study enrollment criteria. Although approximately 15% of residences in 1995 did not sufficiently 
geocode, this missing data was imputed within the Bayesian hierarchical model used in the 
analysis of the first dissertation aim [438, 439].  
 Molecular epidemiologic studies with large numbers of statistical comparisons may find 
statistically significant associations by chance alone. Thus, a number of approaches have been 
suggested as a method to “correct” for this large numbers of statistical tests [440]. However, 
others have advocated for not relying on p-values when interpreting results [474] and thus, not 
correcting for the number of statistical tests when the study is driven by biologically supported 
hypotheses [447]. Potential methods of correction, such as Bonferroni [487] or false discovery 
rate (FDR) [445], adjust the alpha level based on the total number of tests. However, the 
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Bonferroni correction method may be overly conservative and increase the type II error rate via 
reduced sensitivity [447]. Therefore, correction and use of significance testing may miss 
important associations leading to incorrect conclusions. I did not show results corrected for 
multiple comparisons because, for this study, I selected five PAH sources that I found in Aim 1 
to be most notably associated with breast cancer and 13 genes previously chosen to be 
relevant to breast carcinogenesis. I also did not rely heavily on statistical significance when 
interpreting these results and, instead, focused on trends of associations. If results for Aim 2 are 
adjusted for multiple comparisons using an FDR approach [445], a significant association is 
apparent only for the association between synthetic log burning and hypomethylation of 
BRCA1.This finding is not consistent with the direction of methylation expected to be biologically 
relevant and may be indicating elevated expression of BRCA1. However, it is important to note 
that the correlation between BRCA1 methylation at certain CpGs and expression in the TCGA 
data is low (~0.2) [467].  
5.3 Public Health Impact 
The burden of breast cancer in the U.S. remains high and it is the most common cancer 
diagnosed among American women [7]. Despite this, very few easily modifiable strategies exist 
for reducing breast cancer incidence. In the first aim of this dissertation, women were observed 
to be highly exposed to PAHs across multiple sources. Estimates of association in the range of 
30-50% were observed for the different PAH exposure profiles evaluated. This magnitude of 
associations is notable for breast cancer research, particularly for environmental factors. These 
PAH exposure sources, tobacco smoke, grilled/smoked meat intake, indoor/outdoor air 
pollution, are all modifiable and highly prevalent breast cancer risk factors that could be 
intervened upon to potentially reduce breast cancer risk. Reduction strategies for tobacco 
smoke have been implemented in response to the well-established associations with lung 
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cancer and have been largely effective in reducing the prevalence of tobacco use in the U.S 
[458].   
 Previous reports from this study population [74, 175, 192, 230] as well as others [72, 81, 
191] have found associations between these PAH exposure sources and breast cancer 
incidence when considering each PAH exposure source individually. This dissertation included 
all of these predominant PAH exposure sources in a single statistical model primarily for the 
purpose of estimating the association with breast cancer risk corresponding to being exposed to 
multiple sources concurrently. This approach also demonstrated that even when all PAH 
sources are included within a single statistical model, the associations with breast cancer 
remained similar which strengthens the rationale for reducing these sources of PAH exposure. 
Even though the effect estimates reported here are modest, even when considering 
multiple sources simultaneously (ORs ranging from 1.3 to 1.5), the high prevalence of PAH 
source exposures in the LIBCSP study population suggests that these carcinogens could still 
have a potentially large impact on breast cancer incidence. The effect estimates for PAH 
sources reported here are similar to those observed for postmenopausal hormone use 
(RR=1.26, 95%CI 1.00, 1.59) [488], another exposure which was also highly prevalent among 
American women (particularly those who are predominantly white) [489]. After the Women’s 
Health Initiative results on the association between postmenopausal hormones and breast 
cancer risk were published, use of postmenopausal hormones dropped notably [490, 491]. This 
reduction in use resulted in a notable decline in population-levels of breast cancer incidence 
[490, 491]. Therefore, it is possible that the reduction of these PAH sources, given their similar 
effect measure estimate and prevalence to postmenopausal hormone use, could have a 
similarly important impact at least among white postmenopausal women. However, further study 
is needed in order to better inform breast cancer risk reduction strategies for non-white or 
younger groups of women within the U.S.  as well as women outside of the U.S.   
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 Thus, the results from this dissertation suggest that reducing PAH exposure, particularly 
to the indoor sources of tobacco smoke, grilled/smoked meat intake and indoor stove/fireplace 
use, which were highly prevalent in this study population, may be an opportunity to reduce 
breast cancer risk. Additionally, with technological advances DNA methylation represents a 
potential point of intervention and could be utilized for screening purposes to evaluate those that 
might be at a higher risk for breast cancer.  
5.4 Future Directions 
Future efforts focused on examining the association between PAH exposure sources and breast 
cancer could improve on the findings of this investigation by conducting studies in areas where 
vehicular traffic pollution are higher than they were for this study sample. This would help to 
better estimate the association with vehicular traffic in conjunction with other PAH sources as 
well as potential epigenetic alterations that may result from high vehicular traffic exposure.  
It also would be informative to conduct further studies to better understand the 
associations between breast cancer risk and the current, lower levels of ETS and active 
smoking that women diagnosed more recently have been exposed to across their life course in 
contrast to the higher levels of exposure observed in the LIBCSP study population. This study 
would be informative for public health understanding of the health effects associated with these 
lower levels of PAH exposure and additionally, could potentially act as an example of the 
benefits of reducing these modifiable PAH exposure sources if a reduction in risk is observed.  
There have been limited studies evaluating the relationship between indoor air pollution 
and burning wood and synthetic fire logs in association with breast cancer risk although 
associations have been reported with other cancer sites [170].  Future research is needed to 
better understand the differences in indoor air pollution from sealed indoor stoves compared to 
open fireplaces (which could not be discerned based on the design of the questionnaire in this 
study). Additionally, further study on types of material burned in the stove/fireplace and their 
 157 
 
respective contributions to indoor air pollution along with any variation by geographic location 
[156, 174] would help to support public health messaging to reduce these exposure sources.  
A panel of breast cancer-related genes was used for the methylation assays in this 
study. Other studies would benefit from considering an array-based method which may identify 
other methylated sites that are important in the PAH-breast cancer association. Methylation 
research has often been limited by inconsistencies and a lack of reproducibility which is likely 
due at least in part to differences in biologic sample (blood versus tissue) and assay type [281]. 
Very few studies have evaluated predictors of epigenetic changes in breast tumor tissue [466], 
which may be the most relevant in understanding epigenetic changes that occur in the tumor. 
Future research on predictors of DNA methylation would benefit from studies that use consistent 
assays, evaluating methylation in the tumor tissue and using replication samples if possible.  
5.5 Conclusions 
The goal of this dissertation was to estimate the association with breast cancer incidence 
among women exposed to multiple PAH sources, and to evaluate the role that DNA methylation 
may play in this association. Findings from this population-based case-control study of women 
diagnosed in the mid-1990s, found that these women were heavily exposed across many PAH 
sources across the life course. Very few women were characterized as having low exposure to 
PAHs, emphasizing the ubiquitous nature of PAH exposure. Women highly exposed across 
different groups of PAH sources, in particular indoor sources of PAH, were more likely to have 
breast cancer than those women who were low exposed across all PAH sources. The PAH 
exposure sources most notably associated with breast cancer (current active smoking, ETS 
from a spouse, 1995 vehicular traffic, total grilled/smoked meat intake and synthetic log burning) 
were also found to be associated with patterns of aberrant DNA methylation, both global in the 
blood of controls and gene-specific in the tumor tissue of cases. These findings suggest that 
DNA methylation may play an important role in the PAH and breast cancer association. This 
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investigation is the first: (1) to consider the role of multiple PAH sources concurrently on breast 
cancer risk and to evaluate associations across sources (Aim 1); as well as (2) to investigate 
multiple sources of PAH exposure with DNA methylation (Aim 2).  Findings from this dissertation 
suggest that high exposure to PAH is a highly prevalent and modifiable breast cancer risk factor 
and given the direct associations observed between the PAH sources and DNA methylation, 
that epigenetics may be one potential biologic mechanism by which PAHs impact 
carcinogenesis.  
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APPENDIX I: TABLES 
Table A.1 Z matrix for hierarchical model for PAH variables and sources. 
 
No. PAH Variablea 
Active 
Smoking 
ETS Diet 
Stove/Fireplace 
Use 
1 Ever active smoking 1 0 0 0 
2 Current active smoking 1 0 0 0 
3 Smoked before first pregnancy 1 0 0 0 
4 Ever ETS 0 1 0 0 
5 Ever ETS from spouse 0 1 0 0 
6 
Total grilled/bbq and smoked 
meatsb 
0 0 1 0 
7 Grilled/bbq beef, pork and lambc 0 0 1 0 
8 Smoked beef, pork and lambd 0 0 1 0 
9 Ever any stove/fireplace use 0 0 0 1 
10 Ever synthetic log burning 0 0 0 1 
11 Ever wood burning 0 0 0 1 
a 1995 vehicular traffic was excluded from this matrix as second-level effects were not estimated  
btotal grilled/barbecued and smoked meats (<33% vs ≥33% percentile or <55 servings/year, 55+ 
servings/year) 
cgrilled/barbecued beef, pork and lamb (<33% vs ≥33% percentile or <14, 14+ servings/year); 
dsmoked beef, pork and lamb (<50th percentile, ≥50th percentile or <22, 22+ servings/year). 
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Table A.2 Matrix for PAH profile definitions used in hierarchical regression analysesa.  
 PAH Profile Definitions 
PAH Variables Low 
PAH 
Tobacco 
Smoke 
Ingested 
PAH 
Indoor 
stove/ 
fireplace 
use 
Inhaled 
PAHs 
Indoor 
Source 
PAHs 
Five 
PAH 
Sources 
Ever active 
smoking 
0 1 -- -- 1 1 1 
Current active 
smoking 
0 1 -- -- -- -- -- 
Smoked before 
first pregnancy 
0 1 -- -- -- -- -- 
Ever ETS 0 1 -- -- 1  1 
Ever ETS from 
spouse 
0 1 -- -- -- 1  
Total grilled/bbq 
and smoked 
meatsb 
0 -- 1 -- -- 1 1 
Grilled/bbq beef, 
pork and lambc 
0 -- 1 -- -- -- -- 
Smoked beef, 
pork and lambd 
0 -- 1 -- -- -- -- 
Ever any 
stove/fireplace 
use 
0 -- -- 1 1 1 1 
Ever synthetic log 
burning 
0 -- -- 1 -- -- -- 
Ever wood 
burning 
0 -- -- 1 -- -- -- 
1995 Vehicular 
traffic 
0 -- -- -- 1  1 
a Dashed lines indicate that the PAH variable level was not specified in hierarchical regression 
model. For OR estimates, this results in the other PAH sources not included in the definition 
being cancelled out. For the posterior probability graph, the PAH sources are set to zero.    
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Table A.3 Odds Ratios (OR) and 95% credible interval (CrI) from a hierarchical model for 
the association with breast cancer incidence using Z-matrix for route of PAH exposure, 
inhalation and ingestion, LIBCSP 1996-1997a 
Hierarchical Analysis 
PAH Route of 
Exposure (π) PAH Variables (β)b   OR (95% CrI) CrLR 
Inhalation 1.07 (0.96, 1.18) 1.23 
Ever active smoking 1.01 (0.85, 1.19) 1.40 
Ever current active smoking 1.10 (0.93, 1.30) 1.40 
Smoked before first pregnancy 0.98 (0.81, 1.16) 1.43 
Ever ETS 0.99 (0.83, 1.16) 1.40 
Ever ETS from spouse 1.18 (1.02, 1.38) 1.36 
1995 vehicular traffic 1.12 (0.89, 1.41) 1.58 
Ever any stove/fireplace use 1.03 (0.85, 1.23) 1.45 
Ever synthetic log burning 1.27 (1.05, 1.54) 1.47 
Ever wood burning 0.97 (0.80, 1.16) 1.44 
Ingestion 1.13 (0.95, 1.34) 1.41 
Total grilled/bbq and smoked 
meats 1.17 (0.98, 1.38) 1.41 
Grilled/bbq beef, pork and lamb 1.13 (0.96, 1.32) 1.37 
  Smoked beef, pork and lamb   1.09 (0.94, 1.26) 1.34 
a adjusted for age at menarche (≤12, >12), parity (nulliparous, parous), lifetime alcohol intake 
(non-drinkers, <15g/day, 15g-30g/day, ≥30 g/day), education (high school graduate or less, 
some college, college or post-college), income (<$34,999, $35,000-$69,999, ≥$70,000) and the 
matching factor, 5-year age group. 
b See Table 1 for PAH variable cutpoints 
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Table A.4 Odds of gene specific promoter methylation in tumor of cases in association with current active smoking, LIBCSP 
1996-1997a 
 
No active smoking Ever active smoking 
Genes 
Unmethylated 
(N) 
Methylated 
(N) OR (95%CI)   
Unmethylated 
(N) 
Methylated 
(N) OR (95%CI) 
ESR1 187 187 1.00 (reference) 273 196 0.69 (0.52, 0.92) 
PGR 327 51 1.00 (reference) 422 51 0.87 (0.56, 1.35) 
BRCA1 149 229 1.00 (reference) 198 275 0.93 (0.69, 1.24) 
APC 186 166 1.00 (reference) 227 221 1.04 (0.78, 1.40) 
CDKN2A 329 14 1.00 (reference) 418 16 0.75 (0.34, 1.64) 
HIN1 107 223 1.00 (reference) 177 258 0.66 (0.48, 0.91) 
RASSF1a 47 283 1.00 (reference) 66 369 0.99 (0.65, 1.53) 
DAPK1 284 46 1.00 (reference) 373 62 0.96 (0.62, 1.49) 
GSTP1 233 97 1.00 (reference) 319 116 0.84 (0.60, 1.18) 
CCND2 272 58 1.00 (reference) 343 92 1.33 (0.90, 1.98) 
TWIST1 279 51 1.00 (reference) 370 65 0.95 (0.62, 1.46) 
CDH1 311 19 1.00 (reference) 410 25 0.85 (0.44, 1.63) 
RARβ 236 94 1.00 (reference) 318 117 0.90 (0.64, 1.26) 
a adjusted for age at menarche (<12, ≥12 years), parous (nulliparous, parous), lifetime alcohol intake (non-drinkers, <15g/day,  
15g-30g/day, ≥30 g/day), education (high school graduate or less, some college, college or post-college), income (<$34,999, 
$35,000-$69,999, ≥$70,000) and the matching factor, 5-year age group. 
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Table A.5 Association between PAH sources and global methylation in control women without breast cancer measured by 
LINE-1 and LUMA, LIBCSP 1996-1997a 
LINE-1 
 
LUMA 
PAH Sources 
LINE-1                
<medianb 
(N) 
LINE-1  
≥medianb 
(N) OR (95%CI) 
 
LUMA              
<medianc 
(N) 
LUMA 
≥medianc (N) OR (95%CI) 
Grilled/barbecued/smoked 
meat  
0-54 servings 333 315 1.00 (reference) 275 370 1.00 (reference) 
55+ servings 690 690 1.19 (0.90, 1.57) 584 790 0.95 (0.72, 1.26) 
 
Residential ETS  
No residential ETS 555 565 1.00 (reference) 482 630 1.00 (reference) 
Residential ETS 516 472 0.95 (0.74, 1.22) 407 581 1.03 (0.80, 1.32) 
Current active smoking 
No current active 887 865 1.00 (reference) 734 1,011 1.00 (reference) 
Current active 210 200 0.81 (0.59, 1.11) 181 228 0.84 (0.61,1.15) 
Synthetic log use 
Never 911 927 1.00 (reference) 782 1,053 1.00 (reference) 
Ever 185 134 0.59 (0.41, 0.86) 132 182 0.75 (0.52, 1.09) 
Vehicular traffic 
<95th percentile 907 842 1.00 (reference) 724 1,021 1.00 (reference) 
95th+ percentile 53 49 1.21 (0.67, 2.17) 45 55 0.69 (0.38, 1.25) 
a adjusted for age at menarche (≤12, 12+ years), parity (nulliparous, parous), lifetime alcohol intake (non-drinkers, <15g/day, 15g-
30g/day, ≥30 g/day), education (high school graduate or less, some college, college or post-college), income (<$34,999, $35,000-
$69,999, ≥$70,000) and the matching factor, 5-year age group. 
b LINE-1 median is 78.7;c LUMA median is 55.6
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Table A.6 Associations between PAH sources and global methylation measured by LINE-1 with breast cancer risk when 
limited to those breast cancer case participants with blood samples prior to chemotherapy, LIBCSP 1996-1997a 
LINE-1 < medianb 
 
LINE-1 ≥ medianb 
 
PAH Sources 
Controls 
(N) 
Cases 
(N) OR (95%CI)   
Controls 
(N) 
Cases 
(N) OR (95%CI) p-valuec 
Grilled/barbecued/smoked 
meat   
0-54 servings 179 127 1.00 (referent) 168 110 1.00 (referent) 
55+ servings 327 273 1.48 (1.08, 2.01) 344 261 1.34 (0.98, 1.84) 0.5 
Residential ETS 
No residential ETS 295 202 1.00 (referent) 300 193 1.00 (referent) 
Residential ETS 242 214 1.12 (0.85,1.48) 235 194 1.30 (0.98, 1.72) 0.9 
Current active smoking 
No current active 438 347 1.00 (referent) 454 323 1.00 (referent) 
Current active 112 78 0.93 (0.66, 1.32) 94 76 1.28 (0.89, 1.84) 0.5 
Vehicular traffic 
<95th percentile 465 340 1.00 (referent) 434 313 1.00 (referent) 
95th+ percentile 23 23 1.44 (0.77, 2.68) 26 17 0.90 (0.47, 1.73) 0.3 
a adjusted for age at menarche (≤12, 12+ years), parity (nulliparous, parous), lifetime alcohol intake (non-drinkers, <15g/day, 15g-
30g/day, ≥30 g/day), education (high school graduate or less, some college, college or post-college), income (<$34,999, $35,000-
$69,999, ≥$70,000) and the matching factor, 5-year age group. 
b LINE-1 median in women without breast cancer is 78.7 
cmultiplicative interaction p-value 
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Table A.7 PAH sources and global methylation measured by LUMA with breast cancer incidence when limited to those 
breast cancer case participants with blood samples prior to chemotherapy, LIBCSP 1996-1997a 
LUMA < medianb 
 
LUMA≥ median 
 
PAH Sources 
Controls 
(N) 
Cases 
(N) OR (95%CI)   
Controls 
(N) 
Cases 
(N) OR (95%CI) p-valuec 
Grilled/barbecued/smoked 
meat   
0-54 servings 174 74 1.00 (referent) 175 163 1.00 (referent) 
55+ servings 340 171 1.53 (1.06, 2.22) 337 356 1.28 (0.97, 1.70) 0.6 
Residential ETS 
No residential ETS 296 137 1.00 (referent) 298 254 1.00 (referent) 
Residential ETS 236 120 1.01 (0.73,1.39) 243 285 1.28 (0.99, 1.66) 0.8 
Current active smoking 
No current active 441 214 1.00 (referent) 451 451 1.00 (referent) 
Current active 108 49 0.94 (0.63, 1.40) 99 103 1.23 (0.89, 1.72) 0.5 
Synthetic log use         
Never 470 223 1.00 (referent)  485 451 1.00 (referent)  
Ever 78 40 1.36 (0.88, 2.11)  63 102 2.05 (1.43, 2.94) 0.1 
Vehicular traffic 
<95th percentile 444 193 1.00 (referent) 460 452 1.00 (referent) 
95th+ percentile 28 12 1.00 (0.47, 2.13) 20 28 1.25 (0.68, 2.28) 0.5 
a adjusted for age at menarche (≤12, 12+ years), parity (nulliparous, parous), lifetime alcohol intake (non-drinkers, <15g/day, 15g-
30g/day, ≥30 g/day), education (high school graduate or less, some college, college or post-college), income (<$34,999, $35,000-
$69,999, ≥$70,000) and the matching factor, 5-year age group. 
b LUMA median in women without breast cancer is 55.6 
c multiplicative interaction p-value 
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APPENDIX II: FIGURES 
  
Figure A.1 Odds ratios (OR) and 95% credible intervals (CrI) from hierarchical regression 
models for the association between PAH exposure profiles and breast cancer incidence. 
PAH exposure profiles are defined as (1) low PAH: non-smokers, no residential ETS, low intake 
of grilled/smoked foods, low vehicular traffic, no indoor stove/fireplace use; (2) Tobacco smoke: 
current, active smokers who started prior to first pregnancy and were exposed to residential 
ETS from spouse; (3) Ingested PAHs: high intake of overall rilled/smoked/barbecued foods, 
grilled/barbecued beef, pork and lamb and smoked beef, pork and lamb; (4) Indoor 
stove/fireplace users: indoor stove/fireplace users, burned both wood and synthetic logs; (5) 
Inhaled PAHs: active smokers, residential ETS, top 5% vehicular traffic, stove/fireplace users; 
(6) indoor source PAHs: active smokers, residential ETS spouse, high overall grilled/smoked 
foods and stove/fireplace users; (7) Five PAH sources: active smokers, residential ETS, high 
overall grilled/smoked foods, stove/fireplace users, and top 5% of vehicular traffic.   
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Figure A.2 Posterior probability densities for breast cancer incidence among women with 
(1) low PAH (non-smokers, no residential ETS, low intake of grilled/smoked foods, low vehicular 
traffic, no indoor stove/fireplace use); (2) women with indoor source PAH (active smokers, 
residential ETS from spouse, high intake of grilled/smoked foods, stove/fireplace users).  To 
estimate posterior probabilities, confounders were specified at their most likely value (age: 50-
54; income: $35,000-$69,999; education: high school or less; parity: parous; alcohol intake: 
<15g/day; age at menarche: >12) and PAH sources not specified in the definition of the profiles 
were set to the referent category.    
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